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Project Summary 
 
The complex array of extracellular matrix molecules, immune cells, blood and lymph 
systems, and fibroblasts that comprises the tumor’s stromal compartment influences tumor initiation, 
progression, metastasis, and therapeutic response. In breast cancer, myeloid cells make up a 
prominent proportion of the tumor stroma, and enhanced infiltration of these immune cells into 
tumors is associated with advanced disease and decreased relapse-free survival. Furthermore, high-
level infiltration of myeloid cells into tumors following radiation therapy and chemotherapy is 
frequently observed in pre-clinical models. We therefore sought to determine the significance of 
myeloid cell recruitment following chemotherapy treatment and their role in therapeutic resistance. 
Using intravital imaging of tumors in live mice, we observed that the tumors of the polyoma 
middle T antigen (PyMT) mouse model of luminal breast cancer show a stage-dependent sensitivity 
to treatment with doxorubicin. Doxorubicin treatment induces necrosis in drug-sensitive lesions, 
which consequently results in the recruitment of CCR2+Gr1+7/4+CD11b+ immature myeloid cells with 
monocytic morphology. Inhibiting recruitment of these cells via orthotopic transplantation of Ccr2+/+ 
cancer cells from PyMT mice into Ccr2-/- mice delays tumor relapse indicating a role for these 
monocytic cells in chemoresistance. Changes in tumor vasculature and tumor grade accompany the 
delay in host relapse, indicating that CCR2 signaling may also have important effects on tumor 
angiogenesis and cancer cell differentiation and proliferation. This is further confirmed by the fact 
that transgenic PyMT;Ccr2-/- mice respond better to doxorubicin from the outset. The data herein 
presented show that antagonism of CCR2 signaling in combination with cytotoxic chemotherapy 
treatment may be a potentially powerful therapeutic strategy for the treatment of breast cancer. 
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Rationale 
 
Despite major scientific advancements that have resulted in improvements in early detection 
and therapeutics, stabilization of incidence rates, and a decline in death rates, breast cancer remains 
the second leading cause of cancer-related mortality in women in the United States. Furthermore, 
approximately 30% of women who are diagnosed with early breast cancer and successfully enter 
remission will present with recurrent local or metastatic breast cancer that, if not intrinsically 
refractory, acquires resistance to standard systemic chemotherapies, which are the only options 
available for the treatment of disseminated disease (Siegel et al., 2011, Brewster et al., 2008). 
We have an excellent understanding of how cytotoxic therapies induce cell death and how 
cancer cells acquire resistance to these drugs in vitro (Gonzalez-Angulo et al., 2007). Such 
knowledge has resulted in the development of strategies to overcome resistance to cytotoxic therapies 
(Fojo and Bates, 2003). But the biggest challenge at present is the fact that tumors are continually 
evolving tissues, adept at finding ways of circumventing strategies aimed at eliminating malignancies 
and therapeutic resistance. 
What has become evident over the past few decades is that the microenvironment in which 
cancer cells reside is crucial to the development of disease, its progression, and chemotherapy 
resistance, and that targeting different components of the tumor microenvironment may be an 
important and viable strategy in the treatment of both locally advanced and recurrent, chemotherapy 
refractory breast cancer (Hiscox et al., 2011). Thus, we have focused our efforts on determining how 
one component of the breast tumor microenvironment – the myeloid cell – interacts in vivo with 
cancer cells, how these interactions influence therapeutic response, and identifying ways of altering 
these interactions to improve this response. 
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Introduction 
 
Breast cancer: a primer 
Breast cancer is currently the most common malignancy and the leading cause of cancer-
related mortality in women world-wide (Jemal et al., 2011). Despite these global trends, we have 
achieved major advancements in our understanding of the basic biology underlying tumor initiation, 
progression, and metastasis, as well as in our standards of care in the clinic, especially with respect to 
prevention, diagnosis, and treatment (AACR Cancer Progress Report 2011). These advancements 
have resulted in improved early detection of breast cancers, stabilizing incidence rates, and decreasing 
mortality rates (DeSantis et al., 2011). 
One of the most important recent advancements in our understanding of breast cancer has 
been the classification of tumors based on molecular subtype. Traditionally, breast cancers were 
diagnosed based on histopathologic analyses that were broadly classified as in situ (tumors that have 
not yet breached the basement membrane surrounding the mammary epithelium in which the lesion 
has arisen) or invasive (tumors that have breached the basement membrane and invaded the 
surrounding tissues). The type of tumor the patient presented with was then identified based on 
specific morphological features (reviewed in Malhotra et al., 2010). At the turn of the twenty-first 
century, three pivotal studies that analyzed expression data derived from the tumors of human patients 
showed that breast tumors, regardless of whether they are in situ or invasive, could be classified based 
on specific molecular characteristics (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003). This 
classification system identifies four major molecular subtypes of breast cancer – luminal A, luminal 
B, HER2+, and the triple negative/basal-like – as well as two less common subtypes (normal breast-
like and Claudinlow), that can be identified based on the presence (or absence) of a short list of 
immunohistochemical markers. 
Luminal A tumors account for approximately 40% of the breast cancer cases diagnosed, and 
are characterized by low proliferation (by Ki67 staining), expression of the estrogen receptor (ER) 
and/or the progesterone receptor (PR), with low expression of HER2 (human epidermal growth factor 
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receptor 2, also known as ErbB2, neu). These tumors frequently display low to moderate 
histopathologic tumor grade, and have the best prognosis of the six molecular subtypes. Luminal B 
tumors are the second most commonly diagnosed breast cancer subtype, accounting for 
approximately 20% of breast cancers. These tumors are characterized by high proliferation, low 
expression of ER and/or PR, and variable expression of HER2. They often exhibit poorer 
histopathologic grade as compared to luminal A tumors, as well as frequent mutations in the p53 
tumor suppressor gene. The HER2+ subtype accounts for approximately 10-15% of all breast cancers, 
and is characterized by expression of HER2 without expression of ER and PR. Like luminal B 
tumors, tumors of the HER2+ subtype frequently display poorer histopathologic grade than those of 
the luminal A subtype and often harbor p53 mutations. The fourth major subtype, the triple negative/ 
basal-like tumors, also account for approximately 10-15% of all breast cancer cases and are the most 
aggressive of the four major molecular subtypes. Triple negative breast cancers, as their name 
implies, lack expression of ER, PR, and HER2, and frequently exhibit mutations in p53. Importantly, 
not all triple negative breast cancers are basal-like, and not all basal-like breast cancers are triple 
negative. Basal-like tumors are derived from the myoepthelial layer of cells that lines the epithelial 
cells of mammary ducts, and frequently express epidermal growth factor receptor (EGFR, also known 
as ErbB1 or HER1). In contrast, triple negative breast cancers can arise from either this myoepithelial 
cell population or the epithelial cells that form the mammary ductal structures, and frequently result 
from mutations in p53. BRCA1/2-mutant breast cancers frequently fall into the triple negative/basal 
like subtype (reviewed in Malhotra et al., 2010). 
Standard of care for breast cancer continues to consist of breast-conserving surgery to remove 
the primary tumor followed by radiation therapy (this is a preventative measure used to ensure the 
cancer has been completely eradicated, and is preferred over chemotherapy as it is a localized 
therapy). However, in patients where the primary tumors are large, neoadjuvant chemotherapy is used 
to shrink tumors prior to surgery, while in patients with disseminated disease, adjuvant chemotherapy 
is used as the preventative measure instead of radiation therapy. Most chemotherapeutic regimens 
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used to treat breast cancers are anthracycline-based (usually doxorubicin in combination with 
cyclophosphamide), and are often followed by treatment with a taxane (usually paclitaxel). 
Furthermore, patients with tumors positive for hormone receptors receive some form of hormone 
therapy, such as the small molecule antagonist of ER, tamoxifen. With the identification of molecular 
subtypes, novel targeted therapies have also been added to these drug combinations to improve tumor 
shrinkage. For example, patients that are HER2 positive will receive either herceptin, a monoclonal 
antibody that antagonizes HER2, or lapatinib, a small molecule antagonist of EGFR/HER2 
(recommendations for standard of care by the NCI breast cancer work group as described in Carlson 
et al., 2009). Stratification of patients in this manner and the use of these molecular targeted therapies 
have dramatically improved our ability to treat breast cancers. 
 
Therapeutic resistance and cancer 
Despite the major advancements that have been made in breast cancer therapy, resistance to 
systemic therapy is a major obstacle in the treatment of these tumors. It is estimated that 
approximately 30% of patients with breast cancer will present with local and distant recurrences 
(Gonzalez-Angulo et al., 2007). Resistance to systemic therapies (these include cytotoxic 
chemotherapies and hormone therapies) may be intrinsic, that is, due to certain pre-existing qualities 
of the cell, or it may be acquired following prolonged exposure to therapeutic agents. Resistant cells 
that remain undetected after treatment and elimination of the bulk tumor mass (termed minimal 
residual disease) contribute to tumor relapse, both locally and systemically. Furthermore, cancer cells 
that acquire resistance to the chemotherapies used during treatment of the primary tumor are 
frequently resistant to other classes of chemotherapeutics used to treat recurrent (usually metastatic) 
breast cancer, a phenomenon termed cross-resistance. Frequently cross resistance is due to the 
increased expression of drug efflux transporters like the ATP-binding cassette transporter MDR1 or 
anti-apoptotic proteins like BCL-2 (Gonzalez-Angulo et al., 2007). 
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Intrinsic resistance, that is, resistance already inherent to cancer cells before any type of 
therapy is administered, is a relatively infrequent phenomenon when compared with acquired 
resistance. The two most frequently observed examples of intrinsic resistance are pre-existing genetic 
mutations and the exhibition of stem-like properties. Identification of mutations that exist in cancer 
cell populations prior to any form of therapy is becoming an important area of study, especially with 
respect to molecular targeted therapies in leukemias. For example, new studies are focused on 
developing methods for identifying clones of cells containing resistance-conferring mutations in the 
tyrosine kinase domains of the Bcr-Abl fusion oncogene prior to therapeutic treatment to tailor 
molecular targeted therapies (Leder et al., 2011; Pfeifer et al., 2012). 
The second form of intrinsic resistance frequently cited is resistance arising from the 
properties attributed to having a stem-like phenotype. Cancer cells exhibiting stem-like properties 
(whether they are bona fide [Li et al., 2008] or merely exhibit a mesenchymal phenotype with the 
functional characteristics of stem cells [Mani et al., 2008; Blick et al., 2010]) are characterized by 
decreased proliferation, self-renewal, and pluripotency (Visvader and Lindeman, 2008). The slow 
proliferation rate of these stem-like cells is one mechanism that can drive therapeutic resistance in this 
population (Dembinsk and Krauss, 2009). More recently, it has been shown that normal tissue stem 
cells frequently express high levels of ATP-binding cassette transporters that allow for drug efflux 
(expression is turned off following differentiation) to protect this population from drug-induced 
cytotoxicity, and that this is also true of cancer cells exhibiting a stem-like phenotype (reviewed in 
Dean et al., 2009). 
In contrast to intrinsic mechanisms of resistance, acquired resistances are more common, and 
generally come in two flavors: intrinsic and environment-mediated. Intrinsic acquired resistance 
results from adaptations inherent to cancer cells that protect them from drug-induced cytotoxicity. 
Many of the mechanisms by which cancer cells acquire this type of resistance have been elucidated in 
vitro in cancer cell lines. Some of the most common of these mechanisms include altered repair 
mechanisms (e.g. activation of DNA damage repair pathways following cisplatin therapy; reviewed in 
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Martin et al., 2008), mutation of molecular targets (e.g. mutations of Her2 conferring resistance to 
lapatinib; Tortora et al., 2011), and enhanced drug efflux (e.g. through upregulation of drug 
transporters like the breast cancer resistance protein, BCRP; reviewed in Leonessa and Clarke, 2003).  
Although many of these acquired intrinsic resistances have been mechanistically described in vitro, 
few of these mechanisms – with the exception of mutation-driven resistances – have been confirmed 
in vivo, as animal models of minimal residual disease do not currently exist, and the cohorts of 
patients and patient tissues required to do the types of analyses required to confirm these processes 
are widely unavailable (Gilbert and Hemann, 2011). 
The second type of acquired resistance is environment-mediated drug resistance, and it is a 
unique form resistance, in that it is entirely dependent on interactions between cancer cells and their 
surrounding environment, disappearing when cancer cells are removed from this environment. One 
important example that illustrates this type of resistance was published in 1990 by Teicher et al. In 
this study, the group generated mammary carcinoma cell lines (derived from the EMT-6 cell line) that 
were highly resistant to various alkylating agents in vivo by serial passage in chemotherapy-treated 
mice. However, ex vivo testing for therapeutic sensitivity showed that in early passage cultures, these 
same cell lines that showed a high degree of therapeutic resistance in vivo were as sensitive to drug 
treatment as the parental cell line in vitro. Moreover, treatment and further passaging ex vivo did not 
alter in vivo resistance to therapeutic treatment when cell lines were re-implanted into mice. 
As the importance of the microenvironment in therapeutic response has only recently become 
a major area of research, few mechanisms of environment-mediated resistance have been identified. 
The majority of the earlier studies on this type of resistance have focused on the biochemical and 
biophysical properties of tumors that regulate drug distribution and drug activity. These mechanisms 
include abnormal interstitial pressure (usually due to abnormalities in blood and lymphatic 
circulation) that impedes diffusion of drugs from capillaries into tumor tissues (reviewed in Heldin et 
al., 2004), and unusually acidic or anoxic environments in tumor tissues removed from blood vessels 
that can prevent drug activity both by limiting cancer cell proliferation – which is necessary for many 
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cytotoxic chemotherapies to function – or by directly modifying chemotherapies (Mahoney et al., 
2003; Rohwer and Cramer, 2011 [review]; Teicher et al., 1981 [in vitro study]). 
Mechanisms of environment-mediated resistance that involve biological mechanisms, such as 
cell adhesion and soluble factors (e.g. cytokines), have also been identified. Like cancer cell intrinsic-
mechanisms of therapeutic resistance, a majority of the studies that demonstrate these two types of 
resistance have been performed using in vitro co-culture systems. The most common adhesion-
mediated resistance mechanism arises from integrin-mediated (mostly β1 integrins) interactions 
between cancer cells and extracellular matrix components that either activate signaling pathways (e.g. 
the interleukin-6 [IL-6]/signal transducer and activator of transcription 3 [STAT3] pathway) to 
promote cancer cell survival or enhance degradation of pro-apototic proteins (Shain et al., 2009; 
Shain et al., 2001; Hazlehurst et al., 2007). Resistance mediated by soluble factors frequently involves 
paracrine signaling between cancer cells and stromal cells, in which a factor produced by cancer cells 
induces expression of a pro-survival signal in a stromal cell that then acts on the cancer cells. For 
example, in a primary multiple myeloma / bone marrow stromal cell co-culture system, cancer cell-
derived basic fibroblast growth factor (bFGF) induces expression of IL-6 in bone marrow stromal 
cells, which then promotes cancer cell survival (Bisping et al., 2003). 
More recently, tumor microenvironment groups have begun to combine ex vivo organotypic 
co-culture systems involving primary cancer and stromal cell types with in vivo manipulations of 
mouse models of cancer to study environment mediated-resistance; however, only a handful of these 
studies have been performed. One of the earliest of these studies is one that shows that in a mouse 
model of Burkitt’s lymphoma, doxorubicin-induced genotoxic stress induces the production of IL-6 
in thymic endothelial cells, which then goes on to promote the survival of minimal residual disease 
(Gilbert and Hemann, 2010). More recently, blockade of macrophage recruitment into tumors in a 
mouse model of breast cancer via neutralizing antibodies against colony stimulating factor-1 (CSF-1), 
has been shown to improve therapeutic response to paclitaxel and cisplatin (DeNardo et al., 2011). 
These studies have been important in underscoring the necessity of utilizing in vivo systems to 
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identify mechanisms of environment-mediated drug resistance, given the fact that in vivo targeting 
many of the resistance pathways identified using in vitro systems is often unsuccessful. Frequently, 
because of the complexity of the tumor microenvironment, mechanisms of environment-mediated 
resistance identified in vitro either contribute very little to chemoresistance or only account for a part 
of the resistance phenotype. 
 
Solid tumors are complex systems comprised of cancer cells and stromal components that 
promote progression 
Normal organs consist of two major compartments: the cellular compartment responsible for 
organ function, and the stromal compartment responsible for supporting and maintaining the 
environment in an appropriate homeostatic state for proper function. In much the same way, solid 
tumors can be thought of as being similarly organized, although they are structurally and functionally 
abnormal. Taking carcinomas as an example, the epithelial cell population that comprises the 
structures involved in primary organ function, are replaced by cancer cells that hijack and alter 
normal stromal processes to support proliferation and invasiveness (Egeblad et al., 2010). The tumor 
stroma is comprised of two major classes of constituents – a diverse cellular component and 
extracellular matrix (ECM) molecules – which have important functions in cancer cell survival and 
tumor progression (Table 1). 
The primary cellular components of solid tumors include those derived from mesenchymal 
stem cells and cells of the vascular and immune systems. Mesenchyme-derived cells are those that 
differentiate from a tissue-resident mesenchymal stem cell (MSC) niche that exists to replenish the 
cells of the normal tissue stroma required for maintaining proper function. These MSCs can 
differentiate into a wide variety of cell types, including (but not limited to) chondrocytes, osteoblasts, 
adipocytes, and fibroblasts (Kolf et al., 2007). In most tissues, fibroblasts represent one of the major 
MSC-derived cell types in the stroma. Solid tumors will produce factors to activate these fibroblasts, 
generating carcinoma-associated fibroblasts (CAFs), which play active roles in tumor initiation and 
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Cell type Effect on tumors References 
Normal epithelial cells Inhibit (Dong-Le Bourhis et al., 1997) 
Myoepithelial cells Inhibit (invasion, growth) (Gudjonsson et al., 2002; Hu et al., 
2008) 
Fibroblasts Promote (proliferation, angiogenesis, 
invasion) 
(Bhowmick et al., 2004; Olumi et 
al., 1999; Orimo et al., 2005) 
Mesenchymal stem cells Promote (metastasis) (Karnoub et al., 2007) 
Adipocytes Promote (tumor growth, survival, 
angiogenesis) 
(Iyengar et al., 2005; Landskroner-
Eiger et al., 2009) 
Endothelial cells Promote (angiogenesis, niche?) (Ausprunk and Folkman, 1977; 
Calabrese et al., 2007) 
Perivascular cells Promote (vascularization) 
Inhibit (metastasis) 
(Song et al., 2005) 
(Xian et al., 2006) 
Bone marrow-derived cells Promote (proliferation, invasion 
angiogenesis) 
(Coussens et al., 2000; Du et al., 
2008; Lyden et al., 2001) 
Dendritic cells Inhibit (stimulate antitumor immunity) (Knight et al., 1985; Mayordomo et 
al., 1995) 
Myeloid derived suppressor cells; 
Immature myeloid cells 
Promote (angiogenesis, metastasis, reduce 
antitumor immunity) 
(De Palma et al., 2005; Sinha et al., 
2007; Yang et al., 2004; Yang et al., 
2008b) 
Macrophages, M1-like Inhibit (Sinha et al., 2005) 
Macrophages, M2-like Promote (invasion, angiogenesis) (DeNardo et al., 2009; Lin et al., 
2006; Lin et al., 2001) 
Mast cells Promote (angiogenesis) (Coussens et al., 1999; Soucek et al., 
2007; Yang et al., 2008a) 
Neutrophils, N1 Inhibit (stimulate antitumor immunity) (Fridlender et al., 2009) 
Neutrophils, N2 Promote (angiogenesis, reduce antitumor 
immunity) 
(Nozawa et a., 2006; Schmielau and 
Finn 2001; Shojaei et al., 2008) 
T cells, CD4+, T helper 2 Promote (metastasis) (DeNardo et al., 2009) 
T cells, CD8+, cytotoxic Inhibit (tumoricidal) (Romero et al., 1998) 
T cells, CD4+CD25+ regulatory Promote (reduce antitumor immunity) (Casares et al., 2003; Curiel et al., 
2004) 
T cells, gamma/delta Inhibit (stimulate antitumor immunity) (Girardi et al., 2001) 
T cells, Th17 Promote (proliferation, angiogenesis) 
Inhibit (stimulate T cell antitumor 
immunity) 
(Numasaki et al., 2005) 
(Hirahara et al., 2001) 
B cells Promote (reduce antitumor immunity) (Inoue et al., 2006) 
B cells, Immunoglobulins Promote (stimulate inflammation-associated 
progression)  
(Andreu et al., 2010) 
Platelets Promote (metastasis) (Camerer et al., 2004; Nieswandt et 
al., 1999) 
 
Table 1: Stromal components of solid tumors and their effects on tumor progression. From 
Egeblad et al., 2010. 
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progression. CAFs are the primary source of ECM molecules in solid tumors, and have been shown to 
stimulate cancer cell growth via the production of growth factors like transforming growth factor-β 
(TGF-β, Bhowmick et al., 2004), and promote angiogenesis, invasion, and metastasis through the 
production of chemokines like CXCL12 (also known as stromal cell-derived factor 1, Orimo et al., 
2005). 
Cells of the vascular system – the endothelial cells that form blood and lymphatic vessels and 
the pericytes that wrap and support these vessels – comprise another important component of the 
tumor microenvironment. As is true of normal tissues, tumors require blood vessels to deliver 
nutrients and oxygen, and lymphatic vessels to return excess fluid and molecules to the blood 
circulation. In order to generate blood vessels, tumors may co-opt existing vessels for their use 
(Holash et al., 1999), recruit endothelial cells and pericytes (angiogenesis, Carmeliet, 2000), or they 
may recruit bone marrow-derived cells that will differentiate into endothelial cells or pericytes in the 
tumor (vasculogenesis, Song et al., 2005). Unlike the vasculature of normal tissues, however, tumor 
blood vessels are highly abnormal, exhibiting disorganized architecture often with non-functional 
branches that do not reconnect to systemic circulation, irregular capillary beds, altered basement 
membrane structure, disrupted associations between endothelial cells and pericytes, and increased 
permeability. These changes disrupt normal blood flow and interstitial pressure gradients, which can 
impede nutrient, oxygen, and drug delivery and lead to compensatory shifts in expression, including 
upregulation of factors that can further promote angiogenesis, such as hypoxia inducible factor-1 
(HIF-1, Bergers and Benjamin, 2003). In addition, lymphatic vessels that can assist in relieving 
interstitial pressure and returning excess fluids and proteins to blood circulation, also provide a means 
by which cancer cells can metastasize (Skobe et al., 2001). 
The final group of cellular components of the tumor stroma consists of inflammatory cells of 
both the innate and adaptive immune systems. While inflammatory cells can have both pro- and anti-
tumor effects, tumor-associated leukocytes generally show phenotypic and functional traits that allow 
them to provide signals that promote angiogenesis, proliferation, invasion, and subversion of anti-
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tumor immune responses (Coussens and Werb, 2002). Some of the best characterized tumor-
associated leukocytes are myeloid-derived suppressor and regulatory T cells that inhibit anti-tumor T 
cell responses (Sinha et al., 2007; Casares et al., 2003), macrophages that promote angiogenesis and 
invasion (Lin et al., 2001; Wyckoff et a., 2007), and CD4+ T cells that promote metastasis (DeNardo 
et al., 2009). These interactions will be expanded on and discussed with respect to their effects on 
breast tumors in the following section. 
The ECM of solid tumors includes proteoglycans, hyaluronic acid, collagen, fibronectin, and 
laminin. ECM molecules comprise a structural platform that provides physical support for tissues; 
however, changes in the organization of these fibers can promote tumor invasion and progression 
(Provenzano et al., 2006; Levental et al., 2009), and are equally important for tumor angiogenesis 
(Heissig et al., 2003). Interactions between the ECM and cell adhesion molecules (β1 integrin, for 
example) on cancer cells have also been shown to mediate both tumor progression and 
chemotherapeutic resistance (Park et al., 2006; Weaver et al., 1997; Hazlehurst et al., 2007). In 
addition to exerting effects dependent on direct interaction with cancer cells or other stromal cells, the 
ECM can also alter the bioavailability of various growth factors and chemokines (Hawinkels et al., 
2008). 
 
Tumor-associated inflammation in breast cancer 
Interactions between tumor cells and the immune system play a critical role in the 
progression and metastasis of many types of cancers. Leukocytes of both the myeloid (innate) and 
lymphoid (adaptive) lineages exert tumor-promoting and tumor-inhibiting effects, depending on 
context, cell type, and mode of activation (Coussens and Werb, 2002). The two major tumor-
associated inflammatory cell types – T cells and macrophages – exhibit dichotomous functional 
properties that can have dramatic effects on tumor progression and metastasis (Sato et al., 1998). 
These functional states have been extrapolated from the TH1 and TH2 helper T cell polarization states 
exhibited in response to pathogenic infections, are defined by distinct cytokine and chemokine 
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expression profiles (Mosmann and Coffman, 1989), and exhibit opposing functions (Kidd, 2003) 
(Figure 1). Furthermore, this same classification system for helper T cell effector functions has been 
applied to macrophages (Mantovani et al., 2002). In tumors, this polarization of T cells and 
macrophages in one direction heavily influences progression and development. In the simplified 
generalization of these polarization schemes, type 1 responses represent the acute inflammatory 
response and are generally associated with anti-tumor immunity, while type 2 responses represent the 
chronic inflammatory response and tend to promote progression and metastasis (DeNardo and 
Coussens, 2007). 
In breast tumors, the primary leukocyte population is the tumor-associated macrophage, 
which can account for up to 80% of the entire tumor-associated leukocyte population (O'Sullivan and 
Lewis, 1994; this number is about 70% in the MMTV-PyMT mouse model [Egeblad et al., 2008]). 
These macrophages exhibit a type 2 (M2-like or alternatively activated) phenotype, and have been 
shown to promote tumor angiogenesis (Lin et al., 2006), interact with cancer cells to promote 
intravasation (Wyckoff et al., 2007), and contribute to chemotherapeutic response (Ahn et al., 
2010; DeNardo et al., 2011; Shree et al., 2011). Moreover, immunohistochemical analyses of 
human breast tumors show that high numbers of macrophages in tumors is associated with both tumor 
progression and decreased relapse-free survival (Leek et al., 1996). These tumor-associated 
macrophages are predicted to be derived from tumor-infiltrating monocytes (Sica et al., 2000), 
which, if prevented from maturing into tumor-associated macrophages, can also promote progression 
by inhibiting anti-tumor T cell responses (Gabrilovich and Nagaraj, 2009). Thus, therapeutic 
targeting of these tumor-associated macrophages – perhaps by depletion, inhibition of recruitment, re-
polarization, or antagonism of M2 effector functions – may prove to be a potentially powerful means 
of treating breast cancer (Bingle et al., 2002; Luo et al., 2006).  
 
Therapeutic targeting of the tumor microenvironment 
21
Figure 1. Type 1 and type 2 inflammatory responses in tumor progression. Polarized immune cell 
responses can influence tumor initiation and progression. In its simplest representation, type 1 
responses occur following stimulation with interferon-γ (IFN-γ) or bacterial lipopolysaccharide (LPS), 
inducing expression of various cytokines and pro-inflammatory markers and promotoing anti-tumor 
effects. Conversely, type 2 responses occur following stimulation with interleukins -4, -10, and -13, and 
produce cytokines and anti-inflammatory markers that promote various pro-tumorigenic effects.
IFN-γ, LPS Stimulation IL-4, IL-10, IL-13 Stimulation
IL-1, IL-12, IL-23, iNOS TGF-β, IL-10, Arg-1
Tumor cytotoxicity
Immunostimulatory functions
Angiogenesis
Matrix degradation
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Over the past few decades, there has been a vast increase in our understanding of the 
complexities of solid tumor organization, the cues present in the microenvironment, and the physical 
and biochemical interactions that occur between cancer cells, stromal cells, and the ECM (Tlsty and 
Coussens, 2006). What has become apparent from this research field is that the microenvironment in 
which cancer cells reside plays as important a role in tumor initiation, progression, metastasis, and 
therapeutic response, as do the genetic alterations driving carcinogenesis (Liotta and Kohn, 2001). 
Thus, therapeutic targeting of the interactions between cancer cells and stromal components as 
prophylactic and therapeutic strategies has become an increasingly important area of research (Albini 
and Sporn, 2007; Joyce, 2005). Some of the stromal targets that are currently being studied include 
ECM-remodeling enzymes, fibroblasts, cells of the vasculature, and the signals regulating 
angiogenesis, tumor-associated immune cells, and chemokine-receptor pairs involved in drug 
resistance and metastatic spread. 
Interactions between cancer cells and the ECM, as well as remodeling of the ECM, have been 
shown to be important for tumor progression and invasion. Disruption of ECM-cancer cell 
interactions – for example, by blocking β1 integrin signaling (White et al., 2004; Park et al., 2006; 
Bhaskar et al., 2007) – or inhibiting tissue proteases such as matrix metalloproteinases involved in 
cleavage of ECM proteins (Goss et al., 1998; Maquoi et al., 2004) have been shown to impede 
tumor progression and angiogenesis. Fibroblasts provide a variety of ECM proteins, growth factors, 
and chemokines that promote tumor progression. Targeting of factors such as fibroblast activation 
protein (FAP, Lee et al., 2005) or CXCL12 (Orimo et al., 2005) have also shown promise as 
therapeutics. In addition to these targets, fibroblasts express many of the same cell-surface markers 
and tyrosine kinase receptors that the cells of the vascular system express, and so targeting of some of 
these proteins (e.g., the platelet-derived growth factor receptor [PDGFR]) has been shown to impede 
angiogenic processes (Bergers et al., 2003; Sumida et al., 2011). Other anti-angiogenic therapies 
include inhibition of bone-marrow derived progenitor cell homing to tumors (DePalma et al., 2003), 
disruption of VEGF signaling (Yu et al., 2012), or induction of vascular normalization (Jain et al., 
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2001). Modulation of tumor-associated inflammation has been one of the largest areas of stroma-
targeted cancer therapeutics research. These strategies include depletion of specific immune cell 
populations, inhibition of downstream products of immune cell activation (e.g. cathepsins), blocking 
immune cell recruitment, and re-polarization of tumor-resident immune cells (reviewed in Demaria et 
al., 2010). In addition, some of the chemokine-receptor signaling pathways that are important in 
immune cell recruitment also play roles in chemotherapeutic resistance and cancer cell metastasis, 
and inhibition of some of these pathways, including the CXCL12/CXCR4 (Kim et al., 2010) has 
shown therapeutic promise. 
While pre-clinical models have shown that components of the tumor microenvironment are 
important therapeutic targets, few of these strategies have entered the clinic, indicating that more 
research is needed. Two therapeutics targeting the microenvironment currently approved for clinical 
use include: the anti-angiogenic therapy bevacizumab (trade name Avastin), a monoclonal antibody 
that targets vascular endothelial growth factor-A (VEGF-A, Giantonio et al., 2007), and the 
immunomodulatory therapy ipilimumab (trade name Yervoy), a monoclonal antibody that depletes T 
cells expressing the inhibitory co-stimulatory signal cytotoxic T lymphocyte antigen-4 (CTLA-4) to 
potentiate anti-tumor immune responses (Hodi et al., 2010). Another drug currently on the market 
but not yet approved as a stroma-targeting agent, is the Bcr-Abl tyrosine kinase inhibitor imatinib 
(trade name Gleevec), which targets fibroblasts, endothelial cells, and pericytes, by inhibiting PDGFR 
(Bergers et al., 2003; Sumida et al., 2011). 
 
Mouse models of breast cancer 
Mouse models of cancer have proven to be an important tool in cancer biology both in basic 
and translational research. The most widely used models of breast cancer are transgenic models that 
employ the use of viral oncogenes (e.g., simian virus 40 [SV40] large T antigen [Tag], polyoma 
middle T antigen [PyMT]), growth factors (e.g. transforming growth factor-β [Tgf-β]) or their 
receptors (e.g. ErbB2/neu), cell cycle regulators (e.g. Myc), regulators of differentiation (e.g. Wnt1), 
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and knockouts models of tumor suppressor genes (e.g. trp53, pRb). The majority of the transgenic 
models that have been developed use the mouse mammary tumor virus long terminal repeat (MMTV) 
or whey acidic protein (WAP) promoter/enhancer regions to drive gene expression in mammary 
epithelial cells (Hennighausen, 2000). 
The two mouse models we employ are the polyoma middle T antigen (PyMT) model in 
which MMTV drives expression of the PyMT tyrosine kinase oncoprotein (Guy et al., 1992), and the 
large T antigen model in which the rat C3(1) prostatic steroid binding protein promoter drives 
expression of the Tag oncogene (Maroulakou et al., 1994). Tumor formation in the MMTV-PyMT 
model usually occurs through the formation of a PyMT-p60c-src complex, which results in 
autophosophorylation of p60c-src tyrosine kinase, resulting in enhanced activity and transformation 
(Courtneidge and Smith, 1983; Courtneidge et al., 1986). In contrast, tumor formation in the C3(1)-
Tag model results from binding and inactivation of the p53 and pRB tumor suppressor genes 
(reviewed in Ali and DeCaprio, 2001). 
These two mouse models have been useful in the study of breast cancer, because they 
histopathologically and molecularly recapitulate human breast cancers. MMTV-PyMT tumors 
represent the luminal B molecular subtype, exhibiting low expression of the estrogen receptor with 
variable expression of ErbB2 in lesions at the carcinoma stage. C3(1)-Tag tumors represent basal-like 
breast cancers, showing a distinct lack of expression of both the estrogen and progesterone receptors, 
as well as ErbB2, and aberrant expression of cell cycle proteins. Furthermore, both models show 
progressive histopathologic tumor progression that are similar in organization to human breast tumors 
(Lin et al., 2003; Green et al., 2000k). In addition to being relevant models of human breast cancer, 
these transgenic models are useful in that they provide intact microenvironments and immune systems 
that are necessary for studying the contributions of tumor stroma to disease progression and 
therapeutic response. 
While these transgenic models have proven to be very useful, there are a few shortcomings of 
these systems that include non-specific expression of viral oncogenes and large tumor burden.  The 
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promoters used to drive expression of PyMT or Tag are active in other tissues in addition to the 
mammary glands; in both the MMTV-PyMT and C3(1)-Tag models, the primary tissue outside of the 
mammary glands in which tumors arise are the salivary glands. It is interesting to note that the C3(1)-
Tag model was originally developed as a prostate cancer model, and that C3(1) is a “prostate 
specific” promoter. Indeed, while male mice develop prostate intraepithelial neoplasias that progress 
to invasive carcinomas similar to those observed in humans, female mice develop mammary tumors 
with 100% penetrance, although the reasons for mammary-specific expression of C3(1) are still 
unknown. Another shortcoming of both these models is that multiple tumors form in multiple 
mammary glands, resulting in high overall tumor burden that is often not physiologically relevant to 
human cancers.  
 
Intravital imaging as a tool for studying the tumor microenvironment in vivo 
The primary means of studying cancer processes in vivo have been measurements of tumor 
size and the immunohistochemical (or immunofluorescent) staining of tissues derived from animal 
models. However, advancements in microscopy and fluorescent reporters over the past two decades 
have enabled the visualization of various inter- and intracellular processes at high resolution in live, 
anesthetized animals (Pittet and Weissleder, 2011). These intravital microscopy technologies have 
proven to be especially invaluable for spatially and temporally dissecting the in vivo dynamics of 
tumor-stroma interactions (Lohela and Werb, 2010). Processes that have been unraveled by intravital 
imaging include anti-tumor T cell cytotoxicity (Boissonnas et al., 2007; Breart et al., 2008), the 
dynamics of changes in collagen composition and organization following therapeutic treatment 
(Brown et al., 2003), macrophage-dependent cancer cell intravasation and metastasis (Wyckoff et al., 
2007), and vascular permeability (Yuan et al., 1994). 
There are three major requirements for intravital imaging. These include appropriate 
preparation and exposure of tissues for imaging, fluorescent labeling of the tissue components of 
interest, and a paired microscopy-camera system capable of acquiring images (Jain et al., 2002). The 
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most common strategies used to address the these requirements include: heterotopic preparations (e.g. 
inoculation of the ear or eye orbital), permanent imaging windows, or exteriorized preparations (e.g. 
dorsal skin flap); transgenic fluorescent reporters and fluorescent injectables to label tissues; and 
multiphoton or confocal microscopy systems paired with charge-coupled device (CCD) cameras 
(Lohela and Werb, 2010). In our laboratory, using the polyoma middle T antigen mouse model of 
luminal breast cancer as our primary experimental system, we combine transgenic reporters with 
fluorescent injectables (Table 2) to visualize different components of the tumor microenvironment. 
Animals are anesthetized and a skin flap is surgically prepared to expose the inguinal mammary gland 
for imaging. Images are obtained over a period of 12 to 40 hours using an intensified CCD (ICCD) 
camera paired with a four-laser spinning disk confocal microscope system (Egeblad et al, 2008). 
Imaging in this manner has allowed us to study such processes as in vivo drug distribution, stage-
dependent chemotherapeutic responses, in vivo mechanisms of chemotherapy-induced cell death, and 
myeloid cell behavior (Nakasone et al., 2012). 
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Label Type Localization 
ACTB-ECFP Transgenic All cells; used to identify cancer cells 
ACTB-H2B-EGFP Transgenic Nuclei; most visible in nuclei in which the chromatin is decondensed 
c-fms-EGFP Transgenic All myeloid cells 
Lycopersicon esculentum lectin Injectable Blood vessels 
Propidium Iodide Injectable Dead/dying cells 
Ricinus communis agglutinin I Injectable Blood vessels; basement membrane exposed to the vascular lumen 
 
Table 2. Fluorescent labels used to visualize components of the tumor microenvironment. 
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Results 
 
MMTV-PyMT mammary tumors respond to doxorubicin 
In order to understand how various components of intact tumor tissues respond to cytotoxic 
chemotherapeutics, we needed a system in which tumors respond reasonably well to treatment. We 
examined two different mouse models representing two major molecular subtypes of breast cancer, 
whose tumors undergo stage-specific progression and show distinct, but relatively homogeneous 
molecular and histological pathologies (Herschkowitz et al., 2007, Figure 2A-B). These two models 
are the luminal-like MMTV-PyMT model where the murine mammary tumor virus promoter drives 
expression of the polyoma middle T antigen (Guy et al., 1992), and the basal-like C3(1)-Tag model 
where the rat C3(1) promoter drives expression of the simian virus 40 large T antigen (Maroulakou et 
al., 1994). 
MMTV-PyMT and C3(1)-Tag tumor-bearing mice were administered doxorubicin or 
phosphate-buffered saline (PBS) on days 0, 7, and 14, and tumors were measured 2-3 times a week by 
caliper. Doxorubicin treatment significantly reduced tumor volume in MMTV-PyMT mice, as 
compared to PBS-treated control mice (Figure 3A, error depicted as mean ± SEM, where n = 11 
doxorubicin-treated mice with 73 tumors, n = 12 PBS-treated mice with 56 tumors, p < 0.0001 at all 
time points, two-tailed Student’s t-test). In contrast, treatment with doxorubicin did not reduce tumor 
volume in C3(1)-Tag mice as compared to PBS-treated controls (Figure 3B, error depicted as mean ± 
SEM, n = 7 PBS-treated mice with 23 tumors, n = 9 doxorubicin-treated mice with 23 tumors, p = NS 
at all time points, Student’s t-test). Thus, we focused the remainder of our studies on the MMTV-
PyMT mouse model. 
 
MMTV-PyMT tumors relapse despite initial response 
Although MMTV-PyMT mice treated with doxorubicin respond well to treatment, showing a 
decrease in total tumor burden (defined as the sum of the volumes of each tumor present/measured in 
the animal), virtually all tumors relapse following cessation of chemotherapy. Throughout the course 
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Figure 2. Histopathologic progression in two mouse models of breast cancer. (A) MMTV-PyMT 
model of luminal breast cancer. (B) C3(1)-Tag model of basal breast cancer. Scale = 50 μm.
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Figure 3. Tumor response to doxorubicin. (A) Tumors of MMTV-PyMT mice are sensitive to 
doxorubicin, while tumors of C3(1)-Tag mice are not (B). Doxorubicin was administered on the days 
desginated with red arrowheads. Error given as mean ± SEM, p-value based on two-tailed Student’s 
t-test at each time point.
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of chemotherapy treatment, the smallest and largest tumors showed a trend toward being refractory to 
treatment (Figure 4A, n = 10 mice, tumors sorted based on size at the start of treatment, % change in 
volume shown for each tumor 18 days after the first doxorubicin treatment, each color represents a 
different mouse), and new tumor lesions continued to form, albeit at a slower rate, throughout the 
treatment period (Figure 4B, error depicted as mean ± SEM, n = 12 PBS-treated mice with 20 new 
tumors appearing during treatment, n = 11 doxorubicin-treated mice with 18 new tumors appearing). 
MMTV-PyMT tumors that did respond to doxorubicin treatment (usually those measuring 
approximately 8 to 12 mm in the longest diameter) showed signs of becoming refractory to treatment 
(Figure 4C, n = 73 tumors from 11 doxorubicin-treated mice, error depicted as mean ± SEM). On 
average, tumors that responded to the first dose of doxorubicin were less responsive and quicker to re-
grow after each subsequent dose was administered. In addition, by three weeks after the first dose, 
nearly every one of these tumors had reached or surpassed its volumetric size at the start of treatment.  
 
Doxorubicin response is tumor stage-dependent 
That the smallest and largest tumors were mostly insensitive to doxorubicin, and that lesions 
sensitive to doxorubicin at the start of treatment became increasingly resistant to therapy with each 
subsequent dose, led us to hypothesize that doxorubicin response might be tumor stage-dependent. To 
determine the effect of doxorubicin treatment on different tumor stages, we used a combination of 
spinning disk confocal microscopy of live, tumor-bearing mice (Egeblad et al., 2008) and 
immunohistological analyses. While volumetric measurements based on caliper readings are difficult 
to translate into histopathologic staging of tumors, we used the generalization that small tumors tend 
to consist primarily of hyperplastic lesions, while large tumors tend to contain primarily late 
carcinoma lesions. Furthermore, for the pathologic staging of tumors in intravital imaging 
experiments and tissue stains, we classified lesions based on our own modification of a system 
previously described for MMTV-PyMT tumors, that takes into account cell morphology, organization 
of the ECM, and immune cell infiltration (Lin et al., 2003). We staged tumors for intravital imaging 
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Figure 4. MMTV-PyMT tumors show therapeutic resistance to doxorubicin. (A) Waterfall plot of 
the percent change in tumor volume 18 days after the first doxorubicin treatment shows that the 
smallest and largest tumors tend to be refractory to treatment. Each color represents a different mouse, 
and tumors are arranged from smallest to largest as measured at the start of treatment. (B) New tumors 
form, albeit at a slower rate, after doxorubicin treatment. (C) Tumors of doxorubicin-treated mice 
relapse and become increasingly refractory to treatment despite initial response.  Error depicted as 
mean ± SEM. Doxorubicin was administered on the days desginated with red arrowheads.
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experiments as follows: hyperplastic lesions were small lesions with very few infiltrating myeloid 
cells; early carcinoma stages were larger, and showed myeloid cell infiltration and a few blood 
vessels; late carcinomas were large, very densely packed lesions containing many highly abnormal 
blood vessels (see Figure 7 for example, see Egeblad et al., 2008 for further details). We staged 
tumors for histopathologic and immunohistochemical analyses as follows: hyperplastic lesions were 
those exhibiting cancer cell hyperproliferation, with intact basement membrane and remnants of 
ductal structures; early carcinomas were those that exhibited cancer cell invasiveness without any 
recognizable ductal structures, immune cell infiltration, and maintained some degree of “normal” 
stromal tissue (e.g. adipocytes); late carcinomas were very densely packed tissues with highly 
invasive and often undifferentiated cancer cells, exhibiting high degrees of immune cell infiltration 
and areas of high ECM deposition  (see Figure 2 for example). 
We found that tumors responded to doxorubicin with significant decreases in tumor volume 
that are measurable by caliper as early as 24 hours after treatment (Figure 5, error depicted as mean ± 
SEM, n = 89 tumors from 9 mice for PBS-treated controls, and n = 96 tumors from 10 mice for 
doxorubicin-treated mice; change in tumor volume as compared to 0 h for PBS-treated animals, p = 
NS at both time points, change in tumor volume as compared to 0 h for doxorubicin-treated animals, 
p = 4.5 × 10-6 at 24h, p = 3.0 × 10-10 at 48h using a paired two-tailed Student’s t-test; difference in 
tumor volume between PBS- and doxorubicin-treated mice, p = 0.88 at start of treatment, p = 0.02 at 
24h, p = 4.2 × 10-10 at 48h using a two-tailed Student’s t-test). In order to analyze the effects of 
doxorubicin on different tumor stages, we therefore chose to study the acute response to doxorubicin 
treatment, up to 48 hours after treatment. 
For in vivo imaging experiments, MMTV-PyMT mice were first crossbred with ACTB-ECFP 
and c-fms-EGFP reporter mice, so that cancer cells were labeled with enhanced cyan fluorescent 
protein (ECFP) and all myeloid cells were labeled with enhanced green fluorescent protein (EGFP), 
(Figure 6). Expression of these reporters enabled visualization of tumor lesions at different stages and 
tracking of myeloid cells, which represent one of the most abundant stromal components of murine 
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Figure 5. Tumor response to doxorubicin can be detected by caliper measurement as early as 24 
hours after treatment. Error depicted as mean ± SEM. p-value based on two-tailed Student’s t-test.
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Figure 6. Representative still image from a time-lapse movie of a multicolor spinning disk 
confocal intravital imaging experiment. ACTB-ECFP labels cancer cells. c-fms-EGFP labels 
myeloid cells. Propidium iodide labels dying cells. Scale = 100 μm.
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breast tumors (Egeblad et al., 2010). Dead cells were labeled during the imaging session by i.p. 
administration of propidium iodide (PI). Because the mammary glands of MMTV-PyMT mice 
frequently harbor multiple lesions often at different stages of progression, we were able to image 
doxorubicin responses at different tumor stages within the same mouse (Figure 7), controlling for 
mouse-to-mouse variation. 
Mice with inguinal mammary tumors measuring approximately 8 to 10 mm in size were 
administered a single dose of doxorubicin 14 to 30 hours prior to imaging, and imaged for 8 to 40 
hours. Untreated control mice were imaged for similar lengths of time to control for photo-damage 
and any other artifacts that may arise due to the imaging procedure. We imaged approximately five 
fields per tumor, with three optical slices per field in the z-plane. 
Visual inspection of these movies revealed that cell death preferentially occurs in early 
carcinoma lesions. On average, 86% of the Fields Of View (FOV) at the early carcinoma stage were 
positive for PI 31 hours after doxorubicin-treatment, as compared to 12.5% of the FOV of the 
controls (Figure 8A, for = 4 of 23 total FOV from 4 control mice and n = 16 of 25 total FOV from 4 
doxorubicin-treated mice where p = 0.001; for hyperplastic FOV, n = 1 of 8 control versus 1 of 4 
doxorubicin-treated, where p = NS; for early carcinoma FOV, n = 1 of 8 control versus 12 of 14 
doxorubicin-treated, where p = 0.002; for late carcinoma FOV, n = 2 of 7 control versus 3 of 7 
doxorubicin-treated, where p = NS; statistics based on Fisher’s exact test). In contrast, cell death did 
not increase in hyperplastic or late carcinoma lesions after doxorubicin treatment as compared to 
control lesions. Furthermore, quantification of the percentage of tumor area in each field that is 
positive for PI shows a significantly higher average amount of PI in early carcinomas treated with 
doxorubicin as compared to control tumor fields at both 26 hours (Figure 8B, error depicted as mean 
± SEM, n = 8 control and 4 doxorubicin-treated hyperplastic FOV where p = NS, n = 8 control and 14 
doxorubicin-treated early carcinoma lesions where p = 0.04, n = 7 control and 7 doxorubicin-treated 
late carcinoma lesions where p = NS, two-tailed Student’s t-test) and 31 hours (Figure 8C, error 
depicted as mean ± SEM, n = 8 control and 4 doxorubicin-treated hyperplastic FOV where p = NS, n 
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Figure 7. Progressive MMTV-PyMT mouse model allows for imaging different tumor stages in 
the same mouse. Time indicates hh:mm elapsed since doxorubicin treatment. Scale = 100 μm. Note:  
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Figure 8. Intravital imaging shows lesions resembling early carcinomas are the most sensitive to 
doxorubicin. (A) Cell death increases primarily in early carcinoma lesions during the time period 
between 26 and 31 hours following doxorubicin treatment. p-values are based on Fisher’s exact test. 
(B) Quantification of cell death (as the average of the percent area of the field positive for propidium 
iodide) in hyperplastic, early, and late carcinoma lesions of doxorubicin-treated mice as compared to 
those of PBS-treated mice 26 hours after injection. (C) Quantification of cell death 31 hours after 
treatment. p-values for (B) and (C) are based on two-tailed Student’s t-tests.
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= 8 control and 14 doxorubicin-treated early carcinoma lesions where p < 0.0001, n = 7 control and 7 
doxorubicin-treated late carcinoma lesions where p = NS, two-tailed Student’s t-test). Again, there is 
no difference in the average percentage of PI-positive tumor areas between control fields and 
doxorubicin-treated tumor fields at both the hyperplastic and late carcinoma stages at either time 
point. These data suggest marked differences in drug sensitivity between tumor stages.  
To corroborate these finding, we performed immunohistochemical staining for 
phosphorylation of histone H2A variant H2AX at serine 139 (also known as γ-H2AX), a marker of 
DNA double-stranded breaks (Redon et al., 2002). We used γ-H2AX as a surrogate marker for 
doxorubicin activity, as doxorubicin is a DNA-intercalating agent that inhibits type II topoisomerases, 
and leads to double-stranded breaks (Pommier et al., 2010). Furthermore, this method of tissue 
staining afforded us a more reliable means of staging tumors, as hematoxylin counterstaining 
provides details about tissue structure that are not clear by intravital imaging. By this analysis, cancer 
cells in the early carcinoma stage also accumulate more DNA damage 48 hours after doxorubicin 
treatment, as compared to those at the hyperplastic or late carcinoma stages (Figure 9, error depicted 
as mean ± SEM, p-value by one-way ANOVA < 0.0001, n = 5 mice, 1 tumor per mouse with 21 
hyperplastic FOV, 25 early carcinoma FOV, and 24 late carcinoma FOV; for hyperplasia versus early 
carcinoma, p < 0.01 with Bonferroni post-test; for early carcinoma versus late carcinoma, p < 0.0001 
with Bonferroni post-test). Thus, doxorubicin sensitivity is tumor stage-dependent. 
 
In situ differences in cancer cell proliferation do not account for differences in doxorubicin 
sensitivity 
As previously mentioned, doxorubicin is a DNA-intercalating agent and a type II 
topoisomerase inhibitor (Pommier et al., 2010). As topoisomerases are active during cell 
proliferation, acting to relieve DNA supercoils introduced during replication, actively cycling cells 
are expected to be most sensitive to doxorubicin (Campiglio et al., 2003). We therefore tested 
whether the differences in doxorubicin response between tumor stages are due to differences in 
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Figure 9. γ-H2AX staining for DNA damage confirms stage-specific doxorubicin sensitivity 
observed in intravital imaging experiments. (A) Representative images of anti-γ-H2AX 
immunohistochemical staining. Scale = 50 μm. (B) Quantification of γ-H2AX staining. p-values based 
on two-tailed Student’s t-test.
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proliferation. MMTV-PyMT tumor-bearing mice were administered 5-bromo-2ʹ′-deoxyuridine (BrdU) 
prior to doxorubicin treatment, and tumors were harvested 24 or 48 hours after doxorubicin treatment. 
Immunohistochemical staining for BrdU (Figure 10A) showed non-significant differences in 
proliferation between hyperplastic, early, and late carcinoma stages. (Figure 10B, error depicted as 
mean ± SEM, p = NS by one-way ANOVA, n = 6 tumors from 3 mice, with 13 hyperplastic FOV, 19 
early carcinoma FOV, and 28 late carcinoma FOV). This suggests that differences in cellular 
proliferation between tumor stages are not sufficient to explain differences in doxorubicin sensitivity 
in vivo. 
 
Tumor stage-associated doxorubicin sensitivity is microenvironment-dependent 
Breast cancer cells can acquire various molecular changes as they progress from hyperplastic 
lesions to invasive tumors (Bombonati and Sgroi, 2011), and frequently, these changes can give rise 
to changes in sensitivity to chemotherapeutic treatment (Gonzalez-Angulo et al., 2007). Thus, we 
tested whether differences in doxorubicin sensitivity could be attributed to molecular differences 
specific to different tumor stages. To focus exclusively on cancer cell-dependent resistance, cancer 
cells isolated from different tumor stages were tested in the same microenvironment by culturing in 
vitro, either in standard two-dimensional cultures or embedded as carcinoma organoids in MatrigelTM 
in three-dimensional cultures. To determine whether intrinsic differences contributed to stage-specific 
differences in doxorubicin sensitivity, we needed a molecular target that could act as a positive 
control. MMTV-PyMT is a useful model system, because in addition to showing stage-specific 
histopathology, tumors also undergo characteristic molecular changes through progression, including 
down-regulation of the estrogen (ER) and progesterone (PR) receptors and upregulation of the 
ErbB2/Neu receptor tyrosine kinase (Lin et al., 2003). 
We used sensitivity to lapatinib ditosylate (trade name Tykerb, hereafter referred to as 
lapatinib), an ErbB1/2 inhibitor used in the clinic to treat HER2+ breast cancers (Bilancia et al., 
2007) as our positive control. Tumors at the hyperplastic, early, and late carcinoma stages in 
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Figure 10. Differences in proliferation between tumor stages do not account for differential 
sensitivity to doxorubicin. (A) Representative images of anti-BrdU immunohistochemical staining. 
Scale = 25 μm. (B) Quantification of BrdU staining. p-values based on one-way ANOVA.
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untreated MMTV-PyMT;ACTB-ECFP mice were microdissected using a fluorescence dissecting 
microscope (Figure 11A). Cancer cells from different tumor stages were separated from stromal 
components, grown in two-dimensional culture, and treated with increasing doses of lapatinib. As 
expected, tumors at the late carcinoma stage were highly sensitive to lapatinib treatment, even at low 
doses, while hyperplastic and early carcinoma lesions were insensitive to lapatinib unless high doses 
were used (Figure 11B, error depicted as mean ± SEM, values represent 4 experiments, each done in 
triplicate, p = 0.04 for cancer cells from hyperplastic lesions as compared to cancer cells from early 
carcinomas at 1 µM [lapatinib], p = 0.02 for cancer cells from early carcinomas as compared to 
cancer cells from late carcinomas at 1 µM [lapatinib], using a two-tailed Student’s t-test). 
We then tested the sensitivity of cancer cells isolated from different tumor stages to 
doxorubicin in three-dimensional organoid culture. Unlike the results obtained for the lapatinib 
experiments, cancer cells showed no difference in tumor stage-dependent doxorubicin sensitivity ex 
vivo (Figure 12A-B, error depicted as mean ± SEM, values are representative of 4 experiments, each 
done in triplicate, p = NS for all stages at all doxorubicin concentrations, using two-tailed Student’s t-
tests). These results indicate that the stage-dependent doxorubicin sensitivity we observe in vivo is 
most likely due to differences in the tumor microenvironment. 
 
Doxorubicin treatment alters the tumor-associated inflammatory microenvironment 
In addition to cancer cell-intrinsic changes, the microenvironment undergoes changes in both 
composition and organization during progression and chemotherapy response (Polyak and Kalluri, 
2010). Intravital imaging experiments of MMTV-PyMT;ACTB-ECFP;c-fms-EGFP mice showed 
that myeloid cells were recruited into tumors after doxorubicin treatment (Figure 13, n = 12 of 16 
fields for doxorubicin-treated tumors, n = 3 of 16 movies for control tumors, p = 0.004 using Fisher’s 
exact test). Furthermore, the highest degree of myeloid cell infiltration occurred in areas exhibiting a 
high degree of cell death (Figure 14). The structures formed by these infiltrating myeloid cells 
appeared to be similar to granulomas, which are frequently formed in response to chronic infection. 
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Figure 11. MMTV-PyMT cancer cells show tumor stage-dependent sensitivity to the ErbB1/2 
inhibitor lapatinib ex vivo. (A) Microdissected lesions from MMTV-PyMT; ACTB-ECFP mice at the 
indicated stages of tumor progression. Below are the associated changes in expression of hormone 
receptors and the ErbB2 receptor. Scale = 1 mm. (B) Tumors show increasing sensitivity to lapatinib 
with progression. Error depicted as mean ± SEM. p-value based on two-tailed Student’s t-test.
Lapatinib Concentration
1 μM
0
50
100
A
bs
or
ba
nc
e 
at
 4
90
 n
m
 (%
 o
f u
nt
re
at
ed
)
p = 0.04
p = 0.02
10 μM
Hyperplasia Early Carcinoma Late CarcinomaB.
NS
NS
45
Doxorubicin Concentration
0.1 μM
0
50
100
A
bs
or
ba
nc
e 
at
 4
90
 n
m
 (%
 o
f u
nt
re
at
ed
)
Hyperplasia Early Carcinoma Late CarcinomaB.
1.0 μM 2.0 μM 5.0 μM
NS
NS
NS
NS
5 µM2 µM0 µM
H
yp
er
pl
as
ia
Ea
rly
 C
ar
ci
no
m
a
La
te
 C
ar
ci
no
m
a
A.
Figure 12. MMTV-PyMT cancer cells do not show tumor stage-dependent sensitivity to 
doxorubicin ex vivo. (A) Representative images of ex vivo doxorubicin response. Scale = 50 µm. (B) 
Quantification of doxorubicin response in 3D culture shows no difference in tumor stage-dependent 
drug sensitivity.  Error depicted as mean ± SEM. p-value based on two-tailed Student’s t-test.
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Figure 13. Doxorubicin treatment alters the innate inflammatory microenivronment. 
Quantification of myeloid infiltration during intravital imaging. p-value based on Fisher’s exact test.
47
Figure 14. Intravital imaging shows that the highest degree of myeloid infiltration occurs in areas 
exhibiting the highest degrees of cell death. Representative time series. Time represents hh:mm 
elapsed since doxorubicin treatment. Scale = 100 μm.
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We could further confirm this by imaging the tumors of MMTV-PyMT;ACTB-ECFP;c-fms-EGFP 
mice treated with doxorubicin at high-resolution (40×) magnification, which allowed us to observe 
chemotherapy-induced death in individual cancer cells. These experiments confirmed that cancer cell 
death, as evidenced by the accumulation of PI staining in single cells, was followed by infiltration of 
immune cells into the area surrounding these dying cells (Figure 15). 
 
Doxorubicin induces necrosis in vivo 
Anthracyclines have been reported to induce two forms of cell death capable of activating an 
immune response, necrosis and apoptosis (Demoy et al., 2000). To better understand the mechanism 
by which myeloid cells are being recruited into dying tumors and the impact of this recruitment in 
tumor response, we first needed to determine how doxorubicin was inducing cell death. 
We therefore performed intravital imaging at high magnification (40×) of tumors from 
MMTV-PyMT mice cross-bred with ACTB-ECFP and ACTB-H2B-EGFP (Hadjantonakis and 
Papaioannaou, 2004, hereafter referred to as H2B-EGFP) reporter mice. Expression of these 
reporters allowed us to visualize all cancer cells (ECFP) and their nuclei (EGFP). MMTV-
PyMT;ACTB-ECFP;H2B-EGFP mice were administered doxorubicin approximately 30 hours before 
the start of imaging (this time point was chosen because our previous imaging experiments showed 
that cell death started becoming apparent between 24 and 30 hours after doxorubicin treatment, see 
Figure 7). Dead cells were labeled during the imaging session with PI. 
Visual inspection of these movies indicated that there were at least two observable 
mechanisms by which doxorubicin induces cell death in vivo. By far the most common mechanism 
was one in which nuclei maintained their morphology, but gradually acquired PI staining, indicating 
late breakdown of plasma membrane integrity and necrosis. Much less common was a mechanism in 
which major nuclear changes were followed by the formation of chromatin foci that eventually 
became PI positive, a sign typical of apoptosis (Dive et al., 1992). We quantified these two 
mechanisms using the following criteria: a necrotic phenotype was defined as one in which PI-
49
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Figure 15. Myeloid cell recruitment occurs after induction of cell death. Red arrows indicate dying 
cancer cells, as determined by the appearance of propidium iodide staining. White arrows indicate 
myeloid cells recruited to dying tissue. Time represents hh:mm elapsed since doxorubicin treatment. 
Scale = 10 μm.
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positive cells showed maintenance of normal nuclear morphology over time, while an apoptotic 
phenotype was one in which PI-positive cells showed abnormal nuclear morphology resembling 
apoptotic bodies (Figure 16A). These two mechanisms were quantified manually in maximum 
intensity projections (3 z-planes) acquired for each field at the 32- and 42-hour time points after 
doxorubicin administration. This analysis showed us that at both time points, the predominant form of 
doxorubicin-induced cell death was necrosis (Figure 16B, error depicted as mean ± SEM n = 18 fields 
from 3 mice, p = 0.009 at 32 h, p < 0.001 at 42 h, two-tailed Student’s t-test). 
 
The presence of necrotic debris is sufficient to recruit myeloid cells 
Necrosis is known to be a highly immunogenic form of cell death, capable of recruiting cells 
of both the innate and adaptive arms of the immune systems (Kepp et al., 2009;  Vakkila and Lotze, 
2004). In order to confirm that debris generated from cancer cells that had undergone necrosis was 
stimulating the recruitment of myeloid cells into tumors following doxorubicin treatment, we wanted 
to use a system that was independent of any tumor-derived factors that may influence recruitment, as 
well as any effects beyond induction of cancer cell death that doxorubicin might have, such as killing 
of myeloid cells. Thus, we first harvested tumors from MMTV-PyMT mice, labeled them ex vivo 
with CellTrackerTM Red, and generated necrotic debris. These cells were then combined with a 
fluorescently conjugated dextran (to label host tissue) and injected directly into mammary glands of 
non-tumor bearing c-fms-EGFP reporter mice. Control areas in the same mammary gland were 
injected with dextran alone. 
We observed that in areas injected with the dextran alone, there was very little recruitment of 
myeloid cells. However, in areas in which we had injected necrotic debris, there was massive 
infiltration of the tissue with myeloid cells and the formation of granuloma-like structures, similar to 
what we previously observed in tumor areas with large regions of dead or dying cancer cells. Because 
the presence of necrotic debris is sufficient to trigger myeloid cell recruitment, we concluded that 
doxorubicin-induced necrosis probably plays a major role in the recruitment of myeloid cells into 
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Figure 16. In vivo dynamics of cell death show doxorubicin primarily induces necrosis in cancer 
cells. (A) Representative images of apoptotic and necrotic cell death in vivo. Scale = 10 μm. (B) 
Quantification of cell death based on morphology at 32 and 42 hours after doxorubicin treatment. 
p-values based on two-tailed Student’s t-test.
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tumors (Figure 17). 
 
Recruitment of myeloid cells to areas containing necrotic debris is dependent on chemokine 
receptor signaling 
Further analysis of the movies generated from imaging necrotic debris injected into normal 
mammary glands showed that directional migration toward areas containing debris occurred only 
after tissue-resident myeloid cells had interacted with and recognized the debris. This implied that 
resident myeloid cells that detected the debris were releasing some sort of chemoattractant signal. The 
signaling molecules usually responsible for directional migration of myeloid cell are chemokines, and 
the receptor systems that respond to these signals belong to the Gi-protein-coupled receptor family 
(GiPCR, Balkwill, 2004). To confirm that signaling through a chemokine/chemokine receptor 
pathway was regulating myeloid cell infiltration into areas containing necrotic debris, we pre-treated 
non-tumor bearing c-fms-EGFP reporter mice with pertussis toxin, a pan-GPCR inhibitor (Cubillos et 
al., 2010), 12 hours before injection of necrotic debris into the mammary gland, and once again just 
prior to injection of debris and imaging. Inhibition of GiPCR signaling dramatically inhibited the 
recruitment of myeloid cells into areas containing necrotic debris (Figure 18, error depicted as mean ± 
SD, n = 6 fields per condition from two mice; * p = 0.003, ** p < 0.0001, two-tailed Student’s t-test at 
each time point), confirming that this process is dependent on chemokine receptor signaling.  
 
Intratumoral expression of the chemokines CCL2 and CCL12 is upregulated following 
doxorubicin treatment 
Because inhibition of GiPCR signaling prevented the recruitment of myeloid cells into tissues 
containing necrotic debris, we predicted that this same type of signaling pathway was at play when 
myeloid cells were recruited to MMTV-PyMT tumors undergoing doxorubicin-induced necrosis. To 
determine the chemokine/chemokine receptor pair(s) responsible for myeloid cell infiltration, we 
assayed for both cytokines and chemokines that were differentially expressed in the tumors of PBS- 
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Figure 17. Tumor-derived necrotic debris recruits myeloid cells. Injection of necrotic debris (with 
dextran to label the surrounding tissue) into the normal mammary glands of c-fms-EGFP reporter mice  
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Figure 18. Inhibition of Gi-protein-coupled receptor signaling abrogates recruitment of myeloid 
cells. c-fms-EGFP reporter mice were pre-treated with pertussis toxin 12 hours before and again 
immediately prior to injection with necrotic debris and imaging. p-values based on two-tailed Student’s 
t-test at each time point. * p = 0.003, ** p < 0.0001.
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and doxorubicin-treated mice. Whole tumor lysates of tissues harvested from mice 48 hours after 
treatment were applied to a spotted antibody array that detects ~40 cytokines and chemokines (R&D 
Systems). Two chemokines, CCL2 and CCL12, showed increased expression in the tumors of 
doxorubicin-treated mice, as compared to those of PBS-treated controls. Expression of two other 
molecules, macrophage colony stimulating factor (M-CSF/CSF1) and tissue inhibitor of 
metalloproteinase 1 (TIMP-1) were also slightly upregulated in the tumors of doxorubicin-treated 
mice (Figure 19A, n = 6 mice per treatment, 1 tumor per mouse). 
To confirm the upregulation of CCL2 and CCL12, we performed enzyme-linked 
immunosorbent assays (ELISA). There was a strong trend for increased expression of these two 
chemokines in the tumors of doxorubicin-treated mice as compared to those of PBS-treated control 
mice (Figure 19B-C, n = 12 mice per treatment, 1 tumor per mouse, p = NS for both CCL2 and 
CCL12, two-tailed Student’s t-test). The results did not reach significance, most likely a reflecting the 
heterogeneity of MMTV-PyMT tumor responses to doxorubicin, and the difficulties of detecting 
chemokines in whole tumor lysate. 
 
CCL2 is stromally-derived 
Mouse CCL2 (also known as monocyte chemoattractant protein-1, MCP-1) and CCL12 (also 
known as MCP-5) are both orthologues of the human CCL2 gene (Yoshimura et al., 1989; Sarafi et 
al., 1997) and potent chemoattractants for monocytes (Tsui et al., 2007). We focused our efforts on 
understanding the consequences of CCL2 upregulation, as it is one of the best-studied (and first-
identified) chemokines whose functions overlap with those of CCL12. CCL2 is known to be involved 
in the recruitment of myeloid cells into sites of inflammation, as well as into tumor tissues, and has 
been highly implicated in autoimmune and chronic disease (Deshmane et al., 2009). 
We first sought to identify the cell population that expresses CCL2. We used 
immunofluorescence staining for CCL2, as this would provide us with the ability to both quantify the 
number of cells that express CCL2 and determine their localization. CCL2 immunostaining was 
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Figure 19. The chemokines CCL2 and CCL12 are upregulated in tumors of doxorubicin-treated 
mice. (A) Cytokine array on whole-tumor lysate shows upregulation of CCL2 and CCL12. CCL2 (B) 
and CCL12 (C) ELISA confirm upregulation.
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performed on tumor tissues harvested 48 hours after treatment. These stains showed a significantly 
higher number of CCL2-postive cells in tumors derived from doxorubicin-treated mice as compared 
to those from PBS-treated controls (Figure 20B, n = 6 mice per treatment, 1-2 tumors per mouse, 80 
fields from PBS-treated mice, 66 fields from doxorubicin-treated mice, error depicted as mean ± 
SEM). Furthermore, cells that stained positively for CCL2 were confined to the stromal compartment 
(Figure 20A) 
We performed double label immunofluorescence stains to identify the stromal cell population 
that expresses CCL2. We combined staining of CCL2 with staining for the 7/4 (neutrophils and 
monocytes), CD206 (tumor-associated macrophages), α-smooth muscle actin (αSMA, fibroblasts and 
pericytes), and MECA-32 (endothelial cells) markers. We did not detect any CCL2 expression among 
neutrophils, fibroblasts, pericytes, and endothelial cells. Some monocytes and macrophages do 
express CCL2, but they did not account for the majority of the CCL2-positive cells (Figure 21). We 
speculate that CCL2 is expressed by dendritic cells (DC) based on the localization and morphology of 
these cells, but we were unable to confirm this prediction, as markers for DCs did not stain our 
tissues. 
 
CCL2 recruits CCR2-positive monocytes 
We next determined the cell population(s) that were responding to stromal CCL2. CCL2, as 
well as CCL12, are unique chemokines in that they bind exclusively to one receptor, the GiPCR 
CCR2 (Deshmane et al., 2009). Thus, we used a combination of flow cytometry and double label 
immunofluorescence staining to determine the population of cells expressing CCR2. 
We performed flow cytometric analyses on tumors isolated from transplantation models in 
which MMTV-PyMT cancer cells were orthotopically transplanted into syngeneic wildtype hosts. 
Mice were administered PBS or doxorubicin 48 hours prior to euthanization and harvesting of tumors. 
Staining for the CD11b (myeloid cell) and F4/80 (macrophage) markers, we observed no difference in 
the total number of CD11b+ nor the F4/80+CD11b+ double-positive immune cell populations by flow 
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Figure 20. CCL2 is stromally derived. (A) Representative image of an immunofluorescence stain for 
CCL2. Scale = 50 μm. Dashed lines indicate the boundary between tumor and stromal compartments. 
(B) Quantification of CCL2 stains performed on tissue from tumors harvested 48 hours after treatment. 
p-value based on two-tailed Student’s t-test.
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αSMA (fibroblasts, pericytes) MECA-32 (endothelial cells)
7/4 (neutrophils, monocytes)
CCL2     DAPI
CD206 (macrophages)
Figure 21. Double label immunostains show that CCL2 is expressed by some CD206-positive 
macrophages, but is not expressed by fibroblasts, pericytes, endothelial cells, or neutrophils. 
Representative images of indicated stains. Scale = 50 μm.
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cytometry (Figure 22C-D, error depicted as mean ± SEM, n = 11 PBS-treated mice with 1 tumor per 
mouse, n = 10 doxorubicin-treated mice with 1 tumor per mouse, two-tailed Student’s t-test), in the 
tumors of doxorubicin-treated mice, as compared to those of PBS-treated controls. We did, however, 
observe an increase in cells triple-positive for Gr1 (immature myeloid cells), 7/4, and CD11b (Figures 
22A-B, error depicted as mean ± SEM, n = 11 PBS-treated mice with 1 tumor per mouse, n = 10 
doxorubicin-treated mice with 1 tumor per mouse, two-tailed Student’s t-test). 
We could not confirm that the Gr1+7/4+CD11b+ population was also CCR2 positive by flow 
cytometry, as the antibodies targeting CCR2 that we tested detected a population of cells in Ccr2-/- 
mice (data not shown). Instead, we performed double-label immunostains for 7/4 and CCR2 in tumor 
tissue sections (the Gr1, 7/4, and CCR2 triple label stain could not be performed due to species 
limitations of the primary antibodies). Double label immunostains were quantified based on positivity 
for one or both of the markers used, as well as nuclear morphology. Differentiation based on nuclear 
morphology was important because the 7/4 marker detects both neutrophils and monocytes, which 
exert different effects on tumors (see Table 1), and monocytes have the propensity to differentiate 
into the tumor-associated macrophages that promote progression (Mantovani et al., 2002). 
Characterization of neutrophils and monocytes is simple, as they exhibit distinct nuclear 
morphologies: neutrophils, referred to as polymorphonuclear leukocytes, have multi-lobed nuclei; 
monocytes, referred to as mononuclear leukocytes, have single-lobed nuclei (Figure 23A). 
Quantification of these immunostains confirmed the increase in 7/4+ cells, and showed that 
this increase was almost exclusively confined to cells that expressed CCR2 and exhibited monocytic 
nuclear morphology (Figure 23B, error depicted as mean ± SEM, n = 4 mice with 1 tumor per mouse 
and a total of 104 FOV for the PBS group, n = 5 mice with 1 tumor per mouse and a total of 113 FOV 
for the doxorubicin group, p-values indicated are based on two-tailed Student’s t-tests). Although a 
small number of 7/4+ cells exhibiting neutrophilic morphology and positive for CCR2 were detected, 
there was no difference in the numbers of this cell population between tumors from doxorubicin- as 
compared to PBS-treated mice. This trend was also true of cells that expressed CCR2 but were 
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Figure 22. Flow cytometric analyses show increased numbers of Gr1+7/4+CD11b+ immature 
myeloid cells in the tumors of doxorubicin-treated mice. (A) Representative FACS plots for 
Gr1+7/4+CD11b+ triple stains of cells harvested from tumors 48 hours after the indicated treatment. (B) 
Quantification of Gr1+7/4+CD11b+ myeloid cells. (C) Quantificationof total CD11b+ myeloid cells. (D) 
Quantification of F4/80+CD11b+ macrophages. p-values based on two-tailed Student’s t-test. Error 
depicted as mean ± SEM.
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Figure 23. Double label immunostains for 7/4 and CCR2 show increased numbers of 
double-positive immune cells exhibiting a monocytic phenotype in the tumors of doxorubicin 
treated mice. (A) Representative images of neutrophils and monocytes and their staining patterns with 
7/4 and CCR2. Images taken at 63× magnification. (B) Quantification of double label 
immunofluroescence stains. p-values based on two-tailed Student’s t-test.
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negative for the 7/4 antigen. Additionally, the tumors of doxorubicin-treated mice showed a 
significant decrease in the number of cells that expressed the 7/4 antigen but were negative for CCR2, 
regardless of whether they exhibited a monocytic or neutrophilic morphology (Figure 23B). 
 
Small molecule antagonism of CCR2 in vivo 
The monocytic cells that are recruited to tumors can either be myeloid-derived suppressor 
cells (MDSCs) that inhibit anti-tumor immune responses (Lesokhin et al., 2011), or true monocytes 
that will differentiate into tumor-associated macrophages based on microenvironmental cues and 
promote tumor progression (Pollard, 2004). Distinguishing these two populations is, at present, 
difficult as they express the same cell-surface markers (CD11b and Gr1) and exhibit similar 
morphological properties. We hypothesized that the myeloid cells recruited after doxorubicin 
treatment are monocytes, as it has recently been shown that CCL2 recruits monocytes to primary 
murine breast tumors as well as metastatic sites (Qian et al., 2011).  Furthermore, stromal expression 
of CCL2 in human breast cancers is associated with both macrophage infiltration and decreased 
relapse-free survival (Fujimoto et al., 2009). For these reasons we predicted that inhibition of 
CCL2/CCR2 signaling would enhance the response to doxorubicin treatment. 
Inhibiting CCL2/CCR2 signaling is challenging because CCL12 – which is also upregulated 
in the tumors of doxorubicin-treated mice – also activates CCR2 and may compensate for loss of 
CCL2 activity. We therefore decided to focus on antagonizing CCR2, testing the small molecule 
inhibitor RS 504393 (CCR2i, Roche/Iconix, Higgins et al., 2007), which has been previously used 
successfully to inhibit monocyte recruitment in infection and autoimmune models (Yang et al., 2009; 
Yang et al., 2010). 
MMTV-PyMT tumor-bearing mice were pre-treated with either vehicle or RS 504393 every 
12 hours beginning three days before doxorubicin (or PBS) treatment and continuing until just before 
euthanization. Tumor measurements were taken at the start of treatment with vehicle or the inhibitor, 
and on days 0, 1, and 2 of doxorubicin or PBS treatment. Ultrasound was performed on 2-3 tumors 
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per mouse on days -3, 0, and 2 following doxorubicin treatment to determine whether inhibitor 
treatments influenced the degree of tumor necrosis or the occurrence of cystic areas. Flow cytometric 
analyses for the myeloid markers 7/4, F4/80, and Gr1 were performed on cells isolated from one 
tumor from each mouse to determine the effects of the CCR2i on myeloid cell recruitment. In 
addition, we imaged two mice treated with the inhibitor plus doxorubicin and two mice treated with 
the inhibitor plus PBS. 
The inhibitor treatment did not influence the tumor size in either doxorubicin- or PBS-treated 
mice (Figure 24, error depicted as mean ± SEM, n = 9 mice for vehicle with PBS, n = 10 mice for all 
other groups, p = NS for vehicle with PBS as compared to CCR2i with PBS at all time points, p = NS 
for vehicle with doxorubicin as compared to CCR2i with doxorubicin at all time points, two-tailed 
Student’s t-test). Furthermore, ultrasound also revealed no effects of CCR2i treatment on the response 
to doxorubicin (data not shown). Surprisingly, flow cytometric analyses showed a non-significant 
trend toward an increase in the F4/80+CD11b+ population, as well as a decrease in the 7/4+CD11b+ 
and Gr1+CD11b+ populations in tumors after doxorubicin plus CCR2i vehicle (DMSO) treatment as 
compared to the tumors of mice that received PBS plus the vehicle (Figure 25, error depicted as mean 
± SEM, n = 3 mice per group with 1 tumor per mouse). These results are opposite to those obtained in 
the comparison of the tumors from mice treated with doxorubicin to PBS without the CCR2i vehicle 
(see Figure 22). 
Imaging of inhibitor-treated mice also displayed results that are different from those observed 
in animals treated with PBS or doxorubicin alone (Figure 26). In the tumors of inhibitor-treated mice 
that received PBS, high degrees of cancer cell death and myeloid cell infiltration were observed. 
These results were surprising, as PBS treatment by itself does not result in the recruitment of myeloid 
cells, but might be caused by cancer cell death induced by CCR2i (although it is generally not the 
case, some cancer cells do stain positively for CCR2 by immunofluorescence, data not shown). In 
contrast, the tumors of inhibitor-treated mice that received doxorubicin, showed virtually no cancer 
cell death, but a high degree of myeloid cell death. The inhibitor is expected to affect myeloid cells, 
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Figure 24. Treatment of MMTV-PyMT tumor-bearing mice with the CCR2 inhibitor (CCR2i) RS 
504393 has no effect on tumor response to doxorubicin. p-values based on two-tailed Student’s t-test 
at each time point. 
-3 0 1 2
1.0
2.0
3.0
NS
N
or
m
al
iz
ed
 T
um
or
 B
ur
de
n
Vehicle + PBS
Vehicle + Doxorubicin
CCR2i + Doxorubicin
CCR2i + PBS
Time (days after first doxorubicin treatment)
NS
66
Figure 25. Flow cytometric analyses of vehicle-treated mice shows trends opposite to those 
observed in mice treated with PBS or doxorubicin alone. The comparison between mice treated with 
PBS or doxorubicin alone shows increases in the 7/4+CD11b+ and Gr1+CD11b+ populations after 
doxorubicin treatment, with a slight (but non-significant) decrease in the numbers of F4/80+CD11b+ 
population. Adding vehicle (DMSO) to these treatments shows trends towarad the opposite. p-values 
based on two-tailed Student’s t-test.
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Figure 26. Intravital imaging experiments of mice treated with RS 504393 shows cancer 
cell death in PBS-treated mice and stromal cell death in doxorubicin-treated mice. 
Animals treated with the inhibitor and PBS show high degrees of cancer cell death, while 
animals treated with the inhibitor and doxorubicin show high degrees of stromal cell death but 
virtually no cancer cell death. Both treatments result in the recruitment of myeloid cells. Time 
represents hh:mm elapsed since doxorubicin treatment. Scale = 100 μm.
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and it is possible that this could induce myeloid cell death. However, the absence of cancer cell death 
was highly unexpected. We speculate that the vehicle (DMSO) had a direct effect on the mice, as 
mice receiving vehicle alone showed signs of irritation, including sensitivity to touch. In conclusion, 
we have no data supporting that RS 504393 inhibited CCR2 at the dose and schedule used. 
 
Loss of CCR2 in the stromal compartment delays host relapse following cessation of 
doxorubicin treatment 
Because we were unable to use RS 504393, we decided to use a transplantation approach that 
would allow us to remove CCR2 expression from the stromal compartment. We harvested Ccr2+/+ 
cancer cells from the tumors of MMTV-PyMT (C57BL/6) donors and orthotopically injected them 
into Ccr2+/+ and Ccr2-/- (C57BL/6) hosts. 
We observed no differences in tumor take or tumor growth rate between wildtype and Ccr2-/- 
hosts following cancer cell transplantation (Figure 27, n = 17 mice per treatment, log-rank score for 
survival curve, two-tailed Student’s t-test for growth curve). To confirm that loss of stromal CCR2 
prevented myeloid cell recruitment, we performed flow cytometric analyses on tumors harvested from 
mice euthanized 48 hours after doxorubicin treatment. Similar to the results we observed in wildtype 
hosts (Figure 22C-D), we saw no differences in the total CD11b+ and F4/80+CD11b+ populations 
between the tumors of doxorubicin- and PBS-treated mice (Figure 28C-D, error depicted as mean ± 
SEM, n = 11 PBS-treated mice with 1 tumor per mouse, n = 11 doxorubicin-treated mice with 1 
tumor per mouse, two-tailed Student’s t-test). However, unlike wildtype hosts (Figure 22B), Ccr2-/- 
hosts showed a slight but non-significant increase in the number of Gr1+7/4+CD11b+ myeloid cells 
recruited into the tumors of doxorubicin- as compared to those of PBS-treated mice (Figure 28B, 
error depicted as mean ± SEM, n = 11 PBS-treated mice with 1 tumor per mouse, n = 11 doxorubicin-
treated mice with 1 tumor per mouse, two-tailed Student’s t-test), indicating that CCR2-dependent 
recruitment of myeloid cells into tumors after doxorubicin treatment was abrogated in our 
transplantation system. 
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Figure 27. Loss of CCR2 expression in the stromal compartment does not affect tumor take or 
tumor growth. (A) Tumor-free survival of Ccr2+/+ and Ccr2-/- hosts orthotopically transplanted with 
Ccr2+/+ MMTV-PyMT cancer cells. p-value based on log-rank test. (B) Growth curves of tumors of 
Ccr2+/+ and Ccr2-/- hosts orthotopically transplanted with Ccr2+/+ MMTV-PyMT cancer cells. p-value 
based two-tailed Student’s t-test at each time point. Error depicted as mean ± SEM.
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Figure 28. Flow cytometric analyses shows no change in the numbers of Gr1+7/4+CD11b+ 
immature myeloid cells in the tumors of Ccr2-/- hosts treated with doxorubicin. (A) Representative 
FACS plots for Gr1+7/4+CD11b+ triple stains of cells harvested from tumors 48 hours after the 
indicated treatment. (B) Quantification of Gr1+7/4+CD11b+ myeloid cells. (C) Quantification of total 
CD11b+ myeloid cells. (D) Quantification of F4/80+CD11b+ macrophages. p-values based on 
two-tailed Student’s t-test. Error depicted as mean ± SEM.
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When tumor-bearing wildtype and Ccr2-/- hosts were treated with doxorubicin for 3 weeks, 
we found that the initial response to doxorubicin was the same regardless of host genotype. However, 
mice lacking CCR2 expression in the stroma showed a delay in relapse following cessation of therapy 
(Figure 29, n = 8 tumors per genotype, mean ± SEM, * indicates p < 0.05, two-tailed Student’s t-test; 
two mice from each genotype were unhealthy and so they were euthanized on days 13-16). 
 
The tumors of Ccr2-/- mice show differences in histopathology following doxorubicin treatment 
To characterize the effects of losing CCR2 expression on histopathology of doxorubicin-
treated tumors, we performed hematoxylin and eosin (HE) staining on tumors harvested 48 hours 
after doxorubicin treatment. Tumors from Ccr2-/- hosts were far more cystic with decreased cellularity 
as compared to tumors removed from wildtype hosts (Figure 30). Furthermore, tumors removed from 
Ccr2-/- mice 6 weeks after treatment (4 weeks after the last dose) showed a dramatic reduction in 
tumor grade as compared to those harvested from the tumors of wildtype mice at the same time point 
(Figure 31, n = 1 low-grade and 11 high-grade tumors from Ccr2+/+ hosts, n = 10 low-grade and 5 
high-grade tumors in Ccr2-/- hosts, p = 0.005, Fisher’s exact test). 
 
Phenotypic changes in tumor vasculature are apparent when CCR2 expression is lost in the 
stromal compartment 
One of the best-characterized effects of monocyte and macrophage infiltration into tumors is 
their ability to promote angiogenesis by producing factors such as VEGF (Dirkx et al., 2006). Thus, 
we wanted to determine whether there was an effect on the architecture of the tumor vasculature. We 
assessed vascular permeability using lectin staining for Lycopersicon esculentum (tomato) lectin, 
which labels all functional vasculature and Ricinus communis agglutinin I, which labels areas of 
increased vascular leakiness (Thurston et al., 1996). Analyses of these stains showed that the 
density of functional vasculature (as determined by tomato lectin staining) was higher in the tumors 
of Ccr2-/- hosts, while there was no change in the density of leaky vasculature, as determined by 
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Figure 29. Tumor relapse is delayed in Ccr2-/- hosts treated with doxorubicin. * p < 0.05. 
p-values based on two-tailed Student’s t-test at each time point. Error depicted as mean ± 
SEM.
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Figure 30. The tumors of Ccr2-/- hosts are more cystic with fewer cells than those of wildtype hosts, 
48 hours after doxorubicin treatment. Hematoxylin and eosin stain. Scale = 100 µm.
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Figure 31. The tumors of Ccr2-/- hosts are of a lower grade and more differentiated than those of 
wildtype hosts, 6 weeks after the first doxorubicin treatment. Hematoxylin and eosin stain. Scale = 
100 µm.
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Ricinus communis agglutinin I staining (Figure 32A-C, n = 6 mice per genotype with 2 tumors per 
mouse, 48 total fields for Ccr2+/+ hosts and 46 total fields for Ccr2-/- hosts, mean ± SEM, p = 0.005 
for total vasculature, p = NS for leaky vasculature, two-tailed Student’s t-test). The net result of this 
change is a significant reduction in leaky tumor vasculature (Figure 32D). 
To further analyze the vascular structure, we performed immunofluorescence analyses of 
tumor tissues harvested from Ccr2+/+ and Ccr2-/- hosts harvested 48 hours after doxorubicin treatment 
to look at pericyte coverage and phosphorylation of vascular endothelial cadherin (VE-cadherin). 
Double label immunofluorescence staining for CD31 (a marker of endothelial cells) and αSMA (a 
marker of pericytes) showed increased pericyte coverage of blood vessels (Figure 33, n = 3 mice with 
1 tumor per mouse and 19 total fields for Ccr2+/+ hosts, n = 4 mice with 1 tumor per mouse and a 
total of 27 fields for Ccr2-/- hosts, mean ± SEM, p = 0.0268, two-tailed Student’s t-test). Staining for 
phospho-VE-cadherin (a marker of disrupted endothelial-endothelial adherens junctions, (Dejana et 
al., 2008) showed a slight, but non-significant decrease in this parameter (Figure 34, n = 3 mice with 
1 tumor per mouse and 25 total fields for Ccr2+/+ mice, and n = 4 mice with 1 tumor per mouse and 
30 total fields from Ccr2-/- mice, mean ± SEM, p = 0.1890, two-tailed Student’s t-test).  
 
Transgenic MMTV-PyMT;Ccr2-/- mice respond better to doxorubicin than their heterozygous 
littermates 
To further confirm that loss of CCR2 expression improved the response to chemotherapy, we 
crossbred MMTV-PyMT (C57BL/6) mice with Ccr2-/- (C57BL/6) mice to generate MMTV-
PyMT;Ccr2+/- and MMTV-PyMT;Ccr2-/- transgenic mice. Unlike our transplantation model, the loss 
of CCR2 expression in our transgenic model resulted in a better response to doxorubicin from the 
outset, compared to heterozygous controls. Despite this, tumors from MMTV-PyMT;Ccr2-/- mice 
appear to relapse at approximately the same rate as their heterozygous counterparts (Figure 35, n = 15 
tumors for 8 heterozygous mice, n = 26 tumors from 10 knockout mice, mean ± SEM, p < 0.05 for all 
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Figure 32. The tumors of Ccr2-/- mice show increased blood vessel density per tumor area with 
decreased leaky vasculature per tumor area, 48 hours after doxorubicin treatment. (A) 
Represetative fluorescence staining for tumor vasculature. Scale = 100 μm. (B) Quantification of total 
blood vessel volume (tomato lectin signal). (C) Quantification of leaky vascular volume (Ricinus 
communis agglutinin I signal). (D) Degree of vascular leakiness (as the precentage of total vascular 
volume that also stains positively for Ricinus communis agglutinin I). Error depicted as mean ± SEM. 
p-value based on two-tailed Student’s t-test.
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Figure 33. The tumors of Ccr2-/- mice show an increase in pericyte coverage of blood vessels, as 
compared to the tumors of wildtype hosts, 48 hours after doxorubicin treatment. (A) 
Representative images of double label immunofluorescence stains for blood vessels (CD31) and 
pericytes (αSMA). Scale = 50 μm. (B) Quantification of perciyte coverage. Error depicted as mean ± 
SEM. p-value based on two-tailed Student’s t-test.
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Figure 34. The tumors of Ccr2-/- mice show a slight decrease in phosphorylation of VE-cadherin, 
as compared to the tumors of wildtype hosts, 48 hours after doxorubicin treatment. (A) 
Representative image of immunofluorescence stains for blood vessels VE-cadherin phosphorylation. 
Scale = 50 μm. (B) Quantification of VE-cadherin phsophorylation. Error depicted as mean ± SEM. 
p-value based on two-tailed Student’s t-test.
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Figure 35. Transgenic MMTV-PyMT;Ccr2-/- mice respond better to doxorubicin than their 
heterozygous littermates. Mice were treated with doxorubicin on days 0, 14, and 21, and tumors were 
measured by caliper twice a week. Error depicted as mean ± SEM. p-values based on two-tailed 
Student’s t-test.
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*, two-tailed Student’s t-test). 
 
The enhanced response to doxorubicin following loss of CCR2 expression is a general 
phenomenon applicable to other classes of cytotoxic chemotherapeutics 
We wanted to determine whether the loss of CCR2 expression in the stromal compartment 
would delay relapse or enhance the response to another class of chemotherapeutic drugs. To do so, we 
first tested two drugs representing two major classes of clinically relevant chemotherapeutics – the 
alkylating agent cyclophosphamide (trade name Cytoxan) and the platinum-based drug cisplatin – to 
confirm that the tumors of MMTV-PyMT mice respond to these therapies. MMTV-PyMT tumor-
bearing mice were treated on days 0, 7, and 14 and followed for 2 to 3 weeks. Mice responded well to 
both treatments, showing a significant reduction in overall tumor burden as compared to PBS-treated 
control mice (Figure 36, error depicted as mean ± SEM, n = 6 mice per treatment group, ** indicates p 
< 0.004, *** indicates p < 0.001, two-tailed Student’s t-test at the last time point). 
Because cisplatin was significantly more effective in our system than cyclophosphamide, we 
enrolled wildtype and Ccr2-/- hosts transplanted with cancer cells in a cisplatin regimen, treating them 
on days 0, 7, and 14 and then following the mice for up to two weeks. Ccr2-/- hosts displayed a better 
tumor response to cisplatin from the outset, but relapsed at approximately the same rate as wildtype 
hosts (Figure 37, error depicted as mean ± SEM, n = 11 Ccr2+/+ hosts with 22 tumors, n = 12 Ccr2-/- 
hosts with 24 tumors, * p < 0.05, ** p < 0.01, two-tailed Student’s t-test at each time point), indicating 
that the CCR2-dependent recruitment influences the therapeutic response to a range of different 
chemotherapeutic drugs. 
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Figure 36. The tumors of MMTV-PyMT mice respond to both cisplatin and cyclophosphamide. 
Mice were treated on days 0 and 14. Error depicted as mean ± SEM. ** p < 0.004, *** p < 0.0001. 
p-value based on two-tailed Student’s t-test at each time point.
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Figure 37. The tumors of Ccr2-/- mice respond better to cisplatin than those of wildtype hosts. Mice 
were treated with cisplatin on days 0, 14, and 21, and tumors were measured by caliper twice a week. 
Error depicted as mean ± SEM. * p < 0.05, ** p < 0.01. p-values based on two-tailed Student’s t-test.
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Discussion 
 
Using the MMTV-PyMT mouse model of luminal breast cancer, we show that sensitivity to 
doxorubicin in vivo is influenced by the evolving tumor microenvironment. Tumors at the early 
carcinoma stage (as defined by in vivo imaging or histopathology) are highly sensitive to doxorubicin 
treatment, which induces necrosis, a highly immunogenic form of cell death that triggers the 
recruitment of CCR2+ monocytic cells. Loss of CCR2 expression in the stromal compartment results 
in a delay in tumor relapse and a lower histological grade six weeks after doxorubicin treatment. 
Global loss of CCR2 expression enhances the overall response to doxorubicin from the outset. These 
results provide strong evidence that manipulating components of the tumor microenvironment – in 
this case, the tumor-associated myeloid population – in the adjuvant setting can improve 
chemotherapeutic response. 
 
Tumor stage-dependent sensitivity to doxorubicin 
In our mouse model, tumors exhibit stage-dependent sensitivity to doxorubicin that can be 
primarily contributed to the microenvironment. Furthermore, doxorubicin sensitivity itself results in 
necrotic cell death that initiates a reactive change in the tumor-associated inflammatory environment 
with major implications for tumor relapse. While the data herein presented focus on the latter process, 
there are many factors that can contribute to drug sensitivity in vivo. Some of these include increased 
interstitial pressure resulting from abnormal leakage from blood vessels and drainage into lymphatics, 
physical barriers presented by changes in the composition of the extracellular matrix, altered tissue 
oxygenation and pH, limited diffusibility of the drug, and drug uptake by stromal cells (Egeblad et 
al., 2010). 
Other lines of work in our laboratory have shown that the differences in doxorubicin 
sensitivity among tumor stages are due in part to differences in vascular permeability, and by 
extension, drug distribution. While the exact mechanism by which this difference in vascular 
permeability is unclear, it appears as though myeloid cells may have an important role in this process, 
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as intravital imaging experiments show that when animals are intravenously injected with a 
fluorescently conjugated dextran, areas exhibiting the highest degree of dextran leakage into tissues 
are those in which there are high numbers of myeloid cells associated with the tumor vasculature 
(Nakasone et al., 2012). Furthermore, preliminary immunohistological analyses performed in our 
laboratory, as well as work from others, show that the degree to which tumors are infiltrated with 
immune cells is highly correlated with tumor stage and angiogenesis in both the MMTV-PyMT 
mouse model and human breast cancers (Egeblad et al., 2008; Leek et al., 1996, Lin et al., 2003). 
In addition to the role of myeloid cells in regulating tumor stage-dependent doxorubicin 
sensitivity, other factors in the stromal compartment are capable of regulating drug distribution and 
chemotherapy resistance (Trédan et al., 2007, Meads et al., 2009). The effects of these cancer cell-
stromal component interactions may be additive, synergistic, and perhaps even compensatory (in the 
case of depletion), to those exerted by tumor-associated myeloid cells. At present few tractable 
models are available for studying effects attributable to a single component of the tumor stroma in 
vivo due to the complex nature of tumor tissues, and so teasing apart the cells and molecules involved 
in the processes that drive environment-mediated drug resistance will necessitate a combination of 
intravital imaging, immunohistochemistry, and careful manipulation of tumor tissue components in 
both a spatial and temporal manner. 
 
Stromal CCL2/CCR2 signaling as a modulator of myeloid cell recruitment to tumors 
Here we show that expression of CCL2 is upregulated in the stromal compartment following 
doxorubicin treatment, and that the increased presence of this signal mediates the recruitment of 
monocytic cells expressing the Gr1 and 7/4 markers. The functional ramifications of recruiting 
immature myeloid cells ultimately depend on the phenotype they acquire when they reach the tumor. 
Double positivity for the pan-myeloid marker CD11b and Gr1 is used as the primary phenotypic 
identifier of both myeloid-derived suppressor cells (MDSC) and monocytes. MDSCs are a myeloid 
subpopulation that remains undifferentiated even after infiltration into the tumor and functions 
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primarily in the suppression of anti-tumoricidal T-cell activity thereby allowing for tumor progression 
(Gabrilovich and Nagaraj, 2009). While it is tempting to assume that MDSCs are the population that 
is being recruited to MMTV-PyMT tumors after doxorubicin treatment, there is little evidence in 
either the pre-clinical or clinical setting to suggest that MDSC recruitment occurs post-chemotherapy. 
We believe that these tumor-infiltrating myeloid cells are instead monocytes with the propensity to 
mature into M2-like, tumor-associated macrophages. As previously mentioned, monocytes also 
express high levels of both CD11b and Gr1, but in addition to these two antigens, they express high 
levels of CCR2 (Strauss-Ayali et al., 2007).  
Thus, we propose the following model for CCL2/CCR2-dependent recruitment of immature 
myeloid cells to tumors after doxorubicin treatment. A stromal cell population (potentially dendritic 
cells) recognizes necrotic debris generated by doxorubicin-induced cell death, and subsequently 
upregulates expression of CCL2. This CCL2 signal recruits CCR2+Gr1+7/4+CD11b+ monocytes that 
mature into macrophages once they infiltrate the tumor tissue. Tumor-derived signals then push the 
polarization of these macrophages towards that of pro-tumorigenic macrophages that go on to 
produce cytokines and growth factors important for tumor proliferation and progression, ultimately 
resulting in host relapse (Figure 38). 
Derivation of tumor-associated macrophages (TAMs) from tumor-infiltrating monocytes is 
the predicated mechanism for generating TAMs (Mantovani et al., 2002). While there is at present 
little scientific evidence for this occurring in situ, studies of ovarian cancer show that CCR2+ 
monocytes are recruited to tumors, where they downregulate expression of CCR2 as they mature into 
macrophages to prevent migration away from the tumor tissue (Sica et al., 2000). It may be – in 
addition to providing angiogenic and growth factors – that one important functional consequence of 
monocytes maturing into TAMs is to induce cancer cell expression of signals that recruit additional 
macrophages into tumor tissues at a later time. 
Other groups have shown that the numbers of macrophages in MMTV-PyMT tumors is 
increased 7 days after chemotherapy is administered (DeNardo et al., 2011; Shree et al., 2011). 
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Figure 38. Hypothesis describing how stromal CCL2/CCR2 signaling might influence 
chemotherapeutic response. Activation of a stromal cell by interaction with cancer cells that have 
undergone necrotic cell death results in stromal expression of CCL2. CCL2 recruites CCR2+ 
monocytes to tumors, where they differentiate into tumor-associated macrophages and go on to 
enhance pro-tumorigenic functions, including therapeutic resistance, angiogenesis, cancer cell 
differentiation, and metastasis.
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Macrophages recruited in this manner can promote cancer cell survival by secreting cathepsin 
cysteine proteases (Shree et al., 2011), which are capable of releasing and modifying growth factors, 
cytokines, and other proteases sequestered in the ECM to promote angiogenesis and cancer cell 
invasion (Joyce et al., 2004). Recruitment of these macrophages – unlike the monocyte recruitment 
we observe – depends on signaling through the colony-stimulating factor-1 (CSF-1) pathway. It is 
possible, that CCR2+ monocytes and tumor-associated macrophages are recruited through 
independent pathways and influence therapeutic response via different mechanisms. Furthermore, 
there may be additional pathways through which monocytes and macrophages are recruited to tumors 
after chemotherapy. Another such mechanism is the activation of a CXCL12/CXCR4 signaling 
cascade that recruits Tie2+ macrophages into tissues that have suffered hypoxic injury (Welford et 
al., 2011). Because each of these myeloid cell subpopulations has a very different effector function, 
they can influence progression in very different ways once they have infiltrated the tumor tissue. 
Differentiating between these subpopulations and tracking their activity in vivo will require a 
combination of live imaging and carefully constructed reporter mice that can distinguish between 
monocytes and macrophages. 
 
Inhibiting myeloid cell recruitment to enhance chemotherapeutic response 
Monocyte/macrophage recruitment into solid tumors of many different origins has been 
shown to be an important prognostic factor, driver of tumor progression, and mediator of 
chemotherapeutic response. In breast cancers, accumulation of myeloid cells – macrophages in 
particular – is associated with advanced disease and increased risk of relapse in human breast cancer 
patients (Leek et al., 1996), as is elevated expression of monocyte/macrophage chemoattractant 
molecules like CSF-1 (Scholl et al., 1994). Furthermore, antibody-mediated depletion of myeloid 
cells (by targeting CD11b) and neutralization of CSF-1, improve tumor responses to both radiation 
therapy and chemotherapy (Ahn et al., 2010; DeNardo et al., 2011). 
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Here we show that a stromal CCL2/CCR2 signaling pathway modulates chemotherapeutic 
response, and that inhibiting myeloid cell recruitment by removing CCR2 expression from the 
stromal compartment delays tumor relapse. This is of clinical importance because upregulation of 
CCL2 has been reported in human breast tumors and is associated with decreased relapse free 
survival (Ueno et al., 2000; Fujimoto et al., 2009). Thus, the addition of CCL2 neutralization or 
CCR2 antagonism to current chemotherapeutic strategies may improve tumor responses and patient 
outcome. While we were unable to successfully antagonize CCR2 (CCR2 antagonists have been 
tested primarily for treatment of rheumatoid arthritis and have been relatively unsuccessful, Vergunst 
et al., 2008), work done in pre-clinical cancer models, including prostate (Loberg et al., 2007) and 
glioma (Zhu et al., 2011), show that combining neutralizing antibodies against CCL2 with standard 
of care chemotherapy treatment improves tumor responses over chemotherapy alone and prolongs 
survival. Studies looking at CCL2 and CCR2 antagonism for the treatment of cancer have recently 
moved into the clinical setting, where a monoclonal antibody against CCL2 (Janessen Biotech) is in a 
Phase I trial as a combination therapy with standard of care chemotherapy regimens for the treatment 
of various solid tumors and a Phase II trial as a stand alone therapy for metastatic prostate cancer, and 
a monoclonal antibody against CCR2 (Millennium Pharamceuticals) is in a Phase II trial for the 
treatment of bone metastases. 
 
Altering tumor grade after chemotherapy treatment 
In addition to delaying tumor relapse following doxorubicin treatment, chronic loss of CCR2 
expression in the stromal compartment shows a strikingly lower tumor grade at 6 weeks after 
administration of the first dose of doxorubicin as compared to mice that express CCR2 normally. 
Whereas tumors in wildtype mice are necrotic, undifferentiated, and as advanced as the tumors of 
untreated control mice, tumors in Ccr2-/- hosts are differentiated with structures resembling ducts. 
These phenotypic changes imply that the cues present in the microenvironment are altered in Ccr2-/- 
hosts, and that cancer cells are responding to these changes. CCL2/CCR2 signaling may be acting 
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directly on cancer cells or indirectly via other CCL2-responsive cellular stromal components to derive 
growth factors and other cues involved in directing differentiation and motility. Thus, CCL2/CCR2 
signaling may affect not only tumor-infiltrating myeloid cells, but cancer cells as well. 
There is some clinical evidence based on histopathologic examination of breast tumors 
implicating CCL2 expression in promoting both cancer cell proliferation and invasiveness (Valkovic 
et al., 1998;  Dwyer et al., 2007). In a laboratory model of breast cancer, the glycoprotein 
dysadherin upregulated expression of CCL2 in the MDA-MB-231 breast cancer cell line and acted in 
an autocrine fashion to drive cancer cell migration (Nam et al., 2006). Further, in prostate cancer, 
CCL2 expression has been found to regulate the migratory and proliferative potential of prostate 
cancer epithelial cells in a phosphoinositide 3-kinase-dependent manner (Loberg et al., 2006). 
While the effects of CCL2/CCR2 signaling on cancer cell proliferation and invasion are still 
being determined, there are significant clinical implications underlying this lower tumor grade. Both 
understanding mechanistically how the differentiation of invasive, highly undifferentiated tumors 
occurs and determining whether this is entirely CCL2/CCR2-dependent or dependent on more general 
signaling pathways, are of clinical importance because low-grade tumors are generally far easier to 
treat than higher-grade tumors (Elston and Ellis, 1991). Moreover, having the ability to force the 
differentiation of any highly aggressive solid tumor – even in those where CCL2/CCR2 expression is 
not a factor in tumor progression – would be a potentially powerful therapeutic tool. 
 
Normalization of tumor vasculature 
In addition to being more differentiated, tumors derived from Ccr2-/- hosts exhibited a 
distinctly different vascular phenotype from the tumors of wildtype hosts. These differences include, 
an increase in vascular density, a decrease in the leakiness of tumor vasculature, and improved 
pericyte coverage of blood vessels. All of these changes are indicative of vascular normalization, 
which has been proposed as a model for anti-angiogenic cancer therapy (Jain, 2001). This model 
postulates that highly abnormal tumor vasculature impedes proper blood flow through vessels and 
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diffusion of molecules into tissues, and that normalizing vessel architecture will reestablish normal 
blood flow and tissue pressure gradients, thereby improving delivery of cytotoxic chemotherapeutics. 
Our results do not establish a causal role for CCL2/CCR2-signaling in the normalization of 
tumor blood vessels. It may be that chemokine-receptor interaction directly influences this change in 
tumor vasculature, as endothelial cells are purported to express CCR2 and can respond to CCL2 
(Salcedo et al., 2000). Furthermore, recent finding suggest that CCL2/CCR2 signaling might have a 
direct effect on angiogenesis by upregulating expression of the Ets-1 transcription factor in 
endothelial cells (Stamatovic et al., 2006). However, we did not detect CCR2 expression by any 
cellular components of the tumor vasculature in MMTV-PyMT tumors. 
Another plausible explanation for the normalization phenotype we observe is that it is an 
indirect effect resulting from inhibiting myeloid cell recruitment into tumors. Tumor-associated 
macrophages and other tumor-infiltrating myeloid cells produce a variety of factors (including VEGF 
and matrix metalloproteinases) that promote tumor angiogenesis (Murdoch et al., 2008). Blockade of 
tumor angiogenesis via antibody-mediated neutralization of VEGF has been shown to induce tumor 
normalization and improve chemotherapeutic response (Tong et al., 2004; Vosseler et al., 2005). 
Given the effects we observe in our transplantation model, CCL2/CCR2 antagonism may represent 
another approach to targeting tumor angiogenesis. 
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Perspectives 
 
Innate immunity as a modulator of therapeutic response 
Many in vitro studies and a handful of in vivo studies have shown that the tumor 
microenvironment plays an important role in therapeutic response, often by transiently altering cancer 
cell-intrinsic transcriptional programs that protect cells from drug-induced death. However, the 
majority of these resistance mechanisms have been observed primarily in the context of hematologic 
malignancies, and those studies that do focus on resistance in solid tumors frequently concern either 
the biochemical and biophysical properties that hinder drug activity and distribution or interactions 
between cancer cells and the ECM (Minchinton and Tannok, 2006 [review]; Heldin et al., 2004 
[review]; Mahoney et al., 2003; Rohwer and Cramer, 2011 [review]; Teicher et al., 1981 [in vitro 
study]; Shain et al., 2001 [review]). While these studies represent an important step forward in 
understanding the processes that drive environment-mediated drug resistance, many other 
components of the tumor microenvironment influence a wide range of tumor processes, and so it is 
highly likely that factors produced by tumor stromal cells (e.g. chemokines, cytokines, ECM-
remodeling molecules) or the structures formed by these cells (e.g. blood or lymphatic vessels) play 
an equally important role in the response to therapy. One component that would be predicted to have 
a strong influence on therapeutic response is the tumor-associated immune cell population. 
Inflammation has received much scrutiny as an important mediator of tumor initiation, progression, 
and metastasis, but the role of immune cells in therapeutic response has been, until recently, widely 
neglected. 
In breast cancers, infiltration of macrophages in particular is a major predictor of progression 
and relapse-free survival, so it stands to reason that these cells would also be important for therapeutic 
response. In recent years, pre-clinical studies in mouse models of breast cancer have shown that the 
depletion of mature myeloid cells using depleting antibodies against the mature myeloid cell marker 
CD11b (Ahn et al., 2010), inhibition of myeloid cell recruitment using neutralizing antibodies 
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against CSF-1 (the receptor for which is expressed to varying degrees in different myeloid lineage 
populations; DeNardo et al., 2011), or inhibition of macrophage-derived factors (e.g. cathepsins 
[Shree et al., 2011], MMP9 [Nakasone et al., 2012]) can improve chemotherapy and radiation 
therapy responses. In each of these cases, therapeutic response is dependent on the recruitment and/or 
activity of macrophages. 
Because macrophages are the most common myeloid cells associated with breast tumors, they 
have been the chief focus of studies involving immune-mediated therapeutic resistance. However, we 
show here that the recruitment of immature monocytic cells plays just as critical a role in the response 
to chemotherapy as do macrophages. This is an important finding, as it implies that multiple pathways 
can recruit myeloid cells, multiple myeloid cell populations influence therapeutic responses, each of 
these populations exerts a different effect on tumor phenotype and outcome, and that immune-
directed strategies may have to target several different signaling molecules. 
 
Questions that remain 
While we, and others, have shown that myeloid cells negatively influence the response to 
chemotherapy, one of the major details that is lacking in all of these studies is the mechanism by 
which resistance arises. It is clear that multiple mechanisms exist to recruit myeloid cells into tumors, 
including the CCL2/CCR2 pathway, and that the increased presence of these myeloid cells in tumors 
contribute both to host relapse and response to later rounds of chemotherapy. What remains unclear is 
how these myeloid cells promote resistance. 
Identifying the molecular mechanism(s) by which CCL2/CCR2 signaling promotes 
chemotherapeutic resistance in the MMTV-PyMT mouse model of breast cancer is inherently 
challenging for three major reasons. First, explication of the molecular pathways driving monocyte-
dependent chemoresistance requires the use of in vivo models with intact immune systems, where 
other cellular stromal components can both contribute to therapeutic responses themselves and alter 
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the activities of recruited immune cells (which are highly sensitive to external cues) by adapting their 
own functional outputs to changes in the environment arising from the altered immune cell 
population. Furthermore, the presence of the intact tumor microenvironment makes it difficult to 
distinguish the effects due to one stromal population versus another, and it is possible that other 
stromal components regulate (both positively and negatively) therapeutic responses in vivo. 
The second major challenge in determining how CCL2/CCR2 signaling promotes 
chemoresistance is determining the effector functions of the monocytes recruited into tumors 
following chemotherapy treatment. Identification of these functions requires that two major 
considerations be addressed. The first consideration is a confirmation of our prediction that the 
monocytes recruited into tumors following doxorubicin treatment are differentiating into mature, 
tumor-associated macrophages (TAMs) based on cues in the tumor microenvironment. This is 
important, as functions driving chemoresistance are expected to be macrophage-dependent. Perhaps 
the only way to determine whether this differentiation process occurs in vivo is to use intravital 
imaging to track the fate(s) of the infiltrating cells. 
The simplest way to track monocyte differentiation is to observe the loss of expression of a 
monocyte-specific marker with the gain of expression of a macrophage-specific marker. 
Subsequently, a marker of alternatively activated, M2-like macrophages is required, to track 
activation of these newly differentiated macrophages. While this is a straightforward task, confirming 
this process is not quite feasible yet, as our current imaging capabilities prevent the imaging of more 
than four colors in live animals (imaging this process would probably require five to six colors), and 
the available markers of myeloid cell differentiation and activation are not specific enough to 
distinguish monocytes and macrophages using a single marker. Several fluorescent markers would be 
required to track this process in vivo, the first of which is a CCR2 reporter to identify infiltrating 
myeloid cells responding to CCL2 (e.g. the Charo laboratory has generated an RFP knock-in mouse, 
in which RFP replaces the first 270 bp of the N-terminus of Ccr2, which can be maintained as a 
94
hemizygous line; Saederup et al., 2010). To distinguish between monocytes and macrophages, a 
monocyte marker (Ly6C could be used, but it is also expressed on other myeloid cell types) and a 
marker of mature macrophages (F4/80 could be used but experience in our lab as well as others 
[Engelhardt et al., 2012] have shown that this is also expressed on dendritic cells) are also needed. 
The last marker that is required is one that is specific for TAMs (for example, Arginase-1, but this is 
not specific to an M2 phenotype), to confirm tumor-promoting functionality of differentiated 
macrophages. Other markers that are not necessarily required, but would be useful for providing 
tissue context are the ACTB-ECFP, which would give us information about tumor stage, and the c-
fms-EGFP (or a CD11b reporter line such as the CD11b-DTR/EGFP line) reporters that would allow 
us to identify most myeloid cells. 
The second consideration required in explicating how monocytes recruited through 
CCL2/CCR2 signaling promote chemoresistance is to determine the final effector functions of these 
immune cells once they have reached their target and matured. TAMs are known to exert multiple 
effects on tumor progression including, cancer cell proliferation, angiogenesis, metastasis, and ECM 
remodeling. We have shown that there are changes in the differentiation state of tumors and in tumor 
vasculature, and we have preliminary data strongly suggesting an effect on metastasis, following 
chronic loss of CCR2 expression in the stromal compartment. However, the major question is 
whether these effects are due to macrophage activity, or whether these are secondary effects due to a 
changing tumor microenvironment. Untangling the effects that can be ascribed to macrophage activity 
from those that result from changes in the microenvironment (e.g. changes in fibroblast signaling due 
to changes in environmental cues) will be challenging, as the degree to which we can manipulate 
different stromal components in vivo is limited. We may need to utilize more complex in vitro 
systems to recapitulate various aspects of the tumor microenvironment to dissect these different 
pathways, before returning to in vivo models to confirm these pathways. One aspect that we have not 
yet looked at, that may provide some insight into secondary effects of TAM function is whether there 
are changes in ECM organization and distribution following chronic loss of CCR2. Macrophages are 
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known to express various proteases capable of remodeling ECM, thereby altering the bioavailability 
of not only chemotherapeutics, but also growth factors important for angiogenesis and tumor 
proliferation. One recent study demonstrating that this may be true shows that cathepsins (proteases 
capable of remodeling ECM) are produced by TAMs that infiltrate tumors following chemotherapy 
treatment, and inhibition of cathepsin activity improves chemotherapeutic response. Thus, a TAM-
derived, ECM-remodeling enzyme may be altering the bioavailability of various growth factors and 
survival signals that were previously sequestered, thereby explaining changes in both tumor 
differentiation status as well as sensitivity to chemotherapy observed after CCR2 depletion. If this 
proves to be the case, identifying and targeting this ECM-remodeling factor, may prove to be an 
important means of overcoming therapeutic resistance. 
The final major challenge to identifying how CCL2/CCR2 signaling promotes 
chemoresistance is determining whether chemoresistance is dependent solely on the recruitment of 
CCR2-positive monocytes, or whether other cell types that express CCR2 also responding directly to 
CCL2 and contributing to therapeutic resistance. Other such populations include endothelial cells, 
which may respond to CCL2 to form new blood vessels, and cancer cells themselves, which may use 
CCL2 as a metastatic cue. Determining whether CCL2/CCR2 influences chemoresistance will require 
the specific identification of each of the populations expressing CCR2 within MMTV-PyMT tumors, 
and the ability to manipulate each of these components in vivo. To identify CCR2-positive cell 
populations beyond the monocytic population we have identified will require careful 
immunohistochemical analyses, and potentially flow cytometric analyses, to confirm these results. 
Manipulation of each of these cell populations will prove to be the more difficult task, and will most 
likely require specific genetic ablation of CCR2. Two systems that may be of use include, (1) a Cre-
lox model in which a tissue-specific promoter-driven, self-excising, inducible Cre recombinase (e.g. 
CD31-CreER) is paired with homozygous CCR2 floxed alleles, or (2) an inducible transgenic CCR2 
short hairpin mouse model that expresses a TRE-shCCR2 transgene paired with mice expressing 
tissue-specific rtTA promoters (e.g. CD31-rtTA) in which knock down of CCR2 can be reversibly 
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regulated. There are a few caveats, however, as these transgenics do not currently exist, promoters 
specific for only monocytes or cancer cells have yet to be identified to properly regulate Cre, and 
careful characterization of such multiple-transgene models will be necessary to confirm that the 
increased number of transgenes does not affect the pathology and behavior of MMTV-PyMT tumors. 
While a large amount of work is needed to understand the role of CCL2/CCR2 signaling in 
chemoresistance, another area that requires focus is determining why tumors in which there is a 
chronic loss of CCR2 expression still relapse despite improved responses to doxorubicin. Although, 
we have never performed the long-term follow-up studies to determine how CCR2 inhibition affects 
overall survival (we suspect that CCR2 blockade will improve overall survival), it appears that the 
tumor burden in all animals will eventually reach the experimental endpoint. Two major questions 
that need to be answered with respect to combining doxorubicin treatment with CCR2 blockade are 
(1) whether treatment with another class of chemotherapeutics (e.g. a taxane) after completion of the 
doxorubicin regimen will further shrink tumors, and (2) whether surgical resection following 
completion of the chemotherapy regimen would prevent minimal residual disease. 
 
A toolkit for the future 
What is evident from the work herein described is that tumor responses to systemic therapies 
can be dramatically different in vitro and in vivo, and often microenvironment-dependent resistances 
that can only be observed in the intact tumor will arise. Thus, determining how the tumor 
microenvironment drives chemoresistance and identifying the underlying mechanisms by which this 
process occurs using in vivo models will be an important step in treating cancer relapse and 
metastasis. However, there are currently many obstacles to studying the contributions of the tumor 
microenvironment to chemoresistance in vivo.  
Perhaps the biggest obstacle to explicating chemoresistance pathways in vivo is the 
complexity of the tumor microenvironment. To an extent, solid tumors behave as any other normal 
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organ does, in that perturbations in tissue homeostasis will result in compensatory shifts in various 
components of the tumor to maintain proper homeostatic balance. However, because tumors are 
abnormal organs, perturbations to the system may result in dramatic changes in the bioavailability of 
growth factors and cytokines, as well as in tissue organization (e.g. changes in blood vessel structure), 
creating an environment that enhances tumor growth, progression, and metastasis. Even procedures 
such as tumor transplantation, can alter the way tumors develop and progress, as they require 
injection or surgery, which disrupts the recipient tissue (wounding) and results in an inflammatory 
environment that may not exist prior to spontaneous tumor development. 
To circumvent the obstacles mentioned above, tumor microenvironment research will 
necessarily rely on intravital imaging to visualize in real-time the interactions and processes occurring 
in vivo following chemotherapy administration. With the technology currently available, we have 
made major progress in understanding how myeloid cells influence therapeutic response; however, 
because the tumor microenvironment is so complex, major advancements are still needed to begin to 
delve mechanistically into the processes underlying environment-mediated drug resistance. 
One of the most important advancements required is the identification of individual markers 
that are specific for a single cell population (or sub-population). The importance of better markers is 
perhaps best illustrated in two of the most prominent stromal cell components of the breast tumor 
microenvironment, fibroblasts and cells of the immune system. Frequently the markers used to 
identify fibroblasts are also expressed on other cell. For example, in breast tumors, α-SMA can be 
expressed on fibroblasts, pericytes, and myoepithelial cells. While in immunostaining assays, these 
cell types can sometimes be distinguished based on localization, using localization to distinguish 
different microenvironmental components is much more challenging during intravital imaging 
experiments. Markers in the immune system are at least as big a problem as are markers of 
fibroblasts, as multiple markers are usually required to identify immune cell sub-populations, and 
frequently, the same sets of markers will often be used to identify different populations. Thus the 
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complexity of the currently available marker system used to identify various cellular components of 
the microenvironment poses a major problem for intravital imaging, as ideally, one would like to be 
able to use a single marker to identify a specific cell type so that multiple microenvironmental 
components can be simultaneously visualized. 
New transgenic reporter lines must also be developed in conjunction with the identification of 
these new markers, as they are preferable to injectable reporters (the use of biologics such as 
fluorescently-conjugated antibodies have the potential to alter the microenvironment). In addition to 
requiring cell-specific promoters to drive expression of these reporters, new reporters utilizing a 
greater diversity of fluorescent proteins will also be necessary. Currently, most transgenic reporter 
lines express GFP, CFP, or RFP, even though a wider range of fluorescent proteins is available 
(including yellow, orange, and infrared fluorescent proteins) and used in vitro. We are currently 
working on developing a reporter line expressing IFP1.4, the only infrared fluorescent protein that has 
been developed. 
The other major advancement that will be needed is improvements in the technologies 
required to perform these intravital imaging experiments, that is, primarily in the image capturing 
systems and analysis software. While these technologies are continually improving, there are several 
important considerations involved in increasing the number of fluorescent labels being imaged, 
including increases in the speed of photon detection-to-analog conversion (the CCD camera), 
acquisition and conversion of analog to digital images (imaging software). One of the consequences 
of increasing the number of fluorescent labels that are being imaged is increasing the number of 
images that need to be acquired for each time point. For example, in our laboratory, we will image 
approximately seven x,y positions in three z-planes during a typical four-color imaging experiment. 
Thus for each time point, 84 images (1 image × 4 channels × 3 z-planes × 7 positions) need to be 
acquired before the next time point is reached. Adding a single color channel to this increases the 
number of images that need to be taken per time point by 21 (1 image × 1 channel × 3 z-planes × 7 
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positions). This increases both the time required to acquire the data for a single time point, and the 
sophistication of the software used to control stage movement and laser switching, image acquisition, 
and data analysis. Thus, advancements in current software or new software that can increase the speed 
at which the microscope stage moves between z-planes and x,y positions, the rate of analog-to-digital 
conversion of very large datasets, and efficiently handle the analysis of these very large datasets must 
also be developed. 
 
Is antagonism of CCL2/CCR2 signaling clinically relevant? 
Irrespective of the new questions that need answering and the new tools that need 
constructing, the most important question that needs to be addressed is whether inhibition of 
CCL2/CCR2 signaling is clinically relevant. Much of the evidence showing that antagonizing this 
pathway would be beneficial to cancer therapy comes from pre-clinical models of prostate cancer. In 
this system, administration of neutralizing antibodies against CCL2 to syngeneic or xenograft mouse 
models shrinks tumors in monotherapy and improves the response to docetaxel (trade name Taxotere) 
in polytherapy (Loberg et al., 2007). Because the evidence supporting antagonism of CCL2/CCR2 as 
a useful adjuvant to chemotherapy has been quite strong in the prostate models, phase I and II clinical 
trials have been undertaken to combine this treatment with standard of care in prostate and metastatic 
cancer.  
Whether combining CCL2/CCR2 antagonism with chemotherapy treatment will improve 
patient outcome in breast cancer remains to be seen. The mechanisms by which CCL2/CCR2 
signaling drives tumor progression in prostate cancer are different when compared to those observed 
in our breast cancer model. In prostate cancer, CCL2/CCR2 signaling has been shown to directly 
affect cancer cell motility and proliferation (Loberg et al., 2006) and enhance angiogenesis via the 
recruitment of myeloid cells in to tumors (Loberg et al., 2007). In contrast, in our breast cancer 
models, there appears to be no effect of CCL2/CCR2 signaling on tumor growth, as MMTV-
PyMT;Ccr2+/- and MMTV-PyMT;Ccr2-/- littermates show the same tumor latency, and the tumors 
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arising in Ccr2+/+ and Ccr2-/- hosts show the same latency and growth rates. Although we cannot 
exclude that CCL2/CCR2 signaling has no direct effect on cancer cells, as some of these cells do 
express CCR2 by immunofluorescence staining (data not shown), an effect on cancer cell 
proliferation seems unlikely. Furthermore, the angiogenesis phenotype that we observe following 
inhibition of CCL2/CCR2 signaling is opposite to that observed in the prostate model. In the prostate 
model, neutralizing CCL2 inhibits angiogenesis, while in our model it appears as though inhibiting 
CCL2/CCR2 signaling enhances angiogenesis. While the differences in the effect of inhibiting 
CCL2/CCR2 between these two models are striking, a recent study using a glioma model shows 
similar results to our breast cancer results, in that anti-CCL2/CCR2 monotherapy has little effect on 
tumor growth, but combination therapy with temozolomide (trade name Temodar) significantly 
improves survival (Zhu et al., 2011). Thus, polytherapy consisting of an anti-CCL2/CCR2 agent plus 
chemotherapy may prove to be a feasible and potentially powerful therapeutic strategy for the 
treatment of breast cancer. 
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Concluding Remarks 
 
Treatment of mammary tumors with the cytotoxic chemotherapeutic doxorubicin alters the 
tumor-associated inflammatory microenvironment by inducing a reactive recruitment of immature 
myeloid cells via a stromal CCL2/CCR2 signaling axis. The increased presence of these myeloid cells 
promotes chemoresistance, and blockade of this signaling pathway delays host relapse and improves 
overall therapeutic response. 
CCL2/CCR2 blockade results in several phenotypic changes in tumor pathology, including 
tumor grade and vascular organization, implying broader effects than just those indirectly resulting 
from the recruitment of tumor-promoting myeloid cells. While further work is needed to 
mechanistically untangle the in vivo effects of recruiting monocytes cells into tumors and the role of 
CCL2/CCR2 signaling in breast cancer epithelial cell proliferation and tumor angiogenesis, it is 
apparent that targeting CCL2 or CCR2 in combination with chemotherapeutic treatment is a 
potentially powerful therapeutic strategy. 
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Experimental Procedures 
 
Animals 
MMTV-PyMT (FVB/n), ACTB-ECFP (FVB/n), ACTB-H2B-EGFP (obtained on mixed 
background and backcrossed to FVB/n for 6 generations) and Ccr2-/- (C57BL/6) mice were 
purchased from Jackson Labs. C3(1)-Tag (FVB/n) mice (Green et al., 2000) were from the NIH 
Mouse Repository. MMTV-PyMT (C57BL/6) mice were provided by Dr. Kasper Almholt and c-fms-
EGFP mice were provided by Dr. Jeffrey Pollard and backcrossed to FVB/n mice for 6 generations. 
All animal experiments were conducted in accordance with procedures approved by the IACUC at the 
University of California, San Francisco or Cold Spring Harbor Laboratory. 
 
Tumor transplantation experiments 
Virgin females of 6-16 weeks of age were used as hosts for transplantation. Primary cancer 
cells were isolated from tumors derived from MMTV-PyMT (C57BL/6) mice approximately 10-14 
weeks of age with tumors approximately 6-12 mm in size. Briefly, 2-3 tumors at 8-10 mm diameter 
(necrotic and/or cystic tumors were excluded from use for transplantation) were harvested, 
mechanically dissociated, and digested in an RPMI-1640-based solution containing 0.2% w/v 
collagenase A (Sigma), 0.2% w/v trypsin (GIBCO), 5 µg/mL insulin, 50 µg/mL gentamycin 
(GIBCO), and 5% v/v fetal bovine serum (GIBCO). Single cells and debris were removed from the 
resulting carcinoma organoid preparation by repeated rounds of differential centrifugation. Purified 
carcinoma organoids were dissociated into single cell suspension by incubation in 0.25% trypsin with 
0.1% EDTA solution for 30 min at 37°C, and subsequently washed in PBS. Cells (4×105 in 20 mL 
PBS) were injected into each inguinal mammary gland of host mice. 
Refer to Appendices I and II for detailed protocols. 
 
Tumor response to doxorubicin, cisplatin, and cyclophosphamide 
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Mice were administered 8 mg/kg doxorubicin hydrochloride (in PBS, Sigma-Aldrich), 10 
mg/kg cisplatin (in 10% DMSO in PBS, MBL International), or 75 mg/kg cyclophosphamide 
monohydrate (in distilled H2O, MP Biomedicals) intraperitoneally on days 0, 7 and 14. Control mice 
were administered sterile PBS. Tumor size was tracked by caliper measurement 2-3 times a week, and 
tumor volumes were calculated using the equation. Refer to Appendix III for a detailed protocol. 
 
Tumor response to combination therapy with doxorubicin and RS 504393  
MMTV-PyMT tumor-bearing mice were administered the CCR2 small molecule inhibitor RS 
504393 (Roche/Iconix, ordered from Tocris) intraperitoneally at a dose of 2 mg/kg every 12 hours 
beginning three days prior to doxorubicin or PBS treatment, with the last dose being given just prior 
to euthanization. Mice were administered doxorubicin (8 mg/kg) or PBS intraperitoneally and 
euthanized 48 hours after treatment. Tumor size was taken every day by caliper measurement, and 
tumor volumes were calculated using the equation 
length ! width( )2
2
. 
Refer to Appendix IV for a detailed protocol. 
 
Detection of necrosis and intratumoral cysts by ultrasound 
Ultrasound was used to detect changes in necrosis and intratumoral cysts in MMTV-PyMT 
tumor-bearing mice treated with RS 504393. Animal hair was removed using a chemical hair remover 
the day prior to imaging, and the same tumors were imaged the day inhibitor (or vehicle) treatment 
started, the day doxorubicin (or PBS) treatment started, and just prior to sacrifice using a VEVO 
770TM-120 Imaging System (VisualSonics). Necrotic areas were defined as those areas that appeared 
black in ultrasound images. Cystic areas where areas that appeared dark in ultrasound images and 
showed some fluid movement. Measurements were determined using the in-system software. 
 
Spinning disk confocal imaging of live mice 
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Details of the microscope design and imaging procedure have been previously described 
(Egeblad et al., 2008; Ewald et al., 2011a). Briefly, a micro-lensed spinning disk confocal 
microscope (Solamere technologies, Salt Lake City, UT) equipped with 405, 488, 560 and 647 nm 
laser lines and selective emission filters was used with an ICCD camera (XR-Mega-10EX S-30, 
Stanford Photonics, Palo Alto, CA). Images were acquired using either a Fluar 10×/0.5NA or 
40×/1.1NA LD C-Apochromat lens (Zeiss). 
For all live animal experiments, the inguinal mammary fat pad was imaged. To prepare the 
tissue for imaging, the animal was anesthetized with isoflurane and the fat pad was surgically 
exposed. Following the surgical procedure, the mouse was transferred to the microscope stage and 
positioned so the exposed mammary gland was flush against a glass cover slip attached to an imaging 
port on the stage. To prevent body temperature from dropping too low, the animal was covered with a 
heated blanket (Gaymar, Orchard Park, NY; [Ewald et al., 2011c]). Animal hydration was 
maintained by administration 50 µL of sterile PBS was administered via an indwelling intraperitoneal 
line every hour for the duration of each imaging session. For the duration of each imaging session, 
mice received isoflurane at a concentration that was adjusted over time for each individual mouse 
using vital signs monitored using an oximeter probe that indicates the level of anesthesia (MouseOx, 
Starr Life Sciences, PA; [Ewald et al., 2011b]). 
The acute in vivo response to doxorubicin was tracked in MMTV-PyMT;ACTB-ECFP;c-fms-
EGFP or MMTV-PyMT;ACTB-ECFP mice. Mice were administered a single dose of doxorubicin 
(8mg/kg, intraperitoneally) 14 to 30h prior to the start of imaging, and imaged for 10 to 40h. Controls 
were untreated MMTV-PyMT;ACTB-ECFP;c-fms-EGFP or MMTV-PyMT;ACTB-ECFP mice 
imaged for similar time frames. During each imaging session, animals were administered 50 µL/h 
propidium iodide (0.05-0.1 mg/mL in PBS, Invitrogen) rather than PBS, to visualize cell death. Time-
lapse movies were acquired at 10× or 40× magnification. 
MMTV-PyMT;ACTB-ECFP;ACTB-H2B-EGFP mice were used to determine the in vivo 
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mechanism of doxorubicin-induced cell death. Mice were administered a single dose of doxorubicin 
(8 mg/kg, intraperitoneally) 28 to 30h prior to imaging start time, and animals were administered 50 
µL/h propidium iodide (0.05-0.1 mg/mL in PBS, Invitrogen) rather than PBS, to visualize cell death. 
Time-lapse movies were acquired at 40× magnification. 
The ability of myeloid cells to migrate into tissues containing necrotic debris was determined 
in c-fms-EGFP mice. Tumors from MMTV-PyMT mice were minced and digested with collagenase 
(essentially as described above), cultured overnight, and labeled with CellTrackerTM Red (Invitrogen). 
Stained cancer cells were then freeze-thawed to generate necrotic debris. Debris was co-injected with 
10 kD Alexa Fluor® 647-conjugated dextran (in PBS, Invitrogen) into the surface of the exposed 
inguinal mammary glands of c-fms-EGFP mice. Neighboring tissues were injected with the dextran 
alone as controls. Time-lapse movies were acquired at 10× magnification. Dependency on G-protein-
coupled receptor signaling was determined by pre-treating mice with pertussis toxin (2 mg per mouse 
in PBS, intraperitoneally) 12h prior to, and immediately before imaging. 
Refer to Appendices XI and XII for detailed protocols. 
 
Analysis of in vivo imaging experiments 
Images and movies were assembled in Imaris (Bitplane, version 7.0 for Windows XP 
Professional x64). An increase in cell death in a single field was defined as a gain of or visible 
increase in areas positive for propidium iodide (PI) over time. For each field imaged, a time series of 
single optical section images at 1h intervals (roughly covering 26 to 32h post-doxorubicin treatment 
or the corresponding imaging time for control mice) was generated, and the percentage of each field 
positive for PI at each time point was measured using Volocity (PerkinElmer, version 4.1.0 for 
Windows). All images were analyzed without knowledge of the treatment mice received. 
Infiltration of myeloid cells into tumor tissues was similarly defined as a gain of or a visible 
increase in areas of a single field that were positive for EGFP. A time series of maximum intensity 
projection images at 1h intervals (roughly covering 26 to 32h post-doxorubicin treatment or the 
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corresponding imaging time for control mice) was generated, and the percentage of each field positive 
for EGFP at each time point was measured using Volocity. All images were analyzed without 
knowledge of the treatment mice received. 
To quantify the in vivo mechanisms of cell death, maximum intensity projection images of 
each field at 32 and 42h after doxorubicin administration were generated. Dying cancer cells were 
identified based on propidium iodide positivity and morphology, and counted manually using the Cell 
Counter plugin for the ImageJ software (NIH, version 1.45). 
Refer to Appendix XIII for a detailed protocol. 
 
Histology and immunostaining 
Tumor samples harvested for analysis by histology or immunostaining were fixed overnight 
in paraformaldehyde. Animals were administered either PBS or doxorubicin (8 mg/kg 
intraperitoneally) and euthanized 48h later. Animals used for BrdU incorporation studies were 
administered BrdU (100 mg/kg intraperitoneally, Sigma) two hours prior to treatment with PBS or 
doxorubicin and euthanized 24 or 48h after treatment. Tumor tissues were either processed through 
graded ethanol and embedded in paraffin or through graded sucrose and embedded in OCT medium 
(Tissue-Tek). 
For histological analyses, paraformaldehyde-fixed, paraffin-embedded sections were 
deparaffinized, rehydrated, and stained with Mayer’s hematoxylin and eosin. The antibodies used for 
immunostaining are as follows: αSMA (1:1500, Sigma-Aldrich), BrdU (1:200, clone G3G4, 
Developmental Studies Hybridoma Bank, University of Iowa), CCL2 (1:100, AbD Serotec), CCR2 
(1:100, clone E68, Novus Biologicals), CD206 (1:200, clone MR5D3, AbD Serotec), CD31 (1:25 
Abcam), F4/80 (1:200, clone CI:A3-1, AbD Serotec), MECA-32 (1:50, Developmental Studies 
Hybridoma Bank, University of Iowa), phospho-histone H2AX (Ser139, 1:500, clone 20E3, Cell 
Signaling), phospho-VE cadherin (Tyr731, 1:300, Abcam), and neutrophils/monocytes (1:400, clone 
7/4, Cedarlane). 
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Frozen tissue sections were used for CD206 and F4/80 immunostains, while paraffin-
embedded tissue sections were used for all other immunostains. In paraffin-embedded tissues, 
epitopes were exposed by boiling in either Tris-EDTA or citrate buffer at high pressure. For all 
immunostaining procedures, tissues were blocked with Fc Receptor Block (Innovex) prior to 
incubation with primary antibody, except for histone immunostains, in which tissues were blocked 
with 10% bovine serum albumin with goat serum, or immunostains involving αSMA, where tissues 
were blocked with Mouse-on-Mouse blocking kit (Vector Labs). Histone and BrdU immunostains 
were visualized using horseradish peroxidase-conjugated secondary antibodies with 3,3'-
diaminobenzidine (DAB) substrate (Vector Labs) and counterstained with Mayer’s hematoxylin. All 
other immunostains were visualized with a goat-derived Alexa Fluor® 568-conjugated secondary 
antibody for single label immunostains or goat-derived Alexa Fluor® 568- and Alexa Fluor® 647-
conjugated secondary antibodies for double label immunostains. All fluorescently labeled, 
immunostained tissues were counterstained with 4',6-diamidino-2-phenylindole (DAPI, 0.05 mg/ml, 
Invitrogen). 
Images of immunostains visualized with DAB were acquired using a Zeiss AX10 microscope 
equipped with a Zeiss AxioCam HRc camera. Images of immunostains visualized with fluorescent 
secondary antibodies were acquired with the spinning disk confocal microscope described above for 
live imaging experiments. Single label immunostains for CCL2, CD206, phospho-histone H2AX, and 
phospho-histone H3, and double label immunostains for 7/4 and CCR2, CCL2 and MECA-32, and 
CCR2 and MECA-32 were quantified manually using the Cell Counter plugin for the ImageJ 
software (NIH, version 1.45). Nuclear morphology was also used as a classifier for the BrdU and 7/4 
and CCR2 double label immunostains. The F4/80 and phospho-VE-cadherin single label, and the 
CD31 and αSMA double label immunostains were quantified based on fluorescence intensity in 
Volocity (PerkinElmer). All analyses were performed without knowledge of genotype and/or 
treatment. 
Refer to Appendices VI, VII, VIII, and IX for detailed protocols and Appendix XIV for 
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detailed antibody information. 
 
Analysis of myeloid cell infiltration by flow cytometry 
All flow cytometric analyses were performed on tumors harvested from transplantation 
models. Primary cancer cells derived from MMTV-PyMT (C57BL/6) mice were transplanted into 
wildtype and Ccr2-/- C57BL/6 hosts as described above. Tumor-bearing mice were administered a 
single dose of doxorubicin (8 mg/kg, intraperitoneally), and euthanized 48h after treatment. Tumors 
were harvested, mechanically dissociated, and digested in a DMEM-based solution containing 0.1% 
w/v collagenase A (Sigma) with 4 U/mL DNase I (Sigma) for 90 min at 37°C on a rocking platform. 
The resulting cell suspensions were filtered through 100 µm cell strainers, and erythrocytes were 
lysed by incubation in ammonium chloride potassium lysis buffer for 20 min. The cells were washed 
in a fluorescent activated cell sorting (FACS) buffer containing 1% v/v fetal bovine serum (GIBCO), 
0.02% w/v sodium azide in PBS, and incubated for 20 min in FACS buffer containing 40 µL/mL 
Seroblock (BD Biosciences) at 4°C. Cells were labeled with fluorescently-conjugated antibodies 
against various cell surface markers for 30 min at 4°C, washed in FACS buffer, and analyzed using a 
BDTM LSR II flow cytometer. The antibodies used for flow cytometry were as follows: Gr-1-
allophycocyanin-CyTM7 (1:100, BD Bioscience), CD11b-phycoerythrin (1:200, BD Biosciences), 7/4-
Alexa Fluor® 647 (1:100, AbD Serotec), and F4/80-fluorescein isothiocyanate (1:100, AbD Serotec). 
Refer to Appendices V and XV for detailed protocol and antibody information, respectively. 
 
Cytokine/chemokine array and ELISA 
MMTV-PyMT tumor-bearing mice were euthanized 48h following intraperitoneal 
administration of doxorubicin or PBS, and tumors were harvested, flash frozen in liquid nitrogen, and 
stored at -80°C until use. Tumor samples were homogenized on ice in a 1% NP-40 lysis buffer and 
incubated at 4°C with gentle rocking for 30 min. Following this incubation, samples were centrifuged 
at 13,000×g at 4°C for 10 min and the supernatants collected. Undiluted protein samples were applied 
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to the Proteome Profiler Mouse Cytokine Array Kit, Panel A (R&D Systems) according to the 
manufacturer’s protocol to identify treatment-induced changes in protein level between control- and 
doxorubicin-treated tumors. For the chemokines CCL2 and CCL12, treatment-dependent changes in 
protein levels were confirmed by ELISA. Protein concentrations were first determined using the 
Bradford assay (Bio-Rad), and equal amounts of total protein were assayed using the Quantokine 
Mouse CCL2 and CCL12 Immunoassay kits (R&D Systems) according to the manufacturer’s 
protocol. 
 
In vitro drug sensitivity 
The protocol used to isolate primary mammary organoids is based on that described for the 
isolation of normal mammary epithelial organoids (Ewald et al., 2008). A fluorescence dissecting 
microscope was used to stage and harvest tumors as from MMTV-PyMT;ACTB-ECFP mice. 
Harvested tissues were mechanically dissociated and subsequently digested in a DMEM-based 
collagenase/trypsin solution containing 0.2% w/v collagenase A (Sigma), 0.2% w/v trypsin (GIBCO), 
5 µg/mL insulin, 50 µg/mL gentamycin (GIBCO), and 5% v/v fetal bovine serum (GIBCO) in 
DMEM (GIBCO), for 50 min at 37°C on a rocking platform. Collagenase/trypsin digestion was 
followed by incubation in DNase I (Sigma, 20 U/µL in DMEM) for 5 min at room temperature on a 
rocking platform. After treatment with DNAse I, single cells and debris were removed from 
organoids by repeated rounds of differential centrifugation. 
Organoids were seeded at approximately 150 per well in Growth Factor Reduced Matrigel 
(BD Biosciences) in 24-well plates (Falcon, non-tissue culture treated), incubated for 45 min at 37°C, 
and overlaid with 750 µL of a DMEM-based organoid growth medium containing 1% v/v insulin-
transferrin-selenium, 1% v/v penicillin/streptomycin, and 2.5 nM basic fibroblast growth factor 
(Sigma F0291). Medium was replaced 48h after seeding, and organoids were treated with medium 
containing doxorubicin 24h later. Cell proliferation was determined 48h after doxorubicin treatment 
using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega), according to the 
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manufacturer’s protocol. To collect cells for the Cell Proliferation Assay, organoid-Matrigel drops 
were solubilized by mixing with 80 µL of ice cold growth medium. 
Lapatinib sensitivity in 2D culture was measured using single cells from dissociated tumor 
organoids (isolated as described above) dissociated in a 0.25% trypsin with 0.1% EDTA solution. 
Cells were seeded in 10-cm dishes, allowed to proliferate to subconfluency, and re-seeded at 6000 
cells per well in 96-well plates. Medium was exchanged for organoid medium containing the 
indicated drug concentrations 48h after re-seeding. Cell viability was measured 48h after drug 
treatment, as described above. 
 
Vascular permeability 
Vascular permeability was analyzed in tumors harvested from transplantation models. 
Primary cancer cells derived from MMTV-PyMT (C57BL/6) mice were transplanted into wildtype 
and Ccr2-/- (C57BL/6) hosts as described above. When tumors reached approximately 8 to 10 mm in 
diameter, mice were injected intravenously with a 100 µL PBS-based solution containing fluorescein 
isothiocyanate-conjugated Lycopersicon esculentum (tomato) lectin (1 mg/mL, Vector Laboratories), 
and rhodamine-conjugated Ricinus communis agglutinin I (2.5 mg/mL, Vector Laboratories). Tissues 
were perfused and fixed with 4% paraformaldehyde in PBS 10 min after lectin injection through 
cardiac puncture. The tissues were harvested and post-fixed in 4% paraformaldehyde in PBS 
overnight, processed through graded sucrose and embedded in OCT medium (Tissue-Tek®). Frozen 
sections were cut at thickness of approximately 40 µm and counterstained with DAPI. Images were 
acquired using the spinning disk confocal microscope described above for live animal imaging at 1 
µm resolution in the Z-plane. 
Images were assembled and analyzed in Imaris (Bitplane, version 7.0 for Windows XP 
Professional x64). The vascular volume outlined by either the tomato lectin or Ricinus communis 
agglutinin I was calculated as a percentage of the total volume using the Surfaces function, with 
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smoothing set to 0.66 µm, Filter Type set to 500, and the absolute intensity threshold set to 1.3× the 
background intensity. Co-localization of the two lectins was determined by first generating a masked 
channel for each lectin (voxels set to: 0 for inside surface, 255 for outside surfaces). The Co-
Localization View was then used to generate a co-localization channel representing the percentage of 
the masked Ricinus communis agglutinin I channel that co-localizes with the masked tomato lectin 
channel. 
Refer to Appendix XIII for a detailed protocol. 
 
Statistical methods 
Prism® 4 (GraphPad) software was used for all statistical analyses, with α = 0.05. Fisher’s 
exact tests were performed to compare cell death and myeloid cell infiltration between tumor stages. 
All other statistical analyses were performed using ANOVA or two-tailed Student’s t-tests, as 
indicated. 
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Appendices 
 I. Isolation of cancer cells from primary tumor samples 
 
PREPARATION OF BUFFERS: 
1. Prepare 75mL of Collagenase Buffer immediately prior to addition to tumor tissue. 
2. Prepare RPMI with 1% Penicillin and Streptomycin and store at room temperature. 
3. Warm 1X PBS, 0.25% Trypsin with EDTA in 37°C until use. 
 
PREPARATION OF SURGICAL TOOLS: 
1. Prepare mouse hood: move glass bead sterilizer into the hood and turn it on, prepare 
procedure area. 
2. Wash dissecting tools in soap and water (one pair of forceps and scissors for opening the 
mouse, one pair for removing mammary tumors). Sterilize dissecting tools at >200°C for 30s. 
3. Replace blade for retractable scraper (Techni-Edge, Cat No TE05-503) and sterilize at 
>200°C for 30s. 
 
ISOLATION PROTOCOL: 
1. Sacrifice mouse in the microscope room and transfer her to the procedure area in the mouse 
hood. 
2. Remove tumor(s) (with caliper measurement of ~8-12 mm). Be careful to avoid harvesting 
LN, muscle, and adipose tissue. 
3. Place tumor in appropriately labeled tissue culture dish containing ~6 mL collagenase buffer. 
4. Mechanically dissociate tumors with scraper. Chop tumors until they are small chunks, ~1x1 
mm (~2-3 min). 
5. Transfer chopped tumors to 50 mL Falcon tubes (split dissociated tumors into 2-3 tubes). 
6. Add enough Collagenase buffer for a total volume of 35 mL. 
7. Cap tubes and seal with parafilm. 
8. Shake for 1 hour at 120 rpm at 37°C. 
9. Spin tubes at 1500 rpm for 10 minutes at 25°C. 
10. Discard supernatant. 
11. Resuspend pellet in 6 mL RPMI with penicillin and streptomycin. 
12. Spin tubes at 1500 rpm for 10 minutes at 25°C. 
13. Discard supernatant. 
14. Resuspend pellet in 10 mL RPMI with penicillin and streptomycin, and transfer to 15 mL 
Falcon tubes. 
15. Pulse to 1500 rpm, the press STOP button as soon as speed reaches 1500 rpm. 
16. Discard supernatant. 
17. Repeat Steps 14-16 four times. 
18. Resuspend pellet in 10 mL warm PBS. 
19. Spin tubes at 1500 rpm at 25°C for 10 minutes. 
20. Discard supernatant. 
21. Repeat Steps 18-20. 
22. Resuspend pellet in 5 mL 0.25% Trypsin with 0.1% EDTA. 
23. Incubate at 37°C for 15 min. 
24. Gently pipette up and down to dissociate cells. 
25. Add 10 mL RPMI + 10% FBS to inactivate trypsin. Gently invert tubes to mix. 
26. Spin tubes at 1500 rpm at 25°C for 10 minutes. 
27. Discard supernatant. 
28. Resuspend pellets in 10 mL 1X PBS. 
29. Combine all samples into one 50 mL tube, by straining through a 40 µm cell strainer. 
30. Spin tube at 500 rpm at 25°C for 15 min. 
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 31. Discard supernatant. 
32. Resuspend pellets in 35 mL 1X PBS. 
33. Spin tube at 500 rpm at 25°C for 15 min. 
34. Discard supernatant. 
35. Spin tube at 500 rpm at 25°C for 15 min. 
36. Discard supernatant. 
37. Resuspend supernatant in 5 mL 1X PBS. 
 
 
BUFFERS AND SOLUTIONS: 
Collagenase Buffer – Prepare Fresh 
Reagent Final Solution 
1× RPMI 72.5 mL 
FBS (5% final) 2.5 mL 
Gentamycin 50 µL 
Insulin (10 mg/mL stock, 5µg/mL final) 25 µL 
Trypsin 0.15 g 
Collagenase A 0.15 g 
DNAse I, 2U/µL (Final conc. 8U/mL) 600 µL 
Total 75 mL 
 
1) Mix RPMI, FBS, Gentamycin, and Insulin (warmed to 37°C).  
2) Incubate in 37°C water bath. 
3) Weigh trypsin and collagenase A, and add to solution. 
4) Mix solution at RT for > 15 min. 
5) Filter sterilize (0.2 µm filter). 
6) Add DNase I to solution (NOTE: this step must be done in the hood!) 
 
RPMI+10% FBS – Store at 4°C 
Reagent Final Solution 
1× RPMI 45 mL 
Fetal Bovine Serum (FBS) 5 mL 
Total 50 mL 
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 II. Transplantation of primary cancer cells 
 
PREPARATION OF PRIMARY CELLS FOR TRANSPLANTATION: 
1. Calculate the final volume of cell suspension required. Use the following guidelines: 
calculate for 20 µL of cell suspension per injection, and then double this number (doubling 
the volume is necessary, because some of the volume is lost when preparing the sample for 
injection). For example, for 5 mice: 
 
Total volume = 5 mice × 2 glands per mouse × 20 µL × 2 = 800 µL 
 
2. Calculate the number of cells required for this (400,000 cells per injection = 400,000 cells per 
20 µL of cell suspension). For example, for 5 mice: 
 
Total cell count = 5 mice × 2 glands per mouse × 400,00 cells × 2 = 1.6 × 107 cells 
 
3. Count fresh cells using a hemacytometer (See “Isolation of Cells from Primary Tumor 
Samples” for directions on how to isolate cells). 
4. Determine the volume of cells that has the number of acquired cells and transfer this volume 
to a sterile Eppendorf tube (the number of cells that have isolated usually run between 107 
and 109 cells per mL, depending on the amount of tumor tissue originally harvested and the 
volume in which washed cells have been resuspended). 
 
Volume of fresh cells = 1.6 × 107 cells / (1.5 × 108 cells / mL) = 106.7 µL 
 
5. Adjust the final volume to the volume calculated in Step 1. 
 
Volume of PBS = 800 µL – 106.7 µL = 693.3 µL 
 
6. Gently mix cells and leave at room temperature until injection. 
 
PREPARATION OF SURGERY AREA: 
1. Sterilize the flow hood. 
2. Cover the surface of the flow hood with a disposable surgical underpad. Tape the pad in place 
with laboratory tape. 
3. Set up the anesthesia system. Be sure to weigh the activated charcoal canister (it should be 
replace after a 50 gram increase in weight), and replace if necessary. The nose cone may need 
to be taped to the surgical underpad to prevent it from moving. 
4. Place insulin syringes (0.5 mL; 28 gauge, ½ inch, Becton-Dickinson, Cat. No. 329461) and 
sharps container near the procedure area. 
 
TRANSPLANTATION PROCEDURE: 
1. Induce anesthesia at 4% isoflurane. Once the animal’s breathing has slowed, switch the 
anesthesia to the nose cone in the procedure area and transfer the animal. Place the animal 
ventral side up on the surgical underpad (the animal does not have to be completely 
anesthetized at this point). Make sure to secure her nose in the nose cone.  
2. Restrain the mouse with surgical tape. It is easiest to do this by fastening a long piece of tape 
across the ribcage (this will hold the animal in place and ensure she stays in the nose cone) 
and taping the hind limbs to the surgical pad. Make sure the hind limbs are restrained such 
that the lower portion of the mouse is stretched out. 
3. Decrease the anesthesia to 2.5% for the remainder of the procedure. 
130
 4. Prepare two syringes for injection. Gently flick the tube containing the cell suspension for 
transplantation to mix the cells (primary cells are very sticky). Each syringe should contain 
20 µL of cell suspension. Always make sure the rubber portion of the syringe plunger is at the 
same location with respect to the 20 µL line, preparing the syringe. Be sure to avoid touching 
the tip of the needle to any surface. 
5. Disinfect the site of injection with ethanol. 
6. Locate the number 4 and 5 nipples. Location of these two nipples on the right side of the 
animal. 
 
 
 
7. With the beveled edge of the needle facing away from the skin, insert the needle just above 
the number 5 nipple, making sure to avoid piercing the peritoneum. 
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 8. Gently angle the needle toward the number four nipple until the needle hits the epithelium 
resting under the nipple. There should be some resistance to when the needle has entered this 
epithelium. 
 
 
 
9. Slowly and gently inject the cell suspension into the mammary epithelium (this avoids 
causing too much damage to the tissue). A bubble of liquid should form after the injection. 
10. Gently remove the syringe and dispose of it. 
11. Repeat Steps 1-10 for the contralateral mammary gland. 
12. Once both injections have been performed, remove the laboratory tape restraining the animal, 
and allow the animal to recover. The entire procedure should take no more than ~5-7 min. 
 
FOLLOW-UP: 
Allow the animal 1 week to recover from the procedure before beginning to palpate the mammary 
glands for tumors. Tumors arising in animals transplanted with cancer cells isolated from 
MMTV-PyMT mice take approximately 3 weeks before they are palpable. This same procedure 
can be used to transplant cell lines into syngeneic or immunocompromised hosts. 
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 III. Treatment of animals with chemotherapy 
 
All solutions must be prepared in a sterile hood.  
 
DOXORUBICIN RECIPE 
REAGENT SUPPLIER CAT. NO. SIZE  
Doxorubicin Hydrochloride Sigma-Aldrich 44583-10MG 10 mg 
 
DOXORUBICIN STOCK SOLUTION: 10 mg / mL 
COMPONENT Volume  
Doxorubicin Hydrochloride 10 mg 
Sterile dH2O 1 mL  
TOTAL VOLUME 1 mL 
FINAL CONCENTRATION 10 mg/mL 
 
Store Stock Solution at 4°C. Doxorubicin is soluble to 50 mg / mL in dH2O. 
 
DOXORUBICIN WORKING SOLUTION: 0.8 mg / mL (12.5× Dilution of Stock Solution) 
COMPONENT  1×  
Doxorubicin Stock (10 mg/mL) 24 µL  
Sterile PBS  276 µL  
TOTAL VOLUME  300 µL  
FINAL CONCENTRATION 0.8 mg / mL 
 
Working solution must be prepared fresh. 
 
(10 µg / µL) × 24 µL = 240 µg 
240 µg  / 300 µL = 0.8 µg / µL = 0.8 mg / mL 
0.8 µg / µL × 10 µL / g = 8 µg / g = 8 mg / kg 
 
Dosage: 10 µg / µL (8 µg / g of body weight) 
 
 
CYCLOPHOSPHAMIDE RECIPE 
REAGENT SUPPLIER CAT. NO. SIZE  
Cyclophosphamide Monohydrate MP Biomedicals (via Fisher) IC15074905 5g 
 
WORKING SOLUTION: 7.5 mg / mL 
COMPONENT Volume  
Cyclophsophamide Monohydrate 3 mg 
Sterile dH2O 400 µL  
TOTAL VOLUME 400 µL 
FINAL CONCENTRATION 7.5 mg / mL 
 
Cyclophosphamide working solution is prepared fresh. 
 
NOTE: Weigh out appropriate amount of cyclophosphamide and filter-sterilize the final solution. 
Cyclophosphamide is soluble to 40 g/L in water. 
 
(7.5 µg / µL) × (10 µL / g) = 75 µg / g = 75 mg / kg 
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 Dosage: 10 µL / g (75 µg / g of body weight) 
 
 
CISPLATIN RECIPE 
REAGENT SUPPLIER CAT. NO. SIZE  
Cisplatin MBL International Corp. JM-1550-100 1g 
 
STOCK SOLUTION: 10 mg / mL 
COMPONENT Volume  
Cisplatin  0.5 g 
Sterile DMSO 500 µL  
TOTAL VOLUME 500 µL 
FINAL CONCENTRATION 10 mg/mL 
 
WORKING SOLUTION: 1 mg / mL 
COMPONENT 1×  
Cisplatin Stock  30 µL 
Sterile PBS 270 µL  
TOTAL VOLUME 300 µL 
FINAL CONCENTRATION 1 mg/mL 
 
(10 µg / µL) × 30 µL = 300 µg 
300 µg / 300 µL = 1 µg / µL =  1 mg / mL 
1 µg / µL × 10 µL / g = 10 µg / g = 10 mg / kg 
 
Dosage = 10 µL / g    (10 µg / g of body weight) 
 
Cisplatin stock solution is stable for up to 1 week at -20°C (it is better to prepare it fresh). A stock 
solution is prepared so mice are not treated with pure DMSO. 
 
NOTE: Weigh out appropriate amount of cisplatin and filter-sterilize final solution. Cisplatin is 
soluble to 10 mg/mL in DMSO. 
 
SAFETY 
Doxorubicin, cyclophosphamide, and cisplatin are strong cytotoxic agents. Always wear gloves 
and appropriate safety equipment when handling these drugs. 
 
ADMINISTRATION 
1. Palpate mammary glands and measure tumors with calipers. 
2. Divide mice into two groups with tumors of approximately the same size. 
3. Weigh animals. Calculate the volume of chemotherapy needed to administer to each animal. 
4. Inject each animal with the working drug solution or the control solution intraperitoneally. 
Record the time at injection (this time point is 0 hours). 
5. Euthanize mice at the specified time point(s). 
6. Harvest tissue. If tissue is to be used for immunohistochemistry, collect tissue in cassette and 
fix in 4% paraformaldehyde overnight. If tissue is to be used for DNA, RNA, or protein 
analysis, flash freeze tissue in liquid nitrogen and store at -80°C. 
 
NOTE: Controls receive 10 µL / g of the control solution. For doxorubicin, this is 1× PBS. For 
cyclophosphamide, this is sterile water. For cisplatin, this is DMSO diluted 1:10 in 1× PBS. 
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 IV. Treatment of animals with RS 504393 and doxorubicin 
 
SOLUTIONS AND REAGENTS 
Prepare doxorubicin according to the protocol “Treatment of animals with doxorubicin.” 
 
RS 504393 STOCK SOLUTION: 10 mg/mL 
COMPONENT Volume  
RS 504393 (CCR2 inhibitor) 10 mg 
Sterile dH2O 1 mL  
TOTAL VOLUME 1 mL 
FINAL CONCENTRATION 10 mg/mL 
 
Store stock solution at 4°C. 
 
RS 504393 WORKING SOLUTION: 0.2 mg/mL (50× Dilution of Stock Solution) 
COMPONENT 1×  
RS 504393 (10 mg/mL) 6 µL  
Sterile dH2O 294 µL  
TOTAL VOLUME 300 µL  
FINAL CONCENTRATION 0.2 mg/mL  
 
Prepare working solution fresh. 
 
(10 µg / µL) × 6 µL = 6 µg 
6 µg / 300 µL = 0.2 µg / µL =  0.2 mg / mL 
0.2 µg / µL × 10 µL / g = 2 µg / g = 2 mg / kg 
 
Dosage = 10 µL / g    (2 µg / g of body weight) 
 
ADMINISTRATION 
1. Palpate mammary glands and measure tumors with calipers. 
2. Divide mice into four groups with tumors of approximately the same size. 
3. Weigh animals. Calculate the volume of doxorubicin needed to administer to each animal. 
4. Administer the first dose of RS 504393 (two groups) or the DMSO control (two groups) 25 
hours prior to administration of doxorubicin or PBS. 
5. Continuing administering RS 504393 or the DMSO control every 12 hours until 
euthanization. 
6. Administer doxorubicin (one RS 504393 and one DMSO group) or PBS (one RS 504393 and 
one DMSO group) 25 hours after the first RS 504393 or DMOS treatment. 
7. Euthanize mice 48 hours after administration of doxorubicin or PBS. 
8. Harvest tissue. If tissue is to be used for immunohistochemistry, collect tissue in cassette and 
fix in 4% paraformaldehyde overnight. If tissue is to be used for DNA, RNA, or protein 
analysis, flash freeze tissue in liquid nitrogen and store at -80°C. 
 
NOTE: The control for RS 504393 is DMSO diluted in water (6 µL DMSO with 294 µL sterile 
water; RS 504393 precipitates in PBS so water must be used instead). 
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 V. Isolation of primary tumor cells for flow cytometric analyses 
 
PREPARATION OF BUFFERS: 
1. Prepare FACS Buffer up to 5 days prior to use. 
2. Prepare ~15-20 mL of Collagenase Buffer immediately prior to addition to tumor tissue; 
warm 1× RPMI and FBS in 37°C incubator until preparation of buffer. 
3. Prepare ACK Lysis Buffer and store at room temperature (RBC Lysis Buffer (10x) from 
BioLegend, Cat No 420301, may be used in place of ACK Lysis Buffer; dilute RBC Lysis 
Buffer 1:10 in dH2O prior to use). 
 
PREPARATION OF SURGICAL TOOLS: 
1. Wash dissecting tools in soap and water (one pair of forceps and scissors for opening the 
mouse, one pair for removing mammary tumors). Sterilize dissecting tools at >200°C for 30s. 
2. Replace blade for retractable scraper (Techni-Edge, Cat No TE05-503) and sterilize at 
>200°C for 30s. 
 
ISOLATION PROTOCOL: 
1. Sacrifice mice and remove tumor (generally R5 or L5 with a caliper measurement of ~12-15 
mm). If removing L4 or R4, take care to avoid taking the lymph node with the tumor tissue. 
2. Place tumor in appropriately labeled tissue culture dish containing 6 mL ice cold RPMI 
(without FBS) and place on ice. 
3. Weigh tumor samples and calculate amount of Collagenase Buffer required (1 mL / 0.3 g 
tumor tissue; for tumors of size ~12-15 mm, this should require ~3-3.5 mL of Collagenase 
Buffer). 
4. Mechanically dissociate tumors with scraper. Chop tumors until they are mostly fluid, with 
almost no chunks (~7-10 minutes). 
5. Remove Collagenase Buffer from 37°C incubator (or water bath). Add appropriate volume of 
Collagenase Buffer to each sample (1 mL / 0.3 g tumor tissue, as calculated in Step 3) and 
transfer samples to appropriately labeled 50 mL Falcon tubes. 
6. Tighten Falcon tube covers and wrap cover with parafilm. 
7. Lay Falcon tubes flat on the base of a 37°C shaking incubator, and tape down tubes to secure 
them in place.  
8. Shake tubes at 37°C for 90 min at 70 rpm. 
9. Remove tubes from incubator. 
10. Add 10 mL of R-10 to each sample. 
11. Centrifuge at 1500 rpm for 8 min at 4°C. 
12. Transfer supernatants to new 50 mL Falcon tubes spin at 1500 rpm for 8 min at 4°C. 
Meanwhile, resuspend pellets in 8 mL ice cold R-10 with 8 mL ice cold 1× PBS. 
13. Discard supernatant from second spin. 
14. Resuspend second pellet in 2 mL ice cold R-10 with 2 mL ice cold 1× PBS. Transfer 
resuspension to that from Step 14. 
15. Filter each sample into new 50 mL Falcon tube using a 100 µm cell strainer. 
16. Centrifuge samples at 1500 rpm for 8 min at 4°C. 
17. Resuspend pellets in 10 mL ACK Red Blood Cell Lysis Buffer. 
18. Incubate on ice for 3-5 min. 
19. Add 20 mL ice cold R-10 and 20 mL ice cold 1× PBS to each sample. 
20. Centrifuge at 1500 rpm for 6 min at 4°C. 
21. Discard supernatant. 
22. Resuspend pellets in ice cold R-10 (5-10 mL). 
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 23. Strain each resuspension into a new 50 mL Falcon tube using a 40 µm cell strainer. KEEP 
CELLS ON ICE. 
24. Count cells using hemacytometer. 
 
STAINING PROTOCOL: 
1. Plate cells in a 96-well round-bottom plate according to pre-determined template. Each well 
should contain approximately 1×106 cells. 
2. Centrifuge plate at 2000 rpm for 30s at 4°C. 
3. Discard supernatant by flicking plate. Make sure there are cells collected at the bottom of 
each inoculated well. 
4. Resuspend cells in 50 µL ice cold FACS Buffer with Fc Block (1:50 dilution for a 
concentration of 0.5 µg per well). 
5. Incubate at 4°C for >15 min. 
6. While cells are incubating in Fc Block, prepare antibody solutions. All antibodies are used at 
a dilution of 1:100, except for CD11b-PE, which is used at a dilution of 1:200. 
7. Add 50 µL of antibody solution to appropriate wells. Incubate in the dark at 4°C for >30 min. 
8. Adjust volume of each well to 200 µL with ice cold FACS Buffer. 
9. Centrifuge plate at 2000 rpm for 30s at 4°C. 
10. Discard supernatant by flicking plate. Wash 2× with 150 µL ice cold FACS buffer. 
 
FIXING CELLS: 
1. Add 200 µL of 0.5% paraformaldehyde in 1× PBS. 
2. Incubate cells at 4°C overnight (8-12 hours). 
3. Centrifuge plate at 2000 rpm for 30s at 4°C. 
4. Discard supernatant by flicking plate. Wash 2× with 150 µL ice cold FACS buffer. 
5. Resuspend in 150 µL ice cold FACS Buffer (for cells to be stained with 7-AAD, add 2.5 µL 
7-AAD per 150 µL of FACS Buffer). 
 
ANALYSIS: 
1. Transfer cells to labeled 12×75 mm polystyrene test tubes. Keep in dark on ice or at 4°C until 
Flow Cytometry appointment. 
2. Run samples on a LSR II (BD Biosciences) flow cytometer. 
3. Analyzed FACS data using FACSDivaTM (BD Biosciences) software. 
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 BUFFERS AND SOLUTIONS: 
Collagenase Buffer – Prepare Fresh 
Reagent Final Solution 
1× RPMI 10 mL 
Collagenase (Final conc. 2mg/mL) 2 mg/mL 
DNAse I, 1U/µL (Final conc. 4U/mL) 40 µL 
Total 10 mL 
 
ACK Lysis Buffer – Filter sterilize and store at room temperature 
Reagent Final Solution 
NH4Cl (0.15 M) 8.024 g 
KHCO3 (10 mM) 1.001 g 
Na2EDTA⋅2H2O 3.722 mg 
dH2O 1000 mL 
Total 1000 mL 
 
R-10 – Store at 4°C 
Reagent Final Solution 
1× RPMI 45 mL 
Fetal Bovine Serum (FBS) 5 mL 
Total 50 mL 
 
FACS Buffer – Store at 4°C up to 5 days 
Reagent Final Solution 
1× PBS 49.4 mL 
Fetal Bovine Serum (FBS) 0.5 mL 
Sodium Azide (10% w/v) 0.1 mL 
Total 50 mL 
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VI. Immunohistochemical staining of phospho-histone H3 (DAB staining) 
 
NOTE: This is a sample immunohistochemical stain. Antigen retrieval and incubation times may 
vary depending on the antibody. Most antibodies work in sodium citrate buffer (pH 6.0) with a 
retrieval time of 6 min at 6 psi, 60 min primary antibody, and 30 min secondary incubation. This 
protocol, which can also be used to stain for phospho-histone H2AX, is an exception. 
 
1. Warm slides in 56°C oven for 20 min. 
(Tissue slides are kept in slide holder for entire procedure – until drying and mounting) 
 
2. While slides are warming, prepare pressure cooker. 
 
Fill the cooking pot with water up to the 11-cup line. Properly cover and lock the pressure 
cooker. Make sure the dots on the pressure valve and cooker cover are aligned. Plug in the 
pressure cooker. Press Menu twice to set to High Pressure. Press Time four times to set the 
clock to 05 minutes. Press start. 
 
Also during this time, check that all containers for tissue rehydration are full with ‘clean’ 
fluids – if not, refill. 
 
3. Begin rehydration of tissue: 
– Histoclear 5 min 
– Histoclear 5 min 
 
By this point, the pressure cooker should have beeped to signal completion of the 
pressurization cycle. Release pressure valve to depressurize the pressure cooker. BE 
CAREFUL, HOT STEAM IS RELEASED FROM PRESSURE VALVE. When the 
red pin on the cover slides down, unlock and uncover the pressure cooker, and place 
Coplin jar containing Sodium Citrate buffer into pressure cooker. Re-cover the pressure 
cooker without locking it. Press Start/Cancel to turn off the Keep Warm setting. Press 
Menu until the Simmer setting is selected, then press Start/Cancel. This will keep the 
water in the pressure cooker heated until antigen retrieval. 
 
– 100% Ethanol 3 min  
– 100% Ethanol 3 min 
– 95% Ethanol 3 min 
– 95% Ethanol 3 min  
– 70% Ethanol 3 min 
– 70% Ethanol 3 min 
– dWater 3 min 
 
4. Antigen retrieval: 
Press Start/Cancel to turn off the Simmer setting. Press Menu once to select the Low Pressure 
setting. Press Time five times to set the clock to 15 minutes. Cover and lock the pressure 
cooker. Make sure the dots on the pressure valve and cooker cover are aligned. Press 
Start/Cancel. When pressure cooker beeps to signal completion of the cycle, release the 
pressure valve to depressurize the pressure cooker. BE CAREFUL, HOT STEAM IS 
RELEASED FROM PRESSURE VALVE. When the red pin on the cover slides down, 
unlock and uncover the pressure cooker. Using forceps or autoclave gloves, transfer the 
Coplin jar to sink and run cold water into the jar for 10 min to cool down slides. Transfer 
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 cooled slides to PBS to keep slides hydrated. Using a PAP pen, draw around tissue (do not 
let tissue dry out). Transfer slides to clean PBS. 
 
5. Antibody staining: 
– Block endogenous peroxidase activity: 3% H2O2 in PBS 20 min 
– PBS 5 min 
– PBS 5 min 
– Block in 1× Blocking Solution 1 hour 
– PBS 3 min 
– Block with Avidin solution 15 min 
– PBS 10 dips 
– Block with Biotin solution 15 min 
– PBS 10 dips 
– Apply α-pH3 antibody, diluted 1:50 in 0.5× blocking buffer to  
bottom section in humidified chamber at room temperature 1 hour 
– Apply Ready-Made Rabbit Isotype Control to top section in  
humidified chamber at room temperature 1 hour 
– PBS  3 min 
– PBS 3 min 
– PBS 3 min 
– Block in × antibody blocking buffer 15 min 
– Apply biotinylated secondary antibody, α-rabbit, diluted 1:400 in 
0.5× blocking buffer, in humidified chamber 30 min 
– Make up ABC-Elite solution during secondary incubation 
– PBS 3 min 
– PBS 3 min 
– PBS 3 min 
– Apply ABC-Elite solution to sections, in humidified chamber 30 min 
– PBS 2 min 
– PBS 2 min 
– Make up DAB solution during second PBS wash 
– Apply DAB solution      KEEP TIME CONSTANT for all slides 6 min 
– Wash in dH2O 10 dips 
 
6. Counterstaining with Hematoxylin – NO EOSIN 
– Hematoxylin 5 min 
– PBS 5 min 
– 95% Ethanol 10 dips 
– 95% Ethanol 10 dips 
– 100% Ethanol 10 dips 
– 100% Ethanol 10 dips 
– Histoclear 2 min 
– Histoclear 2 min 
 
7. Mounting 
a. Take slides out of slide holder, put them on slide tray covered with paper towels (make 
sure the right side is up!!!). Add 2-3 drops of Cytoseal 60 on top of tissue.  
b. Carefully cover with cover glass, avoiding air bubbles. Remove any excess Cytoseal with 
KimWipes before it dries. 
c. Leave to dry in flow hood for several hours on slide tray 
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Reagents: 
Histoclear: Fisher Scientific 
Hematoxylin: From Zymed / Invitrogen 
PBS: Phosphate Buffered Saline (1× PBS) 
Cover glass: No. 1.5 24×50 mm (Corning) 
3% H2O2: 25 mL of 30% H2O2 and 225 mL 1× PBS 
1× Blocking Buffer: 1 mL: 50 µL goat serum, 250 µL 10% BSA, 700 µL 1× PBS 
0.5× Blocking Buffer: 1 mL: 25 µL goat serum, 125 µL 10 BSA, 850 µL 1× PBS 
Fc Receptor Blocker: Innovex; NB309-15 
10% BSA: 1 g BSA (bovine serum albumin, in fridge) in 10 mL Milli-Q water; 
store in 1 mL aliquots in freezer. 
Avidin / Biotin Kit: Vector Laboratories, SP-2001 
ABC-Elite Solution: Add 1 drop of solution A to 2.5 mL PBS and mix. Add 1 drop of 
solution B and mix. Allow 30 minutes to pass before use. 
DAB-Solution: Liquid DAB black substrate kit, Vector Labs. Keep in the dark until 
use. Add 1 drop of Buffer pH 7.5 to 2.5 mL dH2O and mix. Add 2 
drops of DAB substrate and mix. Add 1 drop of H2O2 and mix. 
Minimize light exposure and use immediately after preparation. 
α-pH3 antibody: Rabbit-α-mouse, Cell Signaling, #9701S 
Control Rabbit IgG: Rabbit isotype control, Invitrogen #08-6199 
Secondary Antibody: Biotinylated α-Rabbit IgG, Fab fragment, made in goat; Santa Cruz, 
# sc-3840 
Cytoseal60: Fisher Scientific, #23-244-256 
Sodium Citrate Buffer: 10 mM Sodium Citrate, 0.05% Tween 20, pH 6.0 
 Dissolve 2.94 g of sodium citrate (dihydrate) in 1000 mL of distilled 
water. Adjust to pH 6.0 with 1N HCl (initially the solution will have 
a pH of ~8.5; 2-3 mL of 1N HCl may be required to adjust the pH 
properly). Add 0.5 mL Tween 20 to the solution and mix well. 
Solution may be stored at room temperature for 3 months, or at 4ºC 
for a longer period of time. 
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 VII. Immunofluorescence staining of α-SMA (Mouse on Mouse staining) 
 
NOTE: This protocol is adaptable for use with any mouse-anti-mouse antibody. Overnight 
incubations should not be used for mouse-α-mouse antibodies, as this results in very low positive 
staining signal with a high level of background. This is protocol is also used for performing dual 
labeling in which one of the primary antibodies is a mouse-α-mouse antibody.  
 
1. Warm slides in 56°C oven for 20 min. 
 
2. While slides are warming, prepare pressure cooker. 
 
Fill the cooking pot with water up to the 11-cup line. Properly cover and lock the pressure 
cooker. Make sure the dots on the pressure valve and cooker cover are aligned. Plug in the 
pressure cooker. Press Menu twice to set to High Pressure. Press Time four times to set the 
clock to 05 minutes. Press start. 
 
Also during this time, check that all containers for tissue rehydration are full with ‘clean’ 
fluids – if not, refill. 
 
3. Begin rehydration of tissue: 
– Histoclear 5 min 
– Histoclear 5 min 
 
By this point, the pressure cooker should have beeped to signal completion of the 
pressurization cycle. Release pressure valve to depressurize the pressure cooker. BE 
CAREFUL, HOT STEAM IS RELEASED FROM PRESSURE VALVE. When the 
red pin on the cover slides down, unlock and uncover the pressure cooker, and place 
Coplin jar containing Sodium Citrate buffer into pressure cooker. Re-cover the pressure 
cooker without locking it. Press Start/Cancel to turn off the Keep Warm setting. Press 
Menu until the Simmer setting is selected, then press Start/Cancel. This will keep the 
water in the pressure cooker heated until antigen retrieval. 
 
– 100% Ethanol 3 min  
– 100% Ethanol 3 min 
– 95% Ethanol 3 min 
– 95% Ethanol 3 min  
– 70% Ethanol 3 min 
– 70% Ethanol 3 min 
– dWater 3 min 
 
4. Antigen retrieval: 
Press Start/Cancel to turn off the Simmer setting. Press Menu once to select the Low Pressure 
setting. Press Time five times to set the clock to 06 minutes. Cover and lock the pressure 
cooker. Make sure the dots on the pressure valve and cooker cover are aligned. Press 
Start/Cancel. When pressure cooker beeps to signal completion of the cycle, release the 
pressure valve to depressurize the pressure cooker. BE CAREFUL, HOT STEAM IS 
RELEASED FROM PRESSURE VALVE. When the red pin on the cover slides down, 
unlock and uncover the pressure cooker. Using forceps or autoclave gloves, transfer the 
Coplin jar to sink and run cold water into the jar for 10 min to cool down slides. Transfer 
142
 cooled slides to PBS to keep slides hydrated. Using a PAP pen, draw around tissue (do not 
let tissue dry out). Transfer slides to clean PBS. 
 
8. Blocking of non-specific binding: 
– PBS 5 min 
– Block in M.O.M. IgG Block Reagent 1 hour 
– PBS 2 min 
– PBS 2 min 
 
9. PBS Primary antibody staining: 
– Incubate tissue sections in working solution M.O.M. diluent 5 min 
– Apply αSMA antibody (1:1500 in M.O.M. diluent) to bottom section in 
humidified chamber at RT 1 hour 
– Apply ready-made Mouse IgG control to top section, 
in humidified chamber at RT 1 hour 
– PBS 3 min 
– PBS 3 min 
– PBS 3 min 
 
FROM THIS POINT, KEEP SLIDES IN THE DARK WHENEVER POSSIBLE 
 
10. Secondary antibody staining: 
– Apply α-Mouse-Alexa568 secondary in M.O.M. diluent in a 
humidified chamber at RT 30 min 
– PBS 10 min 
– PBS 5 min 
– PBS 5 min 
– dH2O 5 min 
– Counterstain with DAPI (diluted 1:100 in dH2O) 10 min 
– dH2O 3 min 
 
11. Mounting: 
a. Add 2-3 drops of FluoroGel on top of tissue. 
b. Carefully cover with cover slip, avoiding air bubbles. 
c. Let dry 30 minutes in the dark. 
d. Seal the edges of the cover slip with Cytoseal 60 and let dry. 
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 Reagents: 
Histoclear: Fisher Scientific 
PBS: Phosphate Buffered Saline (1× PBS) 
Cover slip: No. 1.5 24×50 mm (Corning) 
M.O.M. Kit Vector Labs, Cat. No. BMK-2202  
M.O.M. Mouse Ig Blocking Reagent:  Add 2 drops of stock solution to 2.5 ml of PBS. 
M.O.M. Diluent:  Add 600 µl Protein Concentrate to 7.5 ml of 1× PBS  
α-Smooth muscle actin:      Monoclonal Anti-Actin α Smooth Muscle; Sigma, 
#A5228 
Control Mouse IgG: Mouse isotype control, Invitrogen #08-6599 
α-Mouse-IgG-Alexa568: Alexa Fluor 568 F(ab’)2 fragment of goat anti-mouse 
IgG (H+L), Invitrogen #A11019 
DAPI: Invitrogen, D3571; Frozen stock 5 mg/mL in dH2O 
FluoroGel: with PIPE buffer, Electron Microscopy Sciences, 
#17985-40 
Cytoseal60: Fisher Scientific, #23-244-256 
Sodium Citrate Buffer: 10 mM Sodium Citrate, 0.05% Tween 20, pH 6.0 
 Dissolve 2.94 g of sodium citrate (dihydrate) in 1000 mL 
of distilled water. Adjust to pH 6.0 with 1N HCl 
(initially the solution will have a pH of ~8.5; 2-3 mL of 
1N HCl may be required to adjust the pH properly). Add 
0.5 mL Tween 20 to the solution and mix well. Solution 
may be stored at room temperature for 3 months, or at 
4ºC for a longer period of time. 
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 VIII. Immunofluorescence staining of CD206 (staining of frozen tissue) 
 
NOTE: This protocol can be used for the immunofluorescence staining of most frozen samples. 
Step 3 is not required, but results in better tissue staining. 
 
1. Remove slides from -80°C freezer and allow slides to warm to room temperature (~5 
minutes). If tissues already contain fluorescent molecules (e.g. lectins, dextran, ECFP, EGFP) 
keep slides in dark as much as possible. 
 
2. Using a scalpel, carefully remove the sticky OCT from the slide. If the OCT does not easily 
pull away from the slide, gently pipette PBS onto the slide and let the slide sit for 3 minutes 
at room temperature. Gently tip off the PBS onto a paper towel and then using a scalpel, 
remove the OCT. 
 
3. Post-fix the tissue by gently placing the labeled slides into an upright glass Coplin jar 
containing a 1:1 mixture of ice cold methanol and acetone. Incubate at room temperature for 
10 min. 
 
4. Draw a circle around each tissue section using a PAP pen, and place slides onto a rack in a 
humidifying chamber (from now on, all steps will be done in a humidifying chamber). 
 
5. Using a pipette, gently add 200 µL PBS to each tissue section and incubate at room 
temperature for 5 minutes. Repeat this wash step once. 
 
6. Antibody staining (gently add 200 µL or 2-3 drops of each solution to tissue sections; to 
remove liquid once the incubation has been completed, gently tip off the fluid onto a paper 
towel): 
– Block in Fc Receptor Blocker 30 min 
– PBS 5 min 
 
7. Primary antibody staining: 
– Apply antibody solution (α-CD206 diluted in 1:200 0.5× blocking  
buffer) to bottom section in humidified chamber at room temperature 1 hour 
– Apply Rat IgG2a negative isotype, diluted 1:400 in 0.5× blocking to 
top section in a humidified chamber at room temperature 1 hour 
PBS 3 min 
– PBS 3 min 
– PBS 3 min 
 
FROM THIS POINT, KEEP SLIDES IN THE DARK WHENEVER POSSIBLE 
 
8. Secondary antibody staining: 
– Block in 1× antibody blocking buffer 15 min 
– Apply antibody solution (α-Rat-Alexa568 diluted 1:150 in 0.5×  
blocking buffer) in humidified chamber at room temperature 30 min 
– PBS 10 min 
– dH2O 5 min 
– dH2O with DAPI (diluted 1:100) 10 min 
– dH2O 3 min 
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 Reagents: 
Histoclear: Fisher Scientific 
PBS: Phosphate Buffered Saline (1× PBS) 
Cover glass: No. 1.5 24×50 mm (Corning) 
3% H2O2: 25 mL of 30% H2O2 and 225 mL 1× PBS 
1× Blocking Buffer: 1 mL: 50 µL goat serum, 250 µL 10% BSA, 700 µL 1× PBS 
0.5× Blocking Buffer: 1 mL: 50 µL goat serum, 125 µL 10 BSA, 850 µL 1× PBS 
Fc Receptor Blocker: Innovex; NB309-15 
10% BSA: 1 g BSA (bovine serum albumin, in fridge) in 10 mL Milli-Q water; 
store in 1 mL aliquots in freezer. 
α-CD206 antibody: Rat-α-mouse, AbD Serotec, MCA2235GA 
Control Rat IgG: Rat Negative Isotype IgG2a 
Secondary Antibody: Biotinylated α-Rat IgG, Fab fragment; made in goat (Santa Cruz) 
DAPI: Invitrogen, D3571; Frozen stock 5 mg/mL in dH2O 
Vectashield: Vector Labs, H-1000 
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 IX. Immunofluorescence staining of CCR2 and 7/4 (double label staining) 
 
NOTE: This is a sample double label immunostain. Antigen retrieval and incubation times may 
vary depending on the antibody combination. Most antibodies work in sodium citrate buffer (pH 
6.0) with a retrieval time of 6 min at 6 psi, 60 min primary antibody, and 30 min secondary 
incubation. This protocol is an exception. 
 
1. Warm slides in 56°C oven for 20 min. 
 
2. While slides are warming, prepare pressure cooker. 
 
Fill the cooking pot with water up to the 11-cup line. Properly cover and lock the pressure 
cooker. Make sure the dots on the pressure valve and cooker cover are aligned. Plug in the 
pressure cooker. Press Menu twice to set to High Pressure. Press Time four times to set the 
clock to 05 minutes. Press start. 
 
Also during this time, check that all containers for tissue rehydration are full with ‘clean’ 
fluids – if not, refill. 
 
3. Begin rehydration of tissue: 
– Histoclear 5 min 
– Histoclear 5 min 
 
By this point, the pressure cooker should have beeped to signal completion of the 
pressurization cycle. Release pressure valve to depressurize the pressure cooker. BE 
CAREFUL, HOT STEAM IS RELEASED FROM PRESSURE VALVE. When the 
red pin on the cover slides down, unlock and uncover the pressure cooker, and place 
Coplin jar containing Sodium Citrate buffer into pressure cooker. Re-cover the pressure 
cooker without locking it. Press Start/Cancel to turn off the Keep Warm setting. Press 
Menu until the Simmer setting is selected, then press Start/Cancel. This will keep the 
water in the pressure cooker heated until antigen retrieval. 
 
– 100% Ethanol 3 min  
– 100% Ethanol 3 min 
– 95% Ethanol 3 min 
– 95% Ethanol 3 min  
– 70% Ethanol 3 min 
– 70% Ethanol 3 min 
– dWater 3 min 
 
4. Antigen retrieval: 
Press Start/Cancel to turn off the Simmer setting. Press Menu once to select the Low Pressure 
setting. Press Time five times to set the clock to 20 minutes. Cover and lock the pressure 
cooker. Make sure the dots on the pressure valve and cooker cover are aligned. Press 
Start/Cancel. When pressure cooker beeps to signal completion of the cycle, release the 
pressure valve to depressurize the pressure cooker. BE CAREFUL, HOT STEAM IS 
RELEASED FROM PRESSURE VALVE. When the red pin on the cover slides down, 
unlock and uncover the pressure cooker. Using forceps or autoclave gloves, transfer the 
Coplin jar to sink and run cold water into the jar for 10 min to cool down slides. Transfer 
cooled slides to PBS to keep slides hydrated. Using a PAP pen, draw around tissue (do not 
let tissue dry out). Transfer slides to clean PBS. 
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5. Antibody staining: 
– PBS 5 min 
– 1× Blocking Buffer 1-2 hours 
– PBS 3 min 
– Block in Fc Receptor Blocker 30 min 
– PBS 5 min 
– Apply α-CCR2 antibody (diluted 1:100) and α-7/4 (diluted 1:400) 
in 0.5× blocking buffer to bottom section in humidified chamber 
at room temperature 30 min 
– Apply Ready-Made Rabbit Isotype Control to top section in  
humidified chamber at room temperature 30 min 
– PBS  3 min 
– PBS 3 min 
– PBS 3 min 
 
FROM THIS POINT, KEEP SLIDES IN THE DARK WHENEVER POSSIBLE 
 
6. Secondary antibody staining: 
– Block in 1× antibody blocking buffer 15 min 
– Apply antibody solution (α-Rabbit-Alexa568 and α-Rat-Alexa647 
both diluted1:150 in 0.5× blocking buffer) in humidified chamber 
at room temperature 30 min 
– PBS 10 min 
– dH2O 5 min 
– dH2O with DAPI (diluted 1:100) 10 min 
– dH2O 3 min 
 
7. Mounting: 
e. Add 2-3 drops of Vectashield on top of tissue. 
f. Carefully cover with cover slip, avoiding air bubbles. 
g. Let dry 30-60 minutes in the dark. 
h. Seal the edges of the cover slip with clear nail polish and let dry overnight. 
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 Reagents: 
Histoclear: Fisher Scientific 
Hematoxylin: From Zymed / Invitrogen 
PBS: Phosphate Buffered Saline (1× PBS) 
Cover glass: No. 1.5 24×50 mm (Corning) 
3% H2O2: 25 mL of 30% H2O2 and 225 mL 1× PBS 
1× Blocking Buffer: 1 mL: 50 µL goat serum, 250 µL 10% BSA, 700 µL 1× PBS 
0.5× Blocking Buffer: 1 mL: 25 µL goat serum, 125 µL 10 BSA, 850 µL 1× PBS 
Fc Receptor Blocker: Innovex; NB309-15 
10% BSA: 1 g BSA (bovine serum albumin, in fridge) in 10 mL Milli-Q water; 
store in 1 mL aliquots in freezer. 
α-CCR2 antibody: Rabbit-α-mouse, Abcam, #AB32144 
α-7.4 antibody: Rat-α-mouse, Cedarlane Labs, #CL8993AP 
Control Rabbit IgG: Rabbit isotype control, Invitrogen #08-6199 
α-Rabbit-IgG-Alexa568: Alexa Fluor® 568 F(ab')2 fragment of goat anti-rabbit IgG (H+L), 
Invitrogen #A21069 
α-Rat-IgG-Alexa647: Alexa Fluor® 647 Goat Anti-Rat IgG (H+L), Invitrogen, #A-21247 
DAPI: Invitrogen, D3571; Frozen stock 5 mg/mL in dH2O 
Vectashield: Vector Labs, #H-1000 
Sodium Citrate Buffer: 10 mM Sodium Citrate, 0.05% Tween 20, pH 6.0 
 Dissolve 2.94 g of sodium citrate (dihydrate) in 1000 mL of distilled 
water. Adjust to pH 6.0 with 1N HCl (initially the solution will have 
a pH of ~8.5; 2-3 mL of 1N HCl may be required to adjust the pH 
properly). Add 0.5 mL Tween 20 to the solution and mix well. 
Solution may be stored at room temperature for 3 months, or at 4ºC 
for a longer period of time. 
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X. Detection of vascular permeability by lectin staining 
 
SOLUTIONS AND REAGENTS 
All solutions must be prepared in a sterile hood.  
 
REAGENT SUPPLIER CAT. NO. SIZE STOCK  
Rhodamine-Ricinus communis Agglutinin I Vector Labs RL-1082 5 mg/mL As is 
Fluorescein-Lycopersicon esculentum lectin Vector Labs FL-1171 2 mg/mL As is 
 
WORKING SOLUTION VOLUME [FINAL]  
Ricinus lectin 50 µL 2.5 mg/mL 
Lycopersicon lectin 50 µL 1 mg/mL  
Total 100 µL 
 
PREPARATION FOR PERFUSION: 
1. Prepare fresh 4% paraformaldehyde (PFA) and store at 4°C until use. Keep in mind that ~20-
30 mL will be needed to flush the tubing prior to perfusion, and ~50-60 mL will be needed to 
perfuse the mouse, so calculate the total volume required based on the approximation that 
~100 mL of fixative will be required per animal). 
2. Prepare the fume hood: move the glass bead sterilizer and dissection tray (the base should be 
wax or rubber) into the hood. This procedure should be performed in a fume hood to avoid 
prolonged exposure to paraformaldehyde. 
3. Place an absorbent blue mat on top of the dissection tray (the blue mat should be cut into 
fourths before use), and pin the corners to the dissection tray. 
4. Set up the anesthesia equipment. Be sure to fasten the nose cone to the dissection tray (tape 
the nose cone down with laboratory tape, and pin the tape to keep the cone immobilized). 
5. Prepare four strips of laboratory tape to restrain the animal for the procedure. 
6. Prepare a 60 syringe and winged infusion set. Draw in ~60 mL of 4% PFA into the syringe, 
and screw the female Luer-LokTM end of the infusion set into the male Luer-LockTM end of 
the syringe. Flush 10-15 mL of 4% PFA through the system to remove air bubbles. Keep the 
syringe on ice. 
7. Wash surgical tools in soap and water (two pairs of forceps, two pairs of scissors). Sterilize 
dissecting tools at >200°C for 30s. 
 
VASCULAR LABELING AND PERFUSION: 
1. Induce anesthesia at 4% isoflurane. Keep animal in induction chamber until she is completely 
anesthetized. 
2. Switch the anesthesia from the induction chamber to the nose cone in the procedure area. 
3. Transfer the animal to the procedure area, ventral side up. Make sure the animal’s nose is 
secured in the nose cone. 
4. Gently restrain the animal by fastening the limbs to the procedure area with laboratory tape. 
Leave one limb unrestrained. 
5. Decrease the flow rate of isoflurane to 2.5%. 
6. Make sure the animal is fully anesthetized by performing a footpad pinch on the unrestrained 
limb. The animal should not react to this. If she does, she is not sufficiently anesthetized for 
the procedure. This is a very harsh procedure that causes a lot of pain. The animal cannot be 
awake for any portion of it. 
7. When the animal is sufficiently anesthetized, restrain the final limb. 
8. Inject 100 µL of the Ricinus communis lectin / Lycopersicon esculentum lectin mixture 
intravenously via the tail vein. Wait 10 minutes. 
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 9. During the 10-minute wait, disinfect the ventral surface of the animal with an ethanol wipe. 
10. Carefully make a subcutaneous midline incision beginning from approximately 0.5 cm from 
above the urethra to the top of the ribcage. 
11. Make an incision from the middle of the peritoneal cavity to the base of the rib cage. 
12. Gently pierce the connective tissue below the diaphragm to collapse the lungs and the 
thoracic cavity. 
13. Quickly cut open the ribcage. Make two incisions, one ~2 mm from the left of the midline, 
and one ~2 mm from the right of the midline. 
14. Fold the middle portion of the ribcage up and expose the heart. 
15. Hold the heart steady with a pair of forceps (be sure to use the forceps with the serrated tips, 
not the forceps with teeth – you do not want to puncture the heart). 
16. Using the winged infusion set, gently cannulate the left ventricle, and slide the needle straight 
up into the descending aorta. Be careful not to push the needle to far up (not more than 5 
mm), because you may puncture the heart and disrupt circulation. Systemic circulation must 
remain intact to perfuse the whole body. 
17. Cut the right atrium (pulmonary circulation), and begin to slowly perfuse the tissue. Maintain 
constant pressure on the syringe plunger. Blood should flow steadily out of the incision you 
made in the right atrium. Continue to perfuse until the fluid that flows out of the heart is clear 
(~30-50 mL). Be careful not to perfuse the tissue too quickly, as high perfusion rates will 
rupture vessels (if you are using a sphygmomanometer paired with a gravity drip system or a 
controlled perfusion system, the pressure should be between 60 and 100 mm Hg).  
18. At this point, the animal should be dead. If she is not, quickly remove the heart. 
19. Turn off the anesthesia. 
20. Harvest the tissue and post-fix overnight at 4°C in 4% PFA. 
21. Process the tissue through a graded sucrose solution (12% for ≥ 2 hours, 15% for ≥ 2 hours, 
18% for ≥ 2 hours, 25% over night). 
22. Embed tissue in O.C.T. freezing medium (Tissue-Tek). 
23. Store blocks at -80°C. 
 
COUNTERSTAINING: 
1. Cut thick tissue sections (40 to 80 µm). 
2. Store slides at -80°C until use. 
3. Thaw tissue sections at room temperature (~ 5 min). 
4. Gently remove O.C.T. medium. 
5. Draw a circle around the tissue section with a wax pen. 
6. Wash the tissue in 1× PBS for 5 min at room temperature. 
7. Incubate tissue in dH2O for 5 min at room temperature. 
8. Counterstain with DAPI (diluted 1:100) for 10 min. 
9. Wash in dH2O for 3 min. 
10. Mount cover slips using Vectashield. 
11. Acquire image using confocal microscope. 
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 XI. Operating the Egeblad laboratory spinning disk confocal microscope 
 
1. Turn the computer on. 
2. Turn on the argon laser. 
a. Flip the I/O switch on. 
b. Turn the key to the on position (with the clock). 
c. Adjust the laser power to its minimum level (about 4.75 Amps) using the level on the 
table to the right of the microscope. 
3. Turn on the solid-state lasers (405 nm, 561, 641 nm). 
a. Turn on power strip for laser table. 
b. Turn all three keys to the “on” position. 
c. Verify that the Solamere box (on top of box covering laser path) is turned on. 
 
4. Turn on the microscope accessories and controllers. 
a. Turn on power strip for microscope table. 
b. Check that the following are turned on: 
– X-cite lamp for looking at fluorescence signal through the microscope eyepieces (on 
the shelf behind and above microscope) 
– AOTF controller (on shelf behind and above microscope)  
– Piezo controller (on shelf behind and above microscope) 
– Filter wheel controller (on shelf behind and above microscope) 
– ASI stage controller (on the table to the right of the microscope) 
– Microscope power supply 
 
5. Turn on the microscope. 
a. Turn on the microscope (button on the left side, to the very back of the microscope). 
b. Move the stage to its lowest position using the focus knob on microscope – the monitor 
will say “Lower z reached.” 
c. Turn on the spinning disk (attached to the left of the microscope): turn key to the “on” 
position and push button labeled “shutter”. The light next to the key should turn red. 
 
6. Turning on the software and camera: 
d. Make sure the camera controller (on the table to the left of the computer screen) is in the 
standby position. 
e. Turn on the camera controller. 
f. Double check that the microscope stage is in its lowest position. 
g. Open µManager (all equipment except the camera controller must be turned on before 
opening the software). 
 
7. Troubling-shooting tips 
a. Always leave the camera controller in “standby” when not actively using the camera 
b. Do not turn off microscope if less than 3 hours before next user 
c. The camera controller should be used between 0.65 and 0.9. 
d. If the signal is too bright, even at lowest exposure (33 ms), adjust the laser power with 
the Solamere box (using the relevant knob for the dye). 
e. If the signal is too low for one laser line, increase the exposure time. 
f. If the signal is too low for several laser lines or for a single line (even after attempting to 
increase the exposure time), increase the camera gain (but do not use above 0.9). If the 
signal for GFP (488 nm) is still too low, adjust the laser power using the level on table to 
the right of the microscope.  
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8. Shutting down the system: 
a. Make sure camera controller (on the table to the left of the computer screen) is in the 
standby position and at 0.65-0.85 before turning off camera controller 
b. Close µManager software 
c. Transfer images to server (shut down computer when transfer is complete). 
d. Adjust laser power for argon laser to lowest level possible. 
e. Switch off the key to argon laser (488 nm) – ONLY THE KEY, do not turn off the 
exhaust. 
f. Lower the microscope stage to the lowest possible setting. 
g. Remove the microscope stage insert. 
h. Turn off the spinning disk (using key, it is not necessary to press button). 
i. Turn off the power strip on the microscope table and check that all equipment is turned 
off. 
j. Cover the microscope up. 
k. Turn off the keys to the solid-state lasers (405, 561, 641 nm). 
l. Turn off the power strip to laser table. 
 
9. Turn off Argon laser (I/O button, controls exhaust and may continue even after turned off if 
laser was used for a long period of time) 
 
153
 XII. Preparation of Animals for Intravital Imaging 
 
PREPARATION OF PBS (Do this in a sterile hood!) 
1. Dilute the propidium iodide (1 mg/mL, Invitrogen) 1:15 in 1× PBS in a sterile hood. For a 24 
hour imaging session, prepare ~3 mL. 
2. Draw ~1 mL of the PI solution into a 1 mL syringe. 
3. Attach a winged infusion set (23 gauge, ¾ inch needle, 12 inch tubing, Terumo) to this 
syringe and pump the PI solution through the tubing so that just a drop of PI solution exits the 
needle. 
4. Remove the syringe from the infusion set, and refill it with PI solution. 
5. Reattach the syringe to the infusion set, taking care not to introduce too many bubbles into 
the line. 
6. Attach the syringe to the microscope and cover it with foil. 
 
PREPARATION OF THE MICROSCOPE: 
1. Turn on the microscope computer and the microscope (see protocol “Operating the Egeblad 
laboratory spinning disk confocal microscope”). 
2. Turn on the heating blanket (this is not attached to the microscope system, so it needs to be 
turned on separately). 
3. Disinfect the microscope stage insert with ethanol wipes. 
4. Disinfect two cover slips (No. 1.5, 24 × 50 mm glass) with ethanol wipes. 
5. Place the two cover slips side by side on the microscope stage insert, so that they are covering 
the two imaging ports. 
 
 
 
6. Gently apply pressure to the two cover slips to hold them in place, and tape them down with 
laboratory tape (½ inch tape works best). 
7. Disinfect the prepared microscope stage insert with ethanol wipes. 
8. Cover the prepared microscope stage insert with a piece of sterile gauze. 
9. Position the microscope stage insert on the microscope stage with the imaging ports 
appropriately positioned for imaging the mouse. The nose cone that delivers anesthesia to the 
microscope is placed on the left side of the microscope. Thus, if the tumor to be imaged is on 
the right side of the animal, the side of insert with the imaging ports should sit away from the 
eyepieces. Conversely, if the tumor to be imaged is on the left side of the animal, the side of 
the insert with the imaging ports should sit next to the eyepieces. 
10. At the microscope, tear 4 to 6 pieces of tape (1 inch width), approximately 6 inches in length 
and attach them to the side of the microscope. These pieces of tape will be used to position 
the nose cone delivering anesthesia and fasten it in place. 
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 11. Tear two more pieces of tape (½ inch width) that are about an inch in length. These will be 
used to keep the butterfly needle delivering PBS to the mouse and the microscope slide used 
to expose the tumor in place. 
 
PREPARATION OF THE ANESTHESIA SYSTEM: 
1. Locate the anesthesia system to the right of the microscope. 
2. Add water to the humidifier and screw it in place. If the water in this humidifier evaporates 
very quickly or there is a hissing sound coming from the humidifier, there is probably a crack 
in the plastic, and it needs to be replaced. 
3. Check to make sure the isoflurane tank is filled. If the tank is half full or less, fill it to the top 
line. 
4. Turn on the oxygen sensor (it should not yet be attached to the anesthesia system; if it is, 
unhook it). When the sensor has been equilibrated to the room, attach the oxygen sensor to 
the anesthesia system. 
5. There are two gas tanks attached to the anesthesia system. Turn on both the oxygen tank and 
the nitrogen tank. The nitrogen should be at around 1.0, while the oxygen should be at around 
0.2. 
6. Turn on the in-house vacuum. The vacuum should fluctuate between about 0.5 and 1.0. 
7. Make sure the line to the induction chamber is open, and the lines to the surgery area and the 
microscope are closed. 
8. Check the black rubber bag attached to the anesthesia system to make sure it is inflated. If 
there is a tear in it replace the bag (if there is no replacement, remove the bag, tape it up, and 
replace it). 
9. Check the rubber gauze on each the nose cones delivering anesthesia to the microscope stage 
and the surgical platform. If the gauze is starting to thin, change the gauze. 
 
PREPARATION OF SURGERY AREA: 
1. Collect the lid to a Styrofoam shipping cooler. This will be your surgical platform. 
2. Cover the lid with a piece of blue absorbent mat (cut these mats in fourths, only a fourth of 
the mat is needed). 
3. Place this surgical platform on the empty space in front of the anesthesia system. 
4. Collect two pins (i.e. two pink needles). 
5. Tape (1 inch width) the nose cone to the surgery platform. Insert pins (one on each side of the 
nose cone) into the tape to secure the nose cone in place. 
6. Tape the blue hose delivering the anesthesia into the nose cone to the microscope bench if it 
is not already (this will ensure that the surgical platform remains flat – it is often too light to 
stay flat once the nose cone has been fastened to it). 
7. Set aside two ethanol wipes, a microscope slide, Krazy Glue®, and 4 pieces of tape (½ inch 
width). 
 
PREPARATION OF SURGICAL TOOLS: 
1. Turn on glass bead sterilizer. 
2. Wash dissecting tools in soap and water (one pair of forceps [preferably with teeth] and 
scissors for opening the mouse, one pair of forceps [preferably serrated] and scissors for 
exposing the tumor). Sterilize the dissecting tools at >200°C for 30s. 
3. Place the dissecting tools on the side (making sure to avoid touching the sterilized areas of 
the tools with anything), to let the tools cool enough to perform the procedure. 
 
SURGICAL PROCEDURE: 
1. Transfer the mouse to the induction chamber. 
2. Induce anesthesia at 4% isoflurane. 
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 3. Once the mouse is breathing slowly and deeply, open the anesthesia line to the surgery 
platform. 
4. Transfer the mouse to the surgical platform, placing her ventral side up. Close the anesthesia 
line to the induction chamber. 
5. Turn the anesthesia down to 2.5% isoflurane. 
6. Restrain three of the mouse’s limbs with laboratory tape. 
7. Perform a footpad pinch on the unrestrained limb. The mouse should not react to this. If she 
does, she is not sufficiently anesthetized for the procedure; wait a couple of minutes and 
perform the footpad pinch again. 
8. Once the mouse is sufficiently anesthetized, restrain the final limb with laboratory tape. 
9. Disinfect the ventral surface of the mouse with an ethanol wipe (do this twice). 
10. Using the pair of forceps with teeth and a pair of scissors, make a subcutaneous midline 
incision from approximately 0.5 cm above the urethra to just below the ribcage. Be careful 
not to cut through the peritoneum. 
11. Set this pair of forceps and scissors aside. 
12. Using the second pair of forceps (serrated) and scissors, gently separate the skin covering the 
inguinal mammary gland/tumor to be imaged. The connective tissue that attaches the skin to 
the peritoneum is weak, so the skin pulls away relatively easily. Try to avoid cutting this 
connective tissue, as you may accidentally pierce blood vessels in the skin or puncture the 
peritoneum. 
13. Take the glass microscope slide and position it against the skin flap that you have just 
created. Position the flap so that the bulk of the tumor will sit flat when the mouse is placed 
on the stage, and it does not interfere with the mobility of the hind legs. 
14. Once the microscope slide has been properly positioned, attach it to the skin flap using Krazy 
Glue®. 
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 15. Fold the skin flap back over to cover the exposed peritoneum (this will limit desiccation of 
the tissues as well as limit the collection of dust and other particles, while shifting the mouse 
to the microscope stage). 
 
TRANSFERRING THE MOUSE TO THE STAGE: 
1. Open the anesthesia line to the microscope stage. 
2. Gently remove the laboratory tape restraining the mouse. 
3. Quickly transfer the animal to the microscope stage, ventral side down. 
4. Once the mouse has been transferred, make sure to insert her nose into the nose cone. 
5. Close the anesthesia line to the surgery area. 
6. Carefully position the mouse so that the tumor is in the center of the imaging port (this will 
usually be the imaging port on the right) and that the mouse is in a comfortable position with 
respect to the nose cone. 
7. Once the mouse has been positioned, tape the nose cone down (using the 1 inch tape 
previously prepared). 
8. Insert the butterfly needle into the peritoneum. Avoid puncturing any of the abdominal 
organs. 
9. Attach the oximeter probe either to the hind leg opposite the side being imaged or fix a throat 
collar around the mouse’s neck (the throat collar is more reliable, but can only be used if the 
mouse has small or no tumors in the neck area). 
10. Open the MouseOx software (STARR Life Sciences) on the computer. Select the correct 
probe and settings (adult, anesthetized mouse). Begin monitoring the mouse. Vitals under 
optimal anesthesia conditions should be: 
 
Heart Rate: ≥300 bpm and ≤450 bpm 
Oxygen Saturation: 97-98% 
Breath Rate: 55-65 breaths per minute 
 
The oximeter probe will take several minutes to stabilize, and may need to be repositioned. 
 
11. Once the oximeter probe has been attached to the animal and is reading stable vital signs, tape 
down double check that the mouse is appropriately positioned for imaging. 
12. Tape down the microscope slide and the butterfly needle. 
13. Cover the mouse with the heating pad. 
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 XIII. Using Imaris 
 
CALCULATING TIME STAMPS AND FRAME RATES: 
1. Locate and open the folder containing the raw images captured using the Egeblad laboratory 
spinning disk confocal microscope. µManager saves the files in the following manner (names 
in bold, except for the top two, are sample names for each of these folders): 
 
egeblad (main server folder) 
Name (folder with your name on it) 
Top Folder (usually saved as YY_MMDD) 
Sample Folder (usually saved as MouseID_color1_color2_color3_ 
genotype_lens_Exp#) 
Positions Folder (automatically saved by µManager as Pos0, Pos1, …) 
Original TIFFs Folder (this folder will have three types of files: an 
acquisition file [this will be an XML file], the original TIFF outputs 
[these are saved as TIFFs, and will vary in number], and a metadata 
file [this will be a .txt file]) 
 
µManager automatically stores each individual image that is captured with a certain format. 
Each of your original TIFF files should be named something like this: 
 
img_000000113_2_000 
 
The numbers are interpreted as follows:     img_timepoint_channel_zslice 
 
2. In general, the time between frames that you set in µManager is the time between each frame. 
However, if you have set the time between frames to be 90s, when it actually takes 120s to 
capture the entire stack of images in each channel at each position, you need to calculate this 
value manually for each experiment. In Excel, make a spreadsheet that looks like this: 
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 Column A: Experiment Number (Imaging experiments are saved sequentially. Each experiment 
is saved in a new folder in the Sample Folder, where the experiment number is the number at the 
end of each folder name). 
 
Columns B and C: This is the time at which you have treated the animal (in this case, with 
doxorubicin) on the 24-hour clock. In this example, the animal was treated at 7:40 am, so the time 
is given as is. 
 
Columns D and E: This is the imaging start time for the experiment. We arbitrarily set this time 
to the time at which the first image of the first position was acquired. This value represents the 
hours elapsed since treatment. The hour value requires a little bit of math. This is the time elapsed 
since treatment. For example, if the animal was treated at 22:40 the previous night, and imaging 
was started at 18:33 as in the example below, the hour setting would be 20 (Column D). The 
Minutes column would be entered as simply the actual minute value given (33 in this case, for 
Column E). If instead, the animal has been injected at 22:40 two days prior to imaging, the hour 
quantity becomes 24 + 20. This same calculation is performed for injections 48, 72, etc. hours 
prior to imaging. For untreated mice, the time would simply be 6:33 PM = 18 hours (Column D) 
and 33 min (Column E). If 24, 48, etc. hours have elapsed since the start of imaging, this hour 
quantity becomes 18 + 24, 18 + 48, etc. 
 
 
 
 
Columns F and G: This is the imaging end time for the experiment. We arbitrarily set this time 
to the time at which the last image of the first position was acquired. The same considerations 
apply as per Columns D and E. 
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Column H: This is the number of time points in the Experiment. Look at the last TIFF file in the 
experiment. The file reads img_000000089_3_002. The number in bold represents the last time 
point acquired. The number of time points in the experiment is 89 + 1. µManager starts counting 
at 0, not 1. 
 
Column I: This is the imaging time. This is calculated in minutes. To do this, subtract the hour 
quantity of the Start Time from the End Time, and multiply this by 60 minutes. Do the same for 
the minute quantity. Add the resulting values. 
 
Imaging Time: (Column F – Column D) × 60 min + (Column G – Column E) 
 
Columns J and K: This is the time that elapses between each frame (this is generally on the 
order of 1 min and several seconds). The calculations are as follows: 
 
Minutes (Column J): INT(Imaging Time) / (Time Points – 1) 
= INT(Column I) / (Column H – 1) 
 
The INT function rounds this value to the nearest integer. You must subtract 1 from the number 
of time points, so that the last time point will have the same value as your imaging end time. 
 
Seconds (Column K): (((Imaging Time) / (Time Points– 1)) – Minutes) × 60 sec 
= (((Column I) / (Column H – 1)) – Column J) × 60 sec 
 
The expression enclosed by the red parentheses gives you the imaging time in minutes (the value 
should appear as X.XX, where the X to the left of the decimal point is the same value that appears 
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 in Column J). The expression enclosed by the blue parentheses gives you the values after the 
decimal point. This fraction needs to be converted into a value of seconds, so you need to 
multiply the final number by 60 sec. 
 
Columns L, M, and N: This gives you the time stamp for your movie. We first need to calculate 
the number of minutes elapsed since treatment. The equation for this is as follows: 
 
Minutes (Column L): (Hour Value at Imaging Start) × 60 min + (60 – Min Value at Injection + 
Min Value at Imaging Start) 
= (Column D) × 60 min + (60 – Column C+ Column E) 
 
We go on to calculate the time stamp at the start of the movie, using the following equations. 
 
Hour (Column M): INT(Elapsed Time in minutes) / (60 min) 
= INT(Column L) / (60 min) 
If 24, 48, etc. hours have passed the calculation becomes: 
INT((Column L) / (60 min) – 24 hours) 
 
Minutes (Column N): (Elapsed Time in minutes, i.e. Column L) – (60 min × Hour) 
= (Column L) – (60 min × Column M) 
If 24, 48, etc. hours have passed the calculation becomes: 
(Column L) – (60 min × Hour) – (24 hours × 60 min) 
 
Column O: This is the frame rate. We usually set this to 600× real time speed. The calculation is 
as follows: 
 
Frame Rate: (Desired Frame Rate) / (Minute Value for Time Between Frames × 60 seconds + 
Seconds Value for Time between Frames 
 
COMPILING ORIGINAL TIFF FILES INTO AN IMARIS FILE: 
1. Open Imaris. 
2. Open Batch Convert by going to File > Batch Convert. 
3. The Imaris File Converter window should open. 
 
 
4. Check “Specific Folder,” and then Click on the button that says “Browse…”. Create a new 
folder or choose a location to save the final output file. Then click OK. 
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Once this has been done, click the button that says “Set for All.” 
 
5. Locate and open the folder containing the raw images captured using the Egeblad laboratory 
spinning disk confocal microscope. 
6. Drag a single TIFF file from this folder into the Imaris File Converter window. 
 
 
7. Do this for each position for each experiment. 
8. Click on the “Settings” button next to the first file. The following window will appear. 
 
 
9. Remember that µManager automatically stores each individual image as 
img_timepoint_channel_zslice. Change each box accordingly and click on the “OK” button. 
 
10. Click on the “ … ” button next to the Output for the first file. This button will allow you to 
change the name of the file. The default pathway for saving files in µManager gives you a file 
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 that says something like “img_000000000_1_000.” When Imaris converts files, the original 
Input name is the same as the final Output name, so if this is not changed, all information 
about the experiment is lost. You need to change the names manually before you convert 
the TIFFs to an Imaris file. 
 
 
 
 
11. Click the “Save” button. 
12. Repeat Steps 8-11 for each file that you have dragged into the Imaris File Converter window. 
13. Click the “Start” button. Your files will automatically be saved in the specified folder. 
 
ADJUSTING THE IMAGE SETTINGS:  
1. Open an Imaris file. You will get two windows: the Imaris window and the Display 
Adjustment window (if the Display Adjustment window does not open automatically, go to 
Edit > Show Display Adjustment). 
 
 
2. In the Display Adjustment window, click on the “Channel 1” button. The Image Properties 
window will appear. 
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3. Channel 1 should be highlighted on the left. Change the Name of this channel and the color. 
In this example, this is a β-actin mouse, so the name will be “ACTB-ECFP,” and the color 
will be blue. Generally, Channel 1 = CFP signal, Channel 2 = GFP signal, Channel 3 = RFP 
signal, and Channel 4 = Far Red signal. 
 
 
4. Repeat Step 3 for each channel. 
5. Click on Geometry. The window will now look like this. 
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 6. Input the correct voxel size. (A voxel is a volumetric pixel: this is the three-dimensional 
volume represented by each pixel.) 
 x y z 
10× Objective 0.66 0.66 8 
20× Objective 0.33 0.33 8 
40× Objective 0.167 0.167 2 
These values are in µm. The values input for z will change depending on how many µm apart 
each step between z-slices has been set to. For the z setting, these values are what we usually 
use for intravital imaging experiments (although this may change depending on the 
experiment); for slides, this may be 1-2 µm.  
 
 
7. Click on the “All Equidistant” button. This will allow you to set the time between frames and 
the start time. The Set Equidistant Time Points window will appear. 
 
 
8. Using the information you calculated in the previous section, input the appropriate values for 
“Start Time” and “Time Interval.” 
 
 
9. Click the “OK” button. The Set Equidistant Time Points window will close. 
10. Click the “OK” button in the Image Properties window. It will close. 
11. On the bottom right corner of Imaris, click on the “Fit” button. 
 
 
Your screen will now look something like this: 
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12. You can change the color intensity and background levels for each channel in the Display 
Adjustment window, by dragging the black arrows in each channel or inputting specific 
values under Settings. 
 
 
Adjusting the color using the arrows: The channel surrounded by the yellow box is the 
channel that has been selected. The arrow on the left shows the lower limit cutoff, and will 
usually help to get rid of some of the background as it moves right. The arrow on the right 
shows the upper limit, and enhances the intensity of the signal as it moves left. 
 
 
 
Numbers can be input manually (for example, if you already known your cutoff values for 
quantification purposes). The Gamma should always = 1.00 and the Opacity should always = 
100%. 
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 TAKING PICTURES IN IMARIS: 
1. Click on the “Snapshot” button (the default is usually to have the image in Easy 3D – this 
will give you a maximum intensity projection consisting of the entire z-stack). 
 
 
Your screen will now look like this. 
 
 
2. In the Snapshot Panel 
 
Uncheck the box next to “Crop to fill whole snapshot area.”  
Image Size: select “Predefined Dimensions”  
Width: 1024 (this is in pixels) 
Height: 1024 (this is in pixels) 
Resolution: 600 (this is in dpi) 
Uncheck the box next to “Snapshot size from window size.” 
Designate the location and name for the snapshot by clicking the “ … ” button. 
 
 
 
3. Click the “Do Snapshot!” button. 
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 4. To take images of a single z-slice, click on the Easy 3D button, and select Slice. 
 
 
5. Your work area will now look like this. 
 
 
6. You can scroll through the z-slices on the left, either by moving the pointer up and down to 
another tick, or by manually inputting the slice you want to take a snapshot of (bottom left). 
Frames in the experiment are similarly arranged below the image, so you can scroll between 
each frame or manually input the frame you want to be on (bottom right). 
 
SHOWING THE SCALE BAR AND TIME STAMP: 
1. To show the scale bar, scale size, and image time, go to Edit > Preferences. The Preferences 
window will appear. 
 
 
Under Coordinate Axis / Scale Bar, check boxes next to “Show Scale Bar,” “Show Scale Bar 
Label,” and the “Show Time [HH:MM:SS.S].” 
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2. Click the “OK” button. 
3. The scale bar can be adjusted by clicking on the scale bar and stretching or shrinking it. 
 
EXPORTING MOVIES FROM IMARIS: 
1. Put Imaris into window resize mode. To do this, the buttons at the top right in the Imaris 
window should look like this: 
 
 
If this not what you see, click on the middle button. 
2. On the bottom right corner of Imaris, click on the “Fit” button 
 
 
3. Resize the Imaris window so that Zoom: 50%. Click on the “Fit” button each time you resize 
the Imaris window, so that you know the actual zoom size. 
 
 
4. Click on the Record button (this is the button with the red dot). 
 
 
The Save As Movie window will open. 
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5. Designate a location to save the movie and the movie name (the default is the same name as 
the Imaris file). 
6. Under movie settings, change the Frame Rate to the rate that you previously calculated. The 
compression factor can be left at 5. (You don’t need to compress the movie, but this makes 
the movie file very big). 
 
 
7. Click the “Save” button. 
 
CROPPING 3D IMAGES IN IMARIS: 
1. Go to Edit > Crop 3D. The Crop 3D window will appear. 
 
 
2. Enter in the desired crop dimensions. For x and y, From and To give the location of the area 
to be cropped, while Size gives you the dimension in each direction of the cropped field. 
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 These values are in pixels. For z, From and To designate the slice number (number goes from 
1 = lowest slice to X = top slice), and Size is the number of total slices in the cropped image. 
 
 
In this example, we only want to crop in z, so we set the From and To for x and y to 1 and 
1024, respectively, and just change the values of From and To for z. 
3. Click on the “OK” button. 
4. Go to File > Save As, and save cropped Imaris file. Clicking on Save will overwrite the 
original file, and in most cases you want to save the original file. 
 
QUANTIFICATION OF VASCULAR LEAKAGE: 
1. Crop each image so that the z-slices without any information are removed. Each field will 
have a different number of z-slices after this. The final volume for each field will be (n – 1) 
µm. 
2. Save the cropped Imaris file. 
3. Click on Surpass. 
 
 
Your work area will now look like this. 
 
 
 
4. In the Camera Panel on the right hand of the work space, check the boxes next to “Select” 
and “Orthogonal.” 
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5. In the Surpass panel, the “Surfaces” button. 
 
 
A new line called “Surfaces 1” will appear. 
 
 
 
6. When you highlight this line, a Settings Panel will appear below. 
 
 
7. Click on the Create tab. 
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a. Under Algorithm Settings, check the box next to “Segment Only a Region of Interest” 
 
 
b. Click on the  button. 
c. In the Display Adjustment window, uncheck the boxes next to the DAPI channel and the 
Ricinus lectin channel, and make sure that for the two lectin channels, the left black 
arrows are at the minimum value and the left black arrows are at the maximum value. 
 
 
d. Create 3 regions of interest (50 to 100 pixels in size). 
 
 
Place your regions of interest in areas near blood vessels or in areas containing the 
highest degree of background. 
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 e. Click on the  button. 
f. Select the tomato lectin channel and then check the boxes next to “Smooth” and 
“Absolute Intensity.” You can use the default setting for “Smooth” (this is calculated as 
the x,y voxel size multiplied by 2, so for an image acquired using the 20× objective, the 
value is 0.33 × 2 = 0.66). 
 
 
g. Click on the  button. Your work space will now look like this. 
 
 
h. Change the area of the yellow shading in the Surpass panel (leave the box next “Enable” 
unchecked), so that there are no pixels in any of the three regions of interest that you have 
selected. 
 
 
 
Your work space should look like this. 
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i. Record the number that appears above the histogram. This number multiplied by 1.3 is 
the background setting. (The 1.3 multiplier is not set in stone. You may need to use a 
background cutoff that is higher or lower depending on the tissue sample and how well it 
stained. 
 
  
j. Click the  button until you reach the “Algorithm” page (the first one) of the Surpass 
panel. 
k. Repeat steps 9a through 9i for the Ricinus lectin channel. 
8. Click the  button until you reach the “Algorithm” page (the first one) of the Surpass 
panel. 
9. Check the boxes next to “Segment Only a Region of Interest” and “Process entire Image 
finally.” 
 
 
10. Click on the  button. Make 1 region of interest that encompasses the entire field. The 
workspace should look like this: 
 
 
175
 The Surpass panel should look like this: 
 
 
 
11. Click on the  button. 
12. Select the tomato lectin channel. Make sure that in the Display Adjustment window, only the 
tomato lectin channel is selected. 
13. In the Surpass panel, select the tomato lectin channel and then check the boxes next to 
“Smooth” and “Absolute Intensity.” You can use the default setting for “Smooth” (this is 
calculated as the x,y voxel size multiplied by 2, so for an image acquired using the 20× 
objective, the value is 0.33 × 2 = 0.66). 
 
 
14. Click on the  button. 
15. In the Threshold panel, input the value that you calculated in 7i. 
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 Your workspace should look like this. If the calculated threshold is too stringent, adjust the 
threshold until you get most of the blood vessels and very little background. 
 
 
16. Click on the  button. 
17. In the Filters panel, click on the “+ Area” button to add a filter. Under Filter Type, select 
“Number of Voxels.” The left limit should be green and have a value between 100 and 500. 
The right limit should be red. 
 
 
18. Click on the  button. 
19. Click on the button. Your work space will now look like this. 
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 20. In the Surpass panel, click on the Edit button. 
 
 
21. Click on the “Mask All…” button. 
 
 
22. In the Mask Channel window, select the tomato lectin channel. Check the box next to 
“Duplicate channel before applying mask.” Select the “Constant inside/outside” option. 
 
Set voxels outside surface to: 0 
Set voxels inside surface to: 255 
 
 
 
23. Click on the “OK” button. Another channel should appear in the Display Adjustment 
window. 
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Your work space should look like this. 
 
 
 
24. Create a new Surface, then repeat Steps 8-23 for the Ricinus communis lectin. 
25. Switch to the Colocalization mode by clicking on the “Coloc” button. 
 
 
26. Select the two channels you want to colocalize (these will be the two masked channels). 
 
 
27. In the 2D histogram, set the thresholds so that the pink dot (at the tip of the white arrow) is 
included in this threshold. 
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28. Click on the “Build Coloc Channel” button. 
 
 
29. Click on the new Colocalization channel. The Image Properties window will appear. 
 
 
30. Click on the “Export” button. 
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